

## Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at [info@sentinelssystem.org](mailto:info@sentinelssystem.org).

## Overview for Request: cder\_mpl1r\_wp234

**Request ID:** cder\_mpl1r\_wp234\_nsdv\_v02

**Request Description:** In this report, we characterized dispensing and administration patterns of 16 New Molecular Entities (NMEs) approved from January 1, 2020 to April 30, 2020, stratified by age and sex in the Sentinel Distributed Database (SDD).

**Sentinel Routine Querying Module:** Cohort Identification and Descriptive Analysis (CIDA) module, version 11.0.0, with ad hoc programming.

**Data Source:** We distributed this request to 14 Sentinel Data Partners on February 15, 2023. The study period included data from January 1, 2020 to most recent data available. Please see Appendix A for a list of dates of available data for each Data Partner.

**Study Design:** We identified individuals initiating any of the 16 NMEs drugs. We described demographic and clinical characteristics for individuals initiating each NME based on history recorded in the six months prior to initiation of treatment with NME. The analyses characterized dispensing patterns by examining cumulative exposure episode durations, first exposure episode durations, all exposure episode durations, days supplied per dispensing, and lengths of gaps between episodes, overall and stratified by age and sex. This was a Type 5 analysis in the Query Request Package (QRP) documentation.

**Exposures of Interest:** Our exposures of interest were NMEs approved between January 1, 2020, and April 30, 2020, administered or dispensed in any care setting. These were defined using Healthcare Common Procedure Coding System (HCPCS) procedure codes and National Drug Codes (NDCs). Please see Appendix B for a list of non-proprietary and proprietary names of medical products and Appendix C for a list of procedure codes used to define exposures in this request. All valid exposure episodes were included.

**Cohort Eligibility Criteria:** We defined index exposure as the first qualifying administration or dispensing of a given NME to an individual during the query period. We required individuals to be enrolled in health plans with both medical and drug coverage for at least 183 days prior to their index exposure, during which gaps in coverage of up to 45 days were allowed. The following age groups were included: 0-17, 18-24, 25-40, 41-64, 65+ years.

**Baseline Characteristics:** We described demographic characteristics such as sex, age, and calendar year on the day of each index NME exposure. We also described 31 clinical characteristics based on history recorded in the six months prior to the index exposure. The set of clinical characteristics included 24 chronic conditions and 7 lifestyle-related conditions. Chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse1 (CCW) algorithms and included: acute myocardial infarction, Alzheimer's disease and related conditions, atrial fibrillation, diabetes mellitus, heart failure, hyperlipidemia, hypertension, depression, ischemic heart disease, rheumatoid arthritis/osteoarthritis, stroke/transient ischemic attack (TIA), breast cancer, colorectal cancer, prostate cancer, lung cancer, endometrial cancer, acquired hypothyroidism, anemia, asthma, benign prostatic hyperplasia, chronic kidney disease, chronic obstructive pulmonary disease (COPD) and bronchiectasis, glaucoma, and osteoporosis. Lifestyle-related conditions included obesity, overweight, smoking, alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, and history of coronary angioplasty or bypass. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) procedure codes, HCPCS procedure codes, Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes, and NDCs were used to define the clinical characteristics. Please see Appendix D for a list of diagnosis and procedure codes used to define baseline characteristics in this request and Appendix E for a list of generic and brand names of medical products used to define baseline characteristics in this request.

**Overview for Request: cder\_mpl1r\_wp234**

**Please refer to Appendices F, G, and H for the specifications of parameters used in this request, baseline characteristics used in this request, and a design diagram.**

**Limitations:** Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

**Notes:** Please contact the Sentinel Operations Center ([info@sentinelssystem.org](mailto:info@sentinelssystem.org)) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinelssystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

<sup>1</sup>Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse. <https://www.ccwdata.org/web/guest/condition-categories>

**Table of Contents**

<b><u>Glossary</u></b>	List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report (CIDA)
<b><u>Table 1a</u></b>	Aggregated Baseline Table for Amisulpride in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022
<b><u>Table 1b</u></b>	Aggregated Baseline Table for Avapritinibe in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022
<b><u>Table 1c</u></b>	Aggregated Baseline Table for Bempedoic Acid in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022
<b><u>Table 1d</u></b>	Aggregated Baseline Table for Eptinezumab Jjmr in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022
<b><u>Table 1e</u></b>	Aggregated Baseline Table for Isatuximab in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022
<b><u>Table 1f</u></b>	Aggregated Baseline Table for Lactitol in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022
<b><u>Table 1g</u></b>	Aggregated Baseline Table for Opicapone in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022
<b><u>Table 1h</u></b>	Aggregated Baseline Table for Osilodrostat in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022
<b><u>Table 1i</u></b>	Aggregated Baseline Table for Ozanimod in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022
<b><u>Table 1j</u></b>	Aggregated Baseline Table for Pemigatinib in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022
<b><u>Table 1k</u></b>	Aggregated Baseline Table for Rimegepant in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022
<b><u>Table 1l</u></b>	Aggregated Baseline Table for Sacituzumab Govitecan Hziy in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022
<b><u>Table 1m</u></b>	Aggregated Baseline Table for Selumetinib in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022
<b><u>Table 1n</u></b>	Aggregated Baseline Table for Tazemetostat in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022
<b><u>Table 1o</u></b>	Aggregated Baseline Table for Teprotumumab Trbw in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022
<b><u>Table 1p</u></b>	Aggregated Baseline Table for Tucatinib in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022
<b><u>Table 2a</u></b>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Table 2b</u></b>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Table 2c</u></b>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex
<b><u>Table 2d</u></b>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex
<b><u>Table 2e</u></b>	Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group
<b><u>Table 2f</u></b>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group
<b><u>Table 3a</u></b>	Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Table 3b</u></b>	Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Table 3c</u></b>	Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex

**Table of Contents**

<b><u>Table 3d</u></b>	Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex
<b><u>Table 3e</u></b>	Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group
<b><u>Table 3f</u></b>	Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group
<b><u>Table 4a</u></b>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Table 4b</u></b>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Table 4c</u></b>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex
<b><u>Table 4d</u></b>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex
<b><u>Table 4e</u></b>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group
<b><u>Table 4f</u></b>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group
<b><u>Table 5a</u></b>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Table 5b</u></b>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Table 5c</u></b>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex
<b><u>Table 5d</u></b>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex
<b><u>Table 5e</u></b>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group
<b><u>Table 5f</u></b>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group
<b><u>Table 6a</u></b>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Table 6b</u></b>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Table 6c</u></b>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex

## Table of Contents

<b><u>Table 6d</u></b>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex
<b><u>Table 6e</u></b>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group
<b><u>Table 6f</u></b>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group
<b><u>Table 7a</u></b>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Table 7b</u></b>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex
<b><u>Table 7c</u></b>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group
<b><u>Table 8a</u></b>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Table 8b</u></b>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex
<b><u>Table 8c</u></b>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group
<b><u>Table 9</u></b>	Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Table 10</u></b>	Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Figure 1a</u></b>	Patient Entry into Study by Month for Avapritinib in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Figure 1b</u></b>	Patient Entry into Study by Month for Teprotumumab Trbw in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Figure 1c</u></b>	Patient Entry into Study by Month for Tazemetostat in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Figure 1d</u></b>	Patient Entry into Study by Month for Bempedoic Acid in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Figure 1e</u></b>	Patient Entry into Study by Month for Eptinezumab Jjmr in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Figure 1f</u></b>	Patient Entry into Study by Month for Lactitol in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Figure 1g</u></b>	Patient Entry into Study by Month for Amisulpride in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Figure 1h</u></b>	Patient Entry into Study by Month for Rimegepant in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Figure 1i</u></b>	Patient Entry into Study by Month for Isatuximab in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Figure 1j</u></b>	Patient Entry into Study by Month for Osilodrostat in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Figure 1k</u></b>	Patient Entry into Study by Month for Ozanimod in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022

**Table of Contents**

<b><u>Figure 1l</u></b>	Patient Entry into Study by Month for Selumetinib in the SDD from January 1, 2020 to August 31, 2022
<b><u>Figure 1m</u></b>	Patient Entry into Study by Month for Tucatinib in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Figure 1n</u></b>	Patient Entry into Study by Month for Pemigatinib in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Figure 1o</u></b>	Patient Entry into Study by Month for Sacituzumab Govitecan Hziy in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Figure 1p</u></b>	Patient Entry into Study by Month for Opicapone in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022
<b><u>Appendix A</u></b>	Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (January 17, 2023)
<b><u>Appendix B</u></b>	List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request
<b><u>Appendix C</u></b>	List of Healthcare Common Procedure Coding System, Level II (HCPCS) and Codes Used to Define Exposures in this Request
<b><u>Appendix D</u></b>	List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request
<b><u>Appendix E</u></b>	List of Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request
<b><u>Appendix F</u></b>	Specifications Defining Parameters for this Request
<b><u>Appendix G</u></b>	Specifications Defining Parameters for Baseline Characteristics in this Request
<b><u>Appendix H</u></b>	Design Diagrams of Cohort Entry Requirements and Index Exposure

**Glossary of Terms for Analyses Using  
Cohort Identification and Descriptive Analysis (CIDA) Module\***

**Amount Supplied** - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

**Blackout Period** - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

**Care Setting** - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

**Ambulatory Visit (AV)** - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

**Emergency Department (ED)** - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

**Inpatient Hospital Stay (IP)** - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

**Non-Acute Institutional Stay (IS)** - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

**Other Ambulatory Visit (OA)** - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

**Charlson/Elixhauser Combined Comorbidity Score** - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

**Code Days** - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

**Cohort Definition (drug/exposure)** - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

**Computed Start Marketing Date** - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

**Days Supplied** - number of days supplied for all dispensings in qualifying treatment episodes.

**Eligible Members** - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

**Enrollment Gap** - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

**Episodes** - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

**Episode Gap** - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

**Event Deduplication** - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

**Exposure Episode Length** - number of days after exposure initiation that is considered "exposed time."

**Exposure Extension Period** - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

**Lookback Period** - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).



**Glossary of Terms for Analyses Using  
Cohort Identification and Descriptive Analysis (CIDA) Module\***

**Maximum Episode Duration** - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

**Member-Years** - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

**Minimum Days Supplied** - specifies a minimum number of days in length of the days supplied for the episode to be considered.

**Minimum Episode Duration** - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

**Monitoring Period** - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

**Principal Diagnosis (PDX)** - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

**Query Period** - period in which the modular program looks for exposures and outcomes of interest.

**Switch Evaluation Step Value** - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

**Switch Gap Inclusion Indicator** - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

**Switch Pattern Cohort Inclusion Date** - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

**Switch Pattern Cohort Inclusion Strategy** - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

**Treatment Episode Truncation Indicator** - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

**Washout Period (drug/exposure)** - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

**Washout Period (event/outcome)** - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

**Years at Risk** - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

\*all terms may not be used in this report

**Table 1a. Aggregated Baseline Table for Amisulpride in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Characteristics</b>	<b>Number</b>	<b>Percent</b>
Number of unique patients	301	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	49.2	14.6
	<b>Number</b>	<b>Percent</b>
Age		
0-17 years	*****	*****
18-24 years	15	5.00%
25-40 years	80	26.60%
41-64 years	158	52.50%
≥ 65 years	*****	*****
Sex		
Female	239	79.40%
Male	62	20.60%
Race <sup>1</sup>		
American Indian or Alaska Native	0	0.00%
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.00%
Unknown	268	89.00%
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	0	0.00%
Unknown	*****	*****
Year		
2020	*****	*****
2021	120	39.90%
2022	*****	*****
<b>Health Characteristics</b>		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	*****	*****
Diabetes Mellitus	27	9.0%
Heart Failure	*****	*****
Hyperlipidemia	54	17.9%
Hypertension	76	25.2%
Depression	60	19.9%
Ischemic Heart Disease	14	4.7%
Rheumatoid Arthritis/Osteoarthritis	49	16.3%

**Table 1a. Aggregated Baseline Table for Amisulpride in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Health Characteristics</b>	<b>Number</b>	<b>Percent</b>
Stroke/Transient Ischemic Attack	*****	*****
Breast Cancer	39	13.0%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	32	10.6%
Anemia	38	12.6%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	16	5.3%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	89	29.6%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	31	10.3%
Smoking: diagnosed or identified by smoking cessation procedures	37	12.3%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
<b>Health Service Utilization Intensity Metrics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	23.7	16.4
Mean number of emergency room encounters	0.6	1.5
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	5.4	9.2
Mean number of filled prescriptions	21.6	21.8
Mean number of generics dispensed	8.3	6.6
Mean number of unique drug classes dispensed	7.5	5.6

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~N/A: Not Applicable

**Table 1b. Aggregated Baseline Table for Avapritinibe in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Characteristics</b>	<b>Number</b>	<b>Percent</b>
Number of unique patients	165	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	64.6	12.6
<b>Age</b>	<b>Number</b>	<b>Percent</b>
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	62	37.60%
≥ 65 years	90	54.50%
<b>Sex</b>		
Female	81	49.10%
Male	84	50.90%
<b>Race<sup>1</sup></b>		
American Indian or Alaska Native	0	0.00%
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.00%
Unknown	63	38.20%
White	79	47.90%
<b>Hispanic origin</b>		
Yes	*****	*****
No	95	57.60%
Unknown	*****	*****
<b>Year</b>		
2020	49	29.70%
2021	77	46.70%
2022	39	23.60%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	18	10.9%
Diabetes Mellitus	31	18.8%
Heart Failure	15	9.1%
Hyperlipidemia	52	31.5%
Hypertension	77	46.7%
Depression	39	23.6%
Ischemic Heart Disease	27	16.4%
Rheumatoid Arthritis/Osteoarthritis	33	20.0%

**Table 1b. Aggregated Baseline Table for Avapritinibe in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Health Characteristics</b>	<b>Number</b>	<b>Percent</b>
Stroke/Transient Ischemic Attack	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	19	11.5%
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	35	21.2%
Anemia	87	52.7%
Asthma	*****	*****
Benign Prostatic Hyperplasia	19	11.5%
Chronic Kidney Disease	37	22.4%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	19	11.5%
Glaucoma	*****	*****
Osteoporosis	14	8.5%
Obesity: diagnosed or identified by weight management procedures	40	24.2%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	15	9.1%
Smoking: diagnosed or identified by smoking cessation procedures	60	36.4%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****
<b>Health Service Utilization Intensity Metrics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	37.2	22.0
Mean number of emergency room encounters	1.3	2.5
Mean number of inpatient hospital encounters	1.0	1.4
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	14.5	16.6
Mean number of filled prescriptions	45.3	33.6
Mean number of generics dispensed	12.8	7.0
Mean number of unique drug classes dispensed	11.5	5.8

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~N/A: Not Applicable

**Table 1c. Aggregated Baseline Table for Bempedoic Acid in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	11,324	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	68.6	8.8
<b>Age</b>	<b>Number</b>	<b>Percent</b>
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	3,338	29.50%
≥ 65 years	7,836	69.20%
<b>Sex</b>		
Female	6,794	60.00%
Male	4,530	40.00%
<b>Race<sup>1</sup></b>		
American Indian or Alaska Native	*****	*****
Asian	308	2.70%
Black or African American	592	5.20%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	3,738	33.00%
White	6,669	58.90%
<b>Hispanic origin</b>		
Yes	163	1.40%
No	6,953	61.40%
Unknown	4,208	37.20%
<b>Year</b>		
2020	2,799	24.70%
2021	6,254	55.20%
2022	2,271	20.10%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	128	1.1%
Alzheimer's Disease and related conditions	253	2.2%
Atrial Fibrillation	911	8.0%
Diabetes Mellitus	3,318	29.3%
Heart Failure	1,129	10.0%
Hyperlipidemia	8,783	77.6%
Hypertension	7,153	63.2%
Depression	1,771	15.6%
Ischemic Heart Disease	5,079	44.9%
Rheumatoid Arthritis/Osteoarthritis	2,296	20.3%

**Table 1c. Aggregated Baseline Table for Bempedoic Acid in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Health Characteristics</b>	<b>Number</b>	<b>Percent</b>
Stroke/Transient Ischemic Attack	413	3.6%
Breast Cancer	266	2.3%
Colorectal Cancer	56	0.5%
Prostate Cancer	212	1.9%
Lung Cancer	68	0.6%
Endometrial Cancer	20	0.20%
Acquired Hypothyroidism	1,895	16.7%
Anemia	1,982	17.5%
Asthma	536	4.7%
Benign Prostatic Hyperplasia	505	4.5%
Chronic Kidney Disease	1,386	12.2%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	817	7.2%
Glaucoma	435	3.8%
Osteoporosis	609	5.4%
Obesity: diagnosed or identified by weight management procedures	2,797	24.7%
Obesity: identified by weight management-related prescriptions	139	1.2%
Overweight	1,425	12.6%
Smoking: diagnosed or identified by smoking cessation procedures	1,924	17.0%
Smoking: identified by smoking-related prescriptions	68	0.6%
Alcohol Abuse or Dependence	131	1.2%
Drug Abuse or Dependence	245	2.2%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	1,439	12.7%
<b>Health Service Utilization Intensity Metrics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	23.9	19.7
Mean number of emergency room encounters	0.4	1.0
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.3	7.7
Mean number of filled prescriptions	38.0	31.5
Mean number of generics dispensed	11.2	6.5
Mean number of unique drug classes dispensed	10.2	5.6

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~N/A: Not Applicable

**Table 1d. Aggregated Baseline Table for Eptinezumab Jjmr in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Characteristics</b>	<b>Number</b>	<b>Percent</b>
Number of unique patients	5,619	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Number</b>
Age (years)	54.6	13.3
	<b>Number</b>	<b>Percent</b>
Age		
0-17 years	11	0.20%
18-24 years	170	3.00%
25-40 years	928	16.50%
41-64 years	2,663	47.40%
≥ 65 years	1,847	32.90%
Sex		
Female	4,665	83.00%
Male	954	17.00%
Race <sup>1</sup>		
American Indian or Alaska Native	*****	*****
Asian	22	0.40%
Black or African American	194	3.50%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	2,226	39.60%
White	3,163	56.30%
Hispanic origin		
Yes	59	1.10%
No	2,993	53.30%
Unknown	2,567	45.70%
Year		
2020	1,233	21.90%
2021	3,057	54.40%
2022	1,329	23.70%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	108	1.9%
Atrial Fibrillation	150	2.7%
Diabetes Mellitus	692	12.3%
Heart Failure	181	3.2%
Hyperlipidemia	1,392	24.8%
Hypertension	1,603	28.5%
Depression	2,435	43.3%
Ischemic Heart Disease	462	8.2%
Rheumatoid Arthritis/Osteoarthritis	1,493	26.6%



**Table 1d. Aggregated Baseline Table for Eptinezumab Jjmr in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Health Characteristics</b>	<b>Number</b>	<b>Percent</b>
Stroke/Transient Ischemic Attack	142	2.5%
Breast Cancer	108	1.9%
Colorectal Cancer	16	0.3%
Prostate Cancer	32	0.6%
Lung Cancer	24	0.4%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	859	15.3%
Anemia	859	15.3%
Asthma	501	8.9%
Benign Prostatic Hyperplasia	87	1.5%
Chronic Kidney Disease	382	6.8%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	245	4.4%
Glaucoma	126	2.2%
Osteoporosis	332	5.9%
Obesity: diagnosed or identified by weight management procedures	1,380	24.6%
Obesity: identified by weight management-related prescriptions	71	1.3%
Overweight	479	8.5%
Smoking: diagnosed or identified by smoking cessation procedures	826	14.7%
Smoking: identified by smoking-related prescriptions	25	0.4%
Alcohol Abuse or Dependence	65	1.2%
Drug Abuse or Dependence	326	5.8%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	107	1.9%
<b>Health Service Utilization Intensity Metrics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	36.4	27.1
Mean number of emergency room encounters	1.1	4.0
Mean number of inpatient hospital encounters	0.2	0.8
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	7.7	15.0
Mean number of filled prescriptions	62.9	47.1
Mean number of generics dispensed	16.4	9.4
Mean number of unique drug classes dispensed	14.4	7.8

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~N/A: Not Applicable

**Table 1e. Aggregated Baseline Table for Isatuximab in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	1,059	N/A
<b>Demographic Characteristics</b>		
	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	71.3	8.7
<b>Age</b>		
	<b>Number</b>	<b>Percent</b>
0-17 years	0	0.00%
18-24 years	0	0.00%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	840	79.30%
<b>Sex</b>		
Female	*****	*****
Male	*****	*****
<b>Race<sup>1</sup></b>		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	166	15.70%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	173	16.30%
White	689	65.10%
<b>Hispanic origin</b>		
Yes	34	3.20%
No	792	74.80%
Unknown	233	22.00%
<b>Year</b>		
2020	265	25.00%
2021	511	48.30%
2022	283	26.70%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	15	1.4%
Alzheimer's Disease and related conditions	40	3.8%
Atrial Fibrillation	161	15.2%
Diabetes Mellitus	253	23.9%
Heart Failure	205	19.4%
Hyperlipidemia	394	37.2%
Hypertension	618	58.4%
Depression	225	21.2%
Ischemic Heart Disease	250	23.6%
Rheumatoid Arthritis/Osteoarthritis	222	21.0%

**Table 1e. Aggregated Baseline Table for Isatuximab in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Health Characteristics</b>	<b>Number</b>	<b>Percent</b>
Stroke/Transient Ischemic Attack	32	3.0%
Breast Cancer	44	4.2%
Colorectal Cancer	13	1.2%
Prostate Cancer	47	4.4%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	162	15.3%
Anemia	723	68.3%
Asthma	58	5.5%
Benign Prostatic Hyperplasia	82	7.7%
Chronic Kidney Disease	396	37.4%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	101	9.5%
Glaucoma	52	4.9%
Osteoporosis	67	6.3%
Obesity: diagnosed or identified by weight management procedures	169	16.0%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	124	11.7%
Smoking: diagnosed or identified by smoking cessation procedures	274	25.9%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	19	1.8%
Drug Abuse or Dependence	38	3.6%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	71	6.7%
<b>Health Service Utilization Intensity Metrics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	62.9	36.3
Mean number of emergency room encounters	0.8	1.4
Mean number of inpatient hospital encounters	0.9	1.5
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	20.9	18.3
Mean number of filled prescriptions	55.1	31.6
Mean number of generics dispensed	15.8	7.2
Mean number of unique drug classes dispensed	14.2	6.1

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~N/A: Not Applicable

**Table 1f. Aggregated Baseline Table for Lactitol in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Characteristics</b>	<b>Number</b>	<b>Mean</b>
Number of unique patients	0	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	-	-
Age	<b>Number</b>	<b>Percent</b>
0-17 years	-	-
18-24 years	-	-
25-40 years	-	-
41-64 years	-	-
≥ 65 years	-	-
Sex	-	-
Female	-	-
Male	-	-
Race <sup>1</sup>	-	-
American Indian or Alaska Native	-	-
Asian	-	-
Black or African American	-	-
Native Hawaiian or Other Pacific Islander	-	-
Unknown	-	-
White	-	-
Hispanic origin	-	-
Yes	-	-
No	-	-
Unknown	-	-
Year	-	-
2020	-	-
2021	-	-
2022	-	-
<b>Health Characteristics</b>		
Acute Myocardial Infarction	-	-
Alzheimer's Disease and related conditions	-	-
Atrial Fibrillation	-	-
Diabetes Mellitus	-	-
Heart Failure	-	-
Hyperlipidemia	-	-
Hypertension	-	-
Depression	-	-
Ischemic Heart Disease	-	-
Rheumatoid Arthritis/Osteoarthritis	-	-

**Table 1f. Aggregated Baseline Table for Lactitol in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Health Characteristics</b>	<b>Number</b>	<b>Percent</b>
Stroke/Transient Ischemic Attack	-	-
Breast Cancer	-	-
Colorectal Cancer	-	-
Prostate Cancer	-	-
Lung Cancer	-	-
Endometrial Cancer	-	-
Acquired Hypothyroidism	-	-
Anemia	-	-
Asthma	-	-
Benign Prostatic Hyperplasia	-	-
Chronic Kidney Disease	-	-
Chronic Obstructive Pulmonary Disease and Bronchiectasis	-	-
Glaucoma	-	-
Osteoporosis	-	-
Obesity: diagnosed or identified by weight management procedures	-	-
Obesity: identified by weight management-related prescriptions	-	-
Overweight	-	-
Smoking: diagnosed or identified by smoking cessation procedures	-	-
Smoking: identified by smoking-related prescriptions	-	-
Alcohol Abuse or Dependence	-	-
Drug Abuse or Dependence	-	-
History of Cardiac Arrest	-	-
History of Coronary Angioplasty or Bypass	-	-
<b>Health Service Utilization Intensity Metrics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	-	-
Mean number of emergency room encounters	-	-
Mean number of inpatient hospital encounters	-	-
Mean number of non-acute institutional encounters	-	-
Mean number of other ambulatory encounters	-	-
Mean number of filled prescriptions	-	-
Mean number of generics dispensed	-	-
Mean number of unique drug classes dispensed	-	-

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

\*Data presented by a dash represent missing information. This table may not use all data representations.

~N/A: Not Applicable

**Table 1g. Aggregated Baseline Table for Opicapone in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Characteristics</b>	<b>Number</b>	<b>Percent</b>
Number of unique patients	2,125	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	73.2	8
	<b>Number</b>	<b>Percent</b>
Age		
0-17 years	0	0.00%
18-24 years	0	0.00%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	1,854	87.20%
Sex		
Female	827	38.90%
Male	1,298	61.10%
Race <sup>1</sup>		
American Indian or Alaska Native	*****	*****
Asian	71	3.30%
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	392	18.40%
White	1,607	75.60%
Hispanic origin		
Yes	*****	*****
No	1,652	77.70%
Unknown	*****	*****
Year		
2020	*****	*****
2021	1,297	61.00%
2022	*****	*****
<b>Health Characteristics</b>		
Acute Myocardial Infarction	12	0.6%
Alzheimer's Disease and related conditions	307	14.4%
Atrial Fibrillation	188	8.8%
Diabetes Mellitus	329	15.5%
Heart Failure	159	7.5%
Hyperlipidemia	730	34.4%
Hypertension	895	42.1%
Depression	642	30.2%
Ischemic Heart Disease	400	18.8%
Rheumatoid Arthritis/Osteoarthritis	409	19.2%

**Table 1g. Aggregated Baseline Table for Opicapone in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Health Characteristics</b>	<b>Number</b>	<b>Percent</b>
Stroke/Transient Ischemic Attack	84	4.0%
Breast Cancer	46	2.2%
Colorectal Cancer	11	0.5%
Prostate Cancer	83	3.9%
Lung Cancer	16	0.8%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	219	10.3%
Anemia	468	22.0%
Asthma	55	2.6%
Benign Prostatic Hyperplasia	241	11.3%
Chronic Kidney Disease	207	9.7%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	90	4.2%
Glaucoma	82	3.9%
Osteoporosis	141	6.6%
Obesity: diagnosed or identified by weight management procedures	237	11.2%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	182	8.6%
Smoking: diagnosed or identified by smoking cessation procedures	271	12.8%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	25	1.2%
Drug Abuse or Dependence	38	1.8%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	123	5.8%
<b>Health Service Utilization Intensity Metrics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	32.6	25.4
Mean number of emergency room encounters	0.6	1.7
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.1	0.5
Mean number of other ambulatory encounters	12.3	22.6
Mean number of filled prescriptions	48.8	35.7
Mean number of generics dispensed	11.5	5.9
Mean number of unique drug classes dispensed	10.6	5.2

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~N/A: Not Applicable

**Table 1i. Aggregated Baseline Table for Ozanimod in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	923	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	48.4	12.2
<b>Age</b>	<b>Number</b>	<b>Percent</b>
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	245	26.50%
41-64 years	528	57.20%
≥ 65 years	119	12.90%
<b>Sex</b>		
Female	648	70.20%
Male	275	29.80%
<b>Race<sup>1</sup></b>		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.00%
Unknown	557	60.30%
White	319	34.60%
<b>Hispanic origin</b>		
Yes	14	1.50%
No	295	32.00%
Unknown	614	66.50%
<b>Year</b>		
2020	128	13.90%
2021	547	59.30%
2022	248	26.90%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	14	1.5%
Atrial Fibrillation	15	1.6%
Diabetes Mellitus	71	7.7%
Heart Failure	*****	*****
Hyperlipidemia	145	15.7%
Hypertension	182	19.7%
Depression	238	25.8%
Ischemic Heart Disease	35	3.8%
Rheumatoid Arthritis/Osteoarthritis	92	10.0%



**Table 1i. Aggregated Baseline Table for Ozanimod in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Health Characteristics</b>	<b>Number</b>	<b>Percent</b>
Stroke/Transient Ischemic Attack	14	1.5%
Breast Cancer	12	1.3%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	63	6.8%
Anemia	154	16.7%
Asthma	35	3.8%
Benign Prostatic Hyperplasia	11	1.2%
Chronic Kidney Disease	42	4.6%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	22	2.4%
Glaucoma	18	2.0%
Osteoporosis	35	3.8%
Obesity: diagnosed or identified by weight management procedures	152	16.5%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	72	7.8%
Smoking: diagnosed or identified by smoking cessation procedures	131	14.2%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	19	2.1%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****
<b>Health Service Utilization Intensity Metrics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	21.2	17.0
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	6.4	16.0
Mean number of filled prescriptions	31.0	31.4
Mean number of generics dispensed	8.8	6.4
Mean number of unique drug classes dispensed	8.1	5.7

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~N/A: Not Applicable

**Table 1h. Aggregated Baseline Table for Osilodrostat in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	164	N/A
<b>Demographic Characteristics</b>		
	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	55.3	13.2
<b>Demographic Characteristics</b>		
	<b>Number</b>	<b>Percent</b>
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	69	42.10%
≥ 65 years	60	36.60%
Sex		
Female	133	81.10%
Male	31	18.90%
Race <sup>1</sup>		
American Indian or Alaska Native	0	0.00%
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.00%
Unknown	73	44.50%
White	80	48.80%
Hispanic origin		
Yes	*****	*****
No	85	51.80%
Unknown	*****	*****
Year		
2020	*****	*****
2021	78	47.60%
2022	*****	*****
<b>Health Characteristics</b>		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	75	45.7%
Heart Failure	18	11.0%
Hyperlipidemia	68	41.5%
Hypertension	92	56.1%
Depression	48	29.3%
Ischemic Heart Disease	24	14.6%
Rheumatoid Arthritis/Osteoarthritis	22	13.4%

**Table 1h. Aggregated Baseline Table for Osilodrostat in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Health Characteristics</b>	<b>Number</b>	<b>Percent</b>
Stroke/Transient Ischemic Attack	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	0	0.0%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	68	41.5%
Anemia	32	19.5%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	23	14.0%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	21	12.8%
Obesity: diagnosed or identified by weight management procedures	59	36.0%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	16	9.8%
Smoking: diagnosed or identified by smoking cessation procedures	31	18.9%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
<b>Health Service Utilization Intensity Metrics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	33.4	22.5
Mean number of emergency room encounters	0.7	1.3
Mean number of inpatient hospital encounters	0.4	1.0
Mean number of non-acute institutional encounters	0.1	0.5
Mean number of other ambulatory encounters	13.4	20.5
Mean number of filled prescriptions	51.8	34.8
Mean number of generics dispensed	13.7	7.2
Mean number of unique drug classes dispensed	12.2	6.1

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~N/A: Not Applicable

**Table 1j. Aggregated Baseline Table for Pemigatinib in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	275	N/A
<b>Demographic Characteristics</b>		
	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	65.6	9.9
Age	<b>Number</b>	<b>Percent</b>
0-17 years	0	0.00%
18-24 years	0	0.00%
25-40 years	12	4.40%
41-64 years	86	31.30%
≥ 65 years	177	64.40%
Sex		
Female	164	59.60%
Male	111	40.40%
Race <sup>1</sup>		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	82	29.80%
White	160	58.20%
Hispanic origin		
Yes	*****	*****
No	179	65.10%
Unknown	*****	*****
Year		
2020	88	32.00%
2021	124	45.10%
2022	63	22.90%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	19	6.9%
Diabetes Mellitus	93	33.8%
Heart Failure	23	8.4%
Hyperlipidemia	114	41.5%
Hypertension	156	56.7%
Depression	62	22.5%
Ischemic Heart Disease	64	23.3%
Rheumatoid Arthritis/Osteoarthritis	41	14.9%

**Table 1j. Aggregated Baseline Table for Pemigatinib in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Health Characteristics</b>	<b>Number</b>	<b>Percent</b>
Stroke/Transient Ischemic Attack	*****	*****
Breast Cancer	19	6.9%
Colorectal Cancer	18	6.5%
Prostate Cancer	13	4.7%
Lung Cancer	13	4.7%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	48	17.5%
Anemia	164	59.6%
Asthma	15	5.5%
Benign Prostatic Hyperplasia	16	5.8%
Chronic Kidney Disease	66	24.0%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	24	8.7%
Glaucoma	*****	*****
Osteoporosis	11	4.0%
Obesity: diagnosed or identified by weight management procedures	64	23.3%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	25	9.1%
Smoking: diagnosed or identified by smoking cessation procedures	94	34.2%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	11	4.0%
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	16	5.8%
<b>Health Service Utilization Intensity Metrics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	51.4	24.2
Mean number of emergency room encounters	1.2	1.7
Mean number of inpatient hospital encounters	1.0	1.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	14.8	15.0
Mean number of filled prescriptions	42.3	33.0
Mean number of generics dispensed	14.2	7.5
Mean number of unique drug classes dispensed	12.6	6.3

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~N/A: Not Applicable

**Table 1k. Aggregated Baseline Table for Rimegepant in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Characteristics</b>	<b>Number</b>	<b>Percent</b>
Number of unique patients	71,338	N/A
<b>Demographic Characteristics</b>		
	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	49.3	13.3
Age	<b>Number</b>	<b>Percent</b>
0-17 years	356	0.50%
18-24 years	3,660	5.10%
25-40 years	17,365	24.30%
41-64 years	37,752	52.90%
≥ 65 years	12,205	17.10%
Sex		
Female	61,031	85.60%
Male	10,307	14.40%
Race <sup>1</sup>		
American Indian or Alaska Native	144	0.20%
Asian	431	0.60%
Black or African American	2,586	3.60%
Native Hawaiian or Other Pacific Islander	29	0.00%
Unknown	41,268	57.80%
White	26,880	37.70%
Hispanic origin		
Yes	1,275	1.80%
No	23,040	32.30%
Unknown	47,023	65.90%
Year		
2020	15,363	21.50%
2021	36,746	51.50%
2022	19,229	27.00%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	147	0.2%
Alzheimer's Disease and related conditions	1,022	1.4%
Atrial Fibrillation	1,569	2.2%
Diabetes Mellitus	7,930	11.1%
Heart Failure	2,344	3.3%
Hyperlipidemia	14,340	20.1%
Hypertension	17,591	24.7%
Depression	25,143	35.2%
Ischemic Heart Disease	5,471	7.7%
Rheumatoid Arthritis/Osteoarthritis	14,016	19.6%

**Table 1k. Aggregated Baseline Table for Rimegepant in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Health Characteristics</b>	<b>Number</b>	<b>Percent</b>
Stroke/Transient Ischemic Attack	2,323	3.3%
Breast Cancer	1,059	1.5%
Colorectal Cancer	138	0.2%
Prostate Cancer	218	0.3%
Lung Cancer	157	0.2%
Endometrial Cancer	81	0.1%
Acquired Hypothyroidism	7,991	11.2%
Anemia	9,570	13.4%
Asthma	5,474	7.7%
Benign Prostatic Hyperplasia	698	1.0%
Chronic Kidney Disease	3,879	5.4%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	3,555	5.0%
Glaucoma	1,176	1.6%
Osteoporosis	2,154	3.0%
Obesity: diagnosed or identified by weight management procedures	16,603	23.3%
Obesity: identified by weight management-related prescriptions	1,289	1.8%
Overweight	6,184	8.7%
Smoking: diagnosed or identified by smoking cessation procedures	10,191	14.3%
Smoking: identified by smoking-related prescriptions	661	0.9%
Alcohol Abuse or Dependence	973	1.4%
Drug Abuse or Dependence	3,660	5.1%
History of Cardiac Arrest	55	0.10%
History of Coronary Angioplasty or Bypass	1,140	1.6%
<b>Health Service Utilization Intensity Metrics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	26.8	22.5
Mean number of emergency room encounters	0.9	2.8
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	6.1	11.6
Mean number of filled prescriptions	50.7	43.1
Mean number of generics dispensed	13.7	8.3
Mean number of unique drug classes dispensed	12.3	7.1

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

~N/A: Not Applicable

**Table 11. Aggregated Baseline Table for Sacituzumab Govitecan Hziy in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	2,587	N/A
<b>Demographic Characteristics</b>		
	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	65.4	10.2
	<b>Number</b>	<b>Percent</b>
Age		
0-17 years	0	0.00%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	869	33.60%
≥ 65 years	1,602	61.90%
Sex		
Female	2,217	85.70%
Male	370	14.30%
Race <sup>1</sup>		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	307	11.90%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	775	30.00%
White	1,456	56.30%
Hispanic origin		
Yes	31	1.20%
No	1,661	64.20%
Unknown	895	34.60%
Year		
2020	429	16.60%
2021	1,394	53.90%
2022	764	29.50%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	21	0.8%
Alzheimer's Disease and related conditions	46	1.8%
Atrial Fibrillation	161	6.2%
Diabetes Mellitus	526	20.3%
Heart Failure	266	10.3%
Hyperlipidemia	826	31.9%
Hypertension	1,135	43.9%
Depression	613	23.7%
Ischemic Heart Disease	380	14.7%
Rheumatoid Arthritis/Osteoarthritis	356	13.8%



**Table 1I. Aggregated Baseline Table for Sacituzumab Govitecan Hziy in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Health Characteristics</b>	<b>Number</b>	<b>Percent</b>
Stroke/Transient Ischemic Attack	71	2.7%
Breast Cancer	2,082	80.5%
Colorectal Cancer	44	1.7%
Prostate Cancer	81	3.1%
Lung Cancer	155	6.0%
Endometrial Cancer	21	0.8%
Acquired Hypothyroidism	486	18.8%
Anemia	1,389	53.7%
Asthma	161	6.2%
Benign Prostatic Hyperplasia	62	2.4%
Chronic Kidney Disease	642	24.8%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	226	8.7%
Glaucoma	87	3.4%
Osteoporosis	145	5.6%
Obesity: diagnosed or identified by weight management procedures	434	16.8%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	233	9.0%
Smoking: diagnosed or identified by smoking cessation procedures	750	29.0%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	28	1.1%
Drug Abuse or Dependence	91	3.5%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	86	3.3%
<b>Health Service Utilization Intensity Metrics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	63.2	25.5
Mean number of emergency room encounters	0.9	1.6
Mean number of inpatient hospital encounters	0.8	1.2
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	16.0	16.2
Mean number of filled prescriptions	38.3	26.3
Mean number of generics dispensed	13.7	7.0
Mean number of unique drug classes dispensed	12.2	5.8

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~N/A: Not Applicable

**Table 1m. Aggregated Baseline Table for Selumetinib in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	203	N/A
<b>Demographic Characteristics</b>		
	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	25.8	13.9
Age	<b>Number</b>	<b>Percent</b>
0-17 years	89	43.80%
18-24 years	*****	*****
25-40 years	41	20.20%
41-64 years	33	16.30%
≥ 65 years	*****	*****
Sex		
Female	102	50.20%
Male	101	49.80%
Race <sup>1</sup>		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.00%
Unknown	140	69.00%
White	51	25.10%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	143	70.40%
Year		
2020	101	49.80%
2021	*****	*****
2022	*****	*****
<b>Health Characteristics</b>		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****
Hyperlipidemia	17	8.4%
Hypertension	26	12.8%
Depression	40	19.7%
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****

**Table 1m. Aggregated Baseline Table for Selumetinib in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Health Characteristics</b>	<b>Number</b>	<b>Percent</b>
Stroke/Transient Ischemic Attack	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	0	0.0%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	26	12.8%
Asthma	14	6.9%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	*****	*****
Chronic Obstructive Pulmonary Disease and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	20	9.9%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	17	8.4%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
<b>Health Service Utilization Intensity Metrics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	25.6	22.5
Mean number of emergency room encounters	0.7	1.4
Mean number of inpatient hospital encounters	0.4	0.8
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	9.0	29.2
Mean number of filled prescriptions	27.5	32.1
Mean number of generics dispensed	7.3	6.6
Mean number of unique drug classes dispensed	6.7	5.7

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~N/A: Not Applicable

**Table 1n. Aggregated Baseline Table for Tazemetostat in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	212	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	67	16
	<b>Number</b>	<b>Percent</b>
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	43	20.30%
≥ 65 years	146	68.90%
Sex		
Female	97	45.80%
Male	115	54.20%
Race <sup>1</sup>		
American Indian or Alaska Native	0	0.00%
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	61	28.80%
White	137	64.60%
Hispanic origin		
Yes	*****	*****
No	143	67.50%
Unknown	*****	*****
Year		
2020	49	23.10%
2021	91	42.90%
2022	72	34.00%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	27	12.7%
Diabetes Mellitus	43	20.3%
Heart Failure	33	15.6%
Hyperlipidemia	82	38.7%
Hypertension	106	50.0%
Depression	47	22.2%
Ischemic Heart Disease	50	23.6%
Rheumatoid Arthritis/Osteoarthritis	31	14.6%

**Table 1n. Aggregated Baseline Table for Tazemetostat in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Health Characteristics</b>	<b>Number</b>	<b>Percent</b>
Stroke/Transient Ischemic Attack	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	*****	*****
Lung Cancer	11	5.2%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	30	14.2%
Anemia	101	47.6%
Asthma	11	5.2%
Benign Prostatic Hyperplasia	15	7.1%
Chronic Kidney Disease	52	24.5%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	31	14.6%
Glaucoma	*****	*****
Osteoporosis	11	5.2%
Obesity: diagnosed or identified by weight management procedures	37	17.5%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	26	12.3%
Smoking: diagnosed or identified by smoking cessation procedures	58	27.4%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	22	10.4%
<b>Health Service Utilization Intensity Metrics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	46.3	29.2
Mean number of emergency room encounters	1.1	2.5
Mean number of inpatient hospital encounters	1.0	1.7
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	12.7	19.0
Mean number of filled prescriptions	40.3	34.1
Mean number of generics dispensed	12.9	7.6
Mean number of unique drug classes dispensed	11.5	6.5

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~N/A: Not Applicable

**Table 10. Aggregated Baseline Table for Teprotumumab Trbw in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	2,989	N/A
<b>Demographic Characteristics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	62.8	11.1
	<b>Number</b>	<b>Percent</b>
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	217	7.30%
41-64 years	1,047	35.00%
≥ 65 years	1,691	56.60%
Sex		
Female	2,313	77.40%
Male	676	22.60%
Race <sup>1</sup>		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	191	6.40%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	1,189	39.80%
White	1,563	52.30%
Hispanic origin		
Yes	49	1.60%
No	1,617	54.10%
Unknown	1,323	44.30%
Year		
2020	889	29.70%
2021	1,495	50.00%
2022	605	20.20%
<b>Health Characteristics</b>		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	37	1.2%
Atrial Fibrillation	211	7.1%
Diabetes Mellitus	443	14.8%
Heart Failure	157	5.3%
Hyperlipidemia	902	30.2%
Hypertension	1,059	35.4%
Depression	492	16.5%
Ischemic Heart Disease	364	12.2%
Rheumatoid Arthritis/Osteoarthritis	412	13.8%

**Table 1o. Aggregated Baseline Table for Teprotumumab Trbw in the Sentinel Distributed Database (SDD) between January 1, 2020 and August 31, 2022**

<b>Health Characteristics</b>	<b>Number</b>	<b>Percent</b>
Stroke/Transient Ischemic Attack	45	1.5%
Breast Cancer	121	4.0%
Colorectal Cancer	17	0.6%
Prostate Cancer	39	1.3%
Lung Cancer	11	0.4%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	1,182	39.5%
Anemia	399	13.3%
Asthma	125	4.2%
Benign Prostatic Hyperplasia	61	2.0%
Chronic Kidney Disease	204	6.8%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	185	6.2%
Glaucoma	380	12.7%
Osteoporosis	201	6.7%
Obesity: diagnosed or identified by weight management procedures	561	18.8%
Obesity: identified by weight management-related prescriptions	23	0.8%
Overweight	337	11.3%
Smoking: diagnosed or identified by smoking cessation procedures	593	19.8%
Smoking: identified by smoking-related prescriptions	27	0.9%
Alcohol Abuse or Dependence	33	1.1%
Drug Abuse or Dependence	68	2.3%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	83	2.8%
<b>Health Service Utilization Intensity Metrics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	26.6	16.8
Mean number of emergency room encounters	0.4	1.1
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	6.0	7.1
Mean number of filled prescriptions	30.6	28.8
Mean number of generics dispensed	9.5	6.4
Mean number of unique drug classes dispensed	8.8	5.6

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~N/A: Not Applicable

**Table 1p. Aggregated Baseline Table for Tucatinib in the Sentinel Distributed Database (SDD) between January 1, 2020 and**

<b>Characteristics</b>	<b>Number</b>	<b>Percent</b>
Unique patients	1,317	N/A
<b>Demographic Characteristics</b>		
	<b>Mean</b>	<b>Standard Deviation</b>
Age (years)	59.5	12
<b>Age</b>		
	<b>Number</b>	<b>Percent</b>
0-17 years	0	0.00%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	679	51.60%
≥ 65 years	519	39.40%
<b>Sex</b>		
Female	1,292	98.10%
Male	25	1.90%
<b>Race<sup>1</sup></b>		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	152	11.50%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	527	40.00%
White	590	44.80%
<b>Hispanic origin</b>		
Yes	*****	*****
No	737	56.00%
Unknown	*****	*****
<b>Year</b>		
2020	*****	*****
2021	582	44.20%
2022	*****	*****
<b>Health Characteristics</b>		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	27	2.1%
Atrial Fibrillation	36	2.7%
Diabetes Mellitus	197	15.0%
Heart Failure	193	14.7%
Hyperlipidemia	261	19.8%
Hypertension	437	33.2%
Depression	315	23.9%
Ischemic Heart Disease	130	9.9%
Rheumatoid Arthritis/Osteoarthritis	129	9.8%



**Table 1p. Aggregated Baseline Table for Tucatinib in the Sentinel Distributed Database (SDD) between January 1, 2020 and**

<b>Health Characteristics</b>	<b>Number</b>	<b>Percent</b>
Stroke/Transient Ischemic Attack	76	5.8%
Breast Cancer	1,288	97.8%
Colorectal Cancer	23	1.7%
Prostate Cancer	*****	*****
Lung Cancer	42	3.2%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	149	11.3%
Anemia	490	37.2%
Asthma	78	5.9%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	152	11.5%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	76	5.8%
Glaucoma	22	1.7%
Osteoporosis	73	5.5%
Obesity: diagnosed or identified by weight management procedures	188	14.3%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	99	7.5%
Smoking: diagnosed or identified by smoking cessation procedures	280	21.3%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	19	1.4%
Drug Abuse or Dependence	42	3.2%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	15	1.1%
<b>Health Service Utilization Intensity Metrics</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	51.3	23.9
Mean number of emergency room encounters	0.8	1.4
Mean number of inpatient hospital encounters	0.7	1.1
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	13.7	15.8
Mean number of filled prescriptions	38.8	29.0
Mean number of generics dispensed	12.3	6.7
Mean number of unique drug classes dispensed	11.1	5.7

<sup>1</sup>Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

~N/A: Not Applicable

**Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**

	Number of Dispensings by Days Supplied								
	1-30 Days		31-60 Days		61-90 Days		91+ Days		
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Avapritinib	820	*****	*****	*****	*****	0	0.0%	0	0.0%
Teprotumumab Trbw	18,143	*****	*****	0	0.0%	*****	*****	0	0.0%
Tazemetostat	956	*****	*****	*****	*****	0	0.0%	0	0.0%
Lactitol	0	-	-	-	-	-	-	-	-
Bempedoic Acid	47,807	35,300	73.8%	*****	*****	11,163	23.4%	*****	*****
Eptinezumab Jjmr	15,707	14,737	93.8%	*****	*****	899	5.7%	*****	*****
Amisulpride	306	306	100.00%	0	0.00%	0	0.0%	0	0.0%
Rimegepant	286,197	276,954	96.8%	7,584	2.6%	2,60%	1,647	0.60%	12
Isatuximab	11,646	11,612	99.70%	34	0.30%	0	0.0%	0	0.0%
Osilodrostat	1,040	969	93.20%	34	3.30%	37	3.60%	0	0.00%
Ozanimod	5,959	5,419	90.9%	301	5.1%	*****	*****	*****	*****
Selumetinib	1,456	1,199	82.3%	*****	*****	*****	*****	0	0.0%
Tucatinib	7,376	7,018	95.1%	*****	*****	*****	*****	*****	*****
Pemigatinib	1,780	*****	*****	*****	*****	*****	*****	0	0.0%
Sacituzumab Govitecan Hziy	25,467	25,467	100.0%	0	0.0%	0	0.0%	0	0.0%
Opicapone	9,831	8,348	84.9%	*****	*****	1,236	12.6%	*****	*****

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

**Table 2b. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**

	Distribution of Days Supplied by Dispensing							Standard Deviation
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	
Avapritinib	820	1	30	30	30	60	28.9	5.2
Teprotumumab Trbw	18,143	1	1	1	1	84	2.5	5.5
Tazemetostat	956	1	30	30	30	40	28.4	5.2
Lactitol	0	-	-	-	-	-	-	-
Bempedoic Acid	47,807	1	30	30	46	180	43.2	25.9
Eptinezumab Jjmr	15,707	1	1	1	1	180	6.6	20.3
Amisulpride	306	1	1	1	1	1	1.0	0.0
Rimegepant	286,197	1	8	30	30	382	21.7	11.4
Isatuximab	11,646	1	1	1	1	56	1.4	3.7
Osilodrostat	1,040	1	30	30	30	90	30.5	13.6
Ozanimod	5,959	1	30	30	30	127	30.6	13.4
Selumetinib	1,456	1	30	30	30	90	33.5	12.9
Tucatinib	7,376	1	30	30	30	120	30.0	8.0
Pemigatinib	1,780	1	14	21	21	63	18.1	4.7
Sacituzumab Govitecan Hziy	25,467	1	1	1	1	28	1.1	1.6
Opicapone	9,831	1	30	30	30	150	36.1	21.1

*Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.*

**Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

	Number of Dispensings by Days Supplied								
	1-30 Days		31-60 Days		61-90 Days		91+ Days		
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<b>Avapritinib</b>	<b>820</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	*****	*****	*****	*****	*****	0	NaN	0	NaN
<b>Teprotumumab Trbw</b>	<b>18,143</b>	*****	*****	<b>0</b>	<b>NaN</b>	*****	*****	<b>0</b>	<b>NaN</b>
Female	*****	*****	*****	0	NaN	*****	*****	0	NaN
Male	*****	*****	*****	0	NaN	*****	*****	0	NaN
<b>Tazemetostat</b>	<b>956</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	*****	*****	*****	*****	*****	0	NaN	0	NaN
<b>Lactitol</b>	<b>0</b>	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-
<b>Bempedoic Acid</b>	<b>47,807</b>	<b>35,300</b>	<b>100.0%</b>	*****	*****	<b>11,163</b>	<b>100.0%</b>	*****	*****
Female	28,083	20,734	58.7%	*****	*****	6,522	58.4%	*****	*****
Male	19,724	14,566	41.3%	*****	*****	4,641	41.6%	*****	*****
<b>Eptinezumab Jjmr</b>	<b>15,707</b>	<b>14,737</b>	<b>100.0%</b>	*****	*****	<b>899</b>	<b>100.0%</b>	*****	*****
Female	13,136	12,358	83.9%	*****	*****	726	80.8%	*****	*****
Male	2,571	2,379	16.1%	*****	*****	173	19.2%	*****	*****
<b>Amisulpride</b>	<b>306</b>	*****	*****	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN

**Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

	Number of Dispensings by Days Supplied								
	1-30 Days		31-60 Days		61-90 Days		91+ Days		
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<b>Rimegepant</b>	<b>286,197</b>	<b>276,954</b>	<b>100.0%</b>	<b>7,584</b>	<b>100.0%</b>	<b>1,647</b>	<b>100.0%</b>	<b>12</b>	<b>100.0%</b>
Female	247,882	240,074	86.7%	6,394	84.3%	1,404	85.20%	*****	*****
Male	38,315	36,880	13.3%	1,190	15.7%	243	14.80%	*****	*****
<b>Isatuximab</b>	<b>11,646</b>	<b>11,612</b>	<b>100.0%</b>	<b>34</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	5,641	5,619	48.4%	22	64.70%	0	NaN	0	NaN
Male	6,005	5,993	51.6%	12	35.30%	0	NaN	0	NaN
<b>Osilodrostat</b>	<b>1,040</b>	<b>969</b>	<b>100.0%</b>	<b>34</b>	<b>100.0%</b>	<b>37</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
Female	857	797	82.2%	*****	*****	*****	*****	0	NaN
Male	183	172	17.8%	*****	*****	*****	*****	0	NaN
<b>Ozanimod</b>	<b>5,959</b>	<b>5,419</b>	<b>100.0%</b>	<b>301</b>	<b>100.0%</b>	<b>235</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>
Female	4,272	3,887	71.7%	214	71.1%	*****	*****	*****	*****
Male	1,687	1,532	28.3%	87	28.9%	*****	*****	*****	*****
<b>Selumetinib</b>	<b>1,456</b>	<b>1,199</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN</b>
Female	716	589	49.1%	*****	*****	*****	*****	0	NaN
Male	740	610	50.9%	*****	*****	*****	*****	0	NaN
<b>Tucatinib</b>	<b>7,376</b>	<b>7,018</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>
Female	7,284	6,929	98.7%	*****	*****	*****	*****	*****	*****
Male	92	89	1.3%	*****	*****	*****	*****	*****	*****
<b>Pemigatinib</b>	<b>1,780</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN</b>
Female	1,165	1,161	65.5%	*****	*****	*****	*****	0	NaN
Male	615	611	34.5%	*****	*****	*****	*****	0	NaN

**Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<b>Sacituzumab Govitecan Hziy</b>	<b>25,467</b>	*****	*****	0	NaN	0	NaN	0	NaN
Female	*****	22,893	89.9%	0	NaN	0	NaN	0	NaN
Male	*****	2,574	10.1%	0	NaN	0	NaN	0	NaN
<b>Opicapone</b>	<b>9,831</b>	<b>8,348</b>	<b>100.0%</b>	<b>245</b>	<b>100.0%</b>	<b>1,236</b>	<b>100.0%</b>	*****	*****
Female	3,622	3,071	36.8%	86	35.10%	464	37.5%	*****	*****
Male	6,209	5,277	63.2%	159	64.90%	772	62.5%	*****	*****

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Avapritinib</b>	<b>820</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>28.9</b>	<b>5.2</b>
Female	*****	2	30	30	30	60	28.8	5.7
Male	*****	1	30	30	30	60	29.0	4.6
<b>Teprotumumab Trbw</b>	<b>18,143</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>84</b>	<b>2.5</b>	<b>5.5</b>
Female	*****	1	1	1	1	30	2.4	5.1
Male	*****	1	1	1	1	84	2.8	6.4
<b>Tazemetostat</b>	<b>956</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>40</b>	<b>28.4</b>	<b>5.2</b>
Female	*****	1	30	30	30	30	28.3	5.5
Male	*****	1	30	30	30	40	28.5	5.0
<b>Lactitol</b>	<b>0</b>	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
<b>Bempedoic Acid</b>	<b>47,807</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>46</b>	<b>180</b>	<b>43.2</b>	<b>25.9</b>
Female	28,083	1	30	30	45	142	43.2	25.9
Male	19,724	1	30	30	48	180	43.3	26.0
<b>Eptinezumab Jjmr</b>	<b>15,707</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>180</b>	<b>6.6</b>	<b>20.3</b>
Female	13,136	1	1	1	1	180	6.4	20.0
Male	2,571	1	1	1	1	112	7.4	21.9
<b>Amisulpride</b>	<b>306</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1.0</b>	<b>0.0</b>
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	1	1.0	0.0
<b>Rimegepant</b>	<b>286,197</b>	<b>1</b>	<b>8</b>	<b>30</b>	<b>30</b>	<b>382</b>	<b>21.7</b>	<b>11.4</b>
Female	247,882	1	8	30	30	382	21.7	11.4
Male	38,315	1	8	30	30	150	21.8	11.4

**Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Isatuximab</b>	<b>11,646</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>56</b>	<b>1.4</b>	<b>3.7</b>
Female	5,641	1	1	1	1	56	1.4	4.0
Male	6,005	1	1	1	1	56	1.3	3.4
<b>Osilodrostat</b>	<b>1,040</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>30.5</b>	<b>13.6</b>
Female	857	1	30	30	30	90	30.3	13.4
Male	183	1	30	30	30	90	31.6	14.2
<b>Ozanimod</b>	<b>5,959</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>127</b>	<b>30.6</b>	<b>13.4</b>
Female	4,272	1	30	30	30	97	30.7	13.4
Male	1,687	1	30	30	30	127	30.6	13.5
<b>Selumetinib</b>	<b>1,456</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>33.5</b>	<b>12.9</b>
Female	716	1	30	30	30	60	33.4	12.5
Male	740	1	30	30	30	90	33.6	13.2
<b>Tucatinib</b>	<b>7,376</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>120</b>	<b>30.0</b>	<b>8.0</b>
Female	7,284	1	30	30	30	120	30.0	8.0
Male	92	3	30	30	30	60	28.6	7.2



**Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Pemigatinib</b>	<b>1,780</b>	<b>1</b>	<b>14</b>	<b>21</b>	<b>21</b>	<b>63</b>	<b>18.1</b>	<b>4.7</b>
Female	1,165	2	14	21	21	49	18.4	4.4
Male	615	1	14	21	21	63	17.6	5.3
<b>Sacituzumab Govitecan Hziy</b>	<b>25,467</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>28</b>	<b>1.1</b>	<b>1.6</b>
Female	*****	1	1	1	1	28	1.1	1.6
Male	*****	1	1	1	1	21	1.0	0.6
<b>Opicapone</b>	<b>9,831</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>150</b>	<b>36.1</b>	<b>21.1</b>
Female	3,622	1	30	30	30	120	36.2	21.2
Male	6,209	1	30	30	30	150	36.1	21.0

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group

	Number of Dispensings by Days Supplied								
	1-30 Days		31-60 Days		61-90 Days		91+ Days		
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<b>Avapritinib</b>	<b>820</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	372	368	45.2%	*****	*****	0	NaN	0	NaN
≥ 65 years	385	384	47.1%	*****	*****	0	NaN	0	NaN
<b>Teprotumumab Trbw</b>	<b>18,143</b>	*****	*****	<b>0</b>	<b>NaN</b>	*****	*****	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	*****	0	NaN	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	0.0%	0	NaN
25-40 years	1,268	1,268	7.0%	0	NaN	0	0.0%	0	NaN
41-64 years	6,468	6,468	35.7%	0	NaN	0	0.0%	0	NaN
≥ 65 years	10,203	*****	56.2%	0	NaN	*****	*****	0	NaN
<b>Tazemetostat</b>	<b>956</b>	*****	<b>100.0%</b>	*****	*****	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	44	44	4.6%	0	0.0%	0	NaN	0	NaN
41-64 years	216	*****	22.5%	*****	*****	0	NaN	0	NaN
≥ 65 years	650	*****	68.0%	*****	*****	0	NaN	0	NaN

**Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Number of Dispensings by Days Supplied								
	1-30 Days		31-60 Days		61-90 Days		91+ Days		
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<b>Lactitol</b>	<b>0</b>	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-
<b>Bempedoic Acid</b>	<b>47,807</b>	<b>35,300</b>	<b>100.0%</b>	<b>1,333</b>	<b>100.0%</b>	<b>11,163</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>
0-17 years	*****	*****	*****	0	0.00%	0	0.00%	0	0.0%
18-24 years	*****	*****	*****	0	0.00%	0	0.00%	0	0.0%
25-40 years	689	555	1.6%	13	1.00%	121	1.10%	0	0.0%
41-64 years	14,445	11,108	31.5%	354	26.60%	2,976	26.70%	*****	*****
≥ 65 years	32,656	23,620	66.9%	966	72.50%	8,066	72.30%	*****	*****
<b>Eptinezumab Jjmr</b>	<b>15,707</b>	<b>14,737</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>899</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>
0-17 years	*****	*****	*****	*****	0.0%	0	0.0%	0	0.0%
18-24 years	*****	417	2.8%	*****	*****	*****	*****	0	0.0%
25-40 years	2,531	2,441	16.6%	*****	*****	86	9.6%	0	0.0%
41-64 years	7,442	6,874	46.6%	42	60.9%	524	58.3%	*****	*****
≥ 65 years	5,280	4,974	33.8%	*****	30.4%	285	31.7%	*****	*****

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group

	Number of Dispensings by Days Supplied								
	1-30 Days		31-60 Days		61-90 Days		91+ Days		
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<b>Amisulpride</b>	<b>306</b>	*****	*****	<b>0</b>	NaN	<b>0</b>	NaN	<b>0</b>	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	81	81	26.5%	0	NaN	0	NaN	0	NaN
41-64 years	162	162	52.9%	0	NaN	0	NaN	0	NaN
≥ 65 years	45	45	14.7%	0	NaN	0	NaN	0	NaN
<b>Rimegepant</b>	<b>286,197</b>	<b>276,954</b>	<b>100.0%</b>	<b>7,584</b>	<b>100.0%</b>	<b>1,647</b>	<b>100.0%</b>	<b>12</b>	<b>100.00%</b>
0-17 years	1,088	1,058	0.40%	24	0.30%	*****	*****	0	0.0%
18-24 years	12,229	11,987	4.30%	214	2.80%	*****	*****	*****	*****
25-40 years	71,513	69,831	25.20%	1,443	19.00%	236	14.3%	*****	*****
41-64 years	161,786	156,854	56.6%	4,080	53.8%	845	51.3%	*****	*****
≥ 65 years	39,581	37,224	13.4%	1,823	24.0%	534	32.4%	0	0.0%
<b>Isatuximab</b>	<b>11,646</b>	<b>11,612</b>	<b>100.0%</b>	<b>34</b>	<b>100.0%</b>	<b>0</b>	NaN	<b>0</b>	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	*****	2,312	19.9%	*****	*****	0	NaN	0	NaN
≥ 65 years	9,289	9,259	79.7%	*****	*****	0	NaN	0	NaN

**Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Number of Dispensings by Days Supplied								
	1-30 Days		31-60 Days		61-90 Days		91+ Days		
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<b>Osilodrostat</b>	<b>1,040</b>	<b>969</b>	<b>100.0%</b>	<b>34</b>	<b>100.0%</b>	<b>37</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	191	164	16.9%	16	47.1%	*****	*****	0	NaN
41-64 years	412	392	40.5%	*****	*****	*****	*****	0	NaN
≥ 65 years	355	331	34.2%	*****	*****	18	48.6%	0	NaN
<b>Ozanimod</b>	<b>5,959</b>	<b>5,419</b>	<b>100.0%</b>	<b>301</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	1,498	1,365	25.2%	72	23.9%	60	25.5%	*****	*****
41-64 years	3,471	3,169	58.5%	176	58.5%	124	52.8%	*****	*****
≥ 65 years	754	658	12.1%	*****	*****	*****	*****	*****	*****
<b>Selumetinib</b>	<b>1,456</b>	<b>1,199</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN</b>
0-17 years	623	516	43.0%	106	41.9%	*****	*****	0	NaN
18-24 years	250	214	17.8%	*****	*****	0	0.0%	0	NaN
25-40 years	341	292	24.4%	49	19.4%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	59	23.3%	*****	*****	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN

**Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Number of Dispensings by Days Supplied								
	1-30 Days		31-60 Days		61-90 Days		91+ Days		
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<b>Tucatinib</b>	<b>7,376</b>	<b>7,018</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	3,939	3,733	53.2%	202	57.4%	*****	*****	0	0.0%
≥ 65 years	2,721	2,593	36.9%	*****	*****	*****	*****	*****	*****
<b>Pemigatinib</b>	<b>1,780</b>	<b>*****</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
≥ 65 years	1,086	1,078	60.8%	*****	*****	*****	*****	0	NaN
<b>Sacituzumab Govitecan Hziy</b>	<b>25,467</b>	<b>25,467</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	8,143	8,143	32.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	16,367	16,367	64.3%	0	NaN	0	NaN	0	NaN

**Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Number of Dispensings by Days Supplied								
	1-30 Days		31-60 Days		61-90 Days		91+ Days		
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<b>Opicapone</b>	<b>9,831</b>	<b>8,348</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>1,236</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
41-64 years	*****	1,183	14.2%	*****	*****	*****	*****	0	0.0%
≥ 65 years	8,451	7,135	85.5%	*****	*****	1,108	89.6%	*****	*****

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Distribution of Days Supplied by Dispensing							
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Avapritinib</b>	<b>820</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>28.9</b>	<b>5.2</b>
0-17 years	*****	30	30	30	30	30	30.0	0.0
18-24 years	*****	30	30	30	30	30	30.0	0.0
25-40 years	*****	4	30	30	30	30	28.3	5.5
41-64 years	372	2	30	30	30	60	28.7	6.1
≥ 65 years	385	1	30	30	30	60	29.2	4.1
<b>Teprotumumab Trbw</b>	<b>18,143</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>84</b>	<b>2.5</b>	<b>5.5</b>
0-17 years	*****	1	1	1	1	16	2.0	3.9
18-24 years	*****	1	1	1	1	21	2.0	4.3
25-40 years	1,268	1	1	1	1	21	1.2	1.8
41-64 years	6,468	1	1	1	1	30	2.2	4.7
≥ 65 years	10,203	1	1	1	1	84	2.9	6.1
<b>Tazemetostat</b>	<b>956</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>40</b>	<b>28.4</b>	<b>5.2</b>
0-17 years	*****	4	30	30	30	30	28.3	5.9
18-24 years	*****	14	30	30	30	30	28.7	4.1
25-40 years	44	4	23	30	30	30	25.8	7.4
41-64 years	216	1	30	30	30	40	27.5	6.5
≥ 65 years	650	1	30	30	30	38	28.9	4.4
<b>Lactitol</b>	<b>0</b>	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-



**Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Distribution of Days Supplied by Dispensing							
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Bempedoic Acid</b>	<b>47,807</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>46</b>	<b>180</b>	<b>43.2</b>	<b>25.9</b>
0-17 years	*****	30	30	30	30	30	30.0	0.0
18-24 years	*****	3	3	30	30	30	21.0	15.6
25-40 years	689	2	30	30	30	90	39.6	23.2
41-64 years	14,445	1	30	30	30	180	41.4	24.9
≥ 65 years	32,656	1	30	30	60	142	44.1	26.3
<b>Eptinezumab Jjmr</b>	<b>15,707</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>180</b>	<b>6.6</b>	<b>20.3</b>
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	84	2.5	9.1
25-40 years	2,531	1	1	1	1	90	4.3	15.5
41-64 years	7,442	1	1	1	1	180	7.9	22.4
≥ 65 years	5,280	1	1	1	1	90	6.1	19.7
<b>Amisulpride</b>	<b>306</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1.0</b>	<b>0.0</b>
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	81	1	1	1	1	1	1.0	0.0
41-64 years	162	1	1	1	1	1	1.0	0.0
≥ 65 years	45	1	1	1	1	1	1.0	0.0
<b>Rimegepant</b>	<b>286,197</b>	<b>1</b>	<b>8</b>	<b>30</b>	<b>30</b>	<b>382</b>	<b>21.7</b>	<b>11.4</b>
0-17 years	1,088	1	8	30	30	90	21.7	11.5
18-24 years	12,229	1	8	30	30	120	21.9	10.5
25-40 years	71,513	1	8	30	30	161	21.7	10.9
41-64 years	161,786	1	8	30	30	382	21.6	11.3
≥ 65 years	39,581	1	8	28	30	90	22.0	12.7

**Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Distribution of Days Supplied by Dispensing							
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Isatuximab</b>	<b>11,646</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>56</b>	<b>1.4</b>	<b>3.7</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	56	1.2	2.7
≥ 65 years	9,289	1	1	1	1	56	1.4	3.9
<b>Osilodrostat</b>	<b>1,040</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>30.5</b>	<b>13.6</b>
0-17 years	*****	15	27	30	30	30	26.4	6.5
18-24 years	*****	14	30	30	30	30	29.4	2.7
25-40 years	191	1	30	30	30	90	33.8	16.6
41-64 years	412	1	30	30	30	90	29.4	11.6
≥ 65 years	355	1	26	30	30	90	30.4	15.1
<b>Ozanimod</b>	<b>5,959</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>127</b>	<b>30.6</b>	<b>13.4</b>
0-17 years	*****	30	30	30	30	30	30.0	0.0
18-24 years	*****	2	30	30	30	69	28.5	7.1
25-40 years	1,498	1	30	30	30	127	30.6	13.6
41-64 years	3,471	1	30	30	30	97	30.3	13.0
≥ 65 years	754	1	30	30	30	97	32.9	16.1
<b>Selumetinib</b>	<b>1,456</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>33.5</b>	<b>12.9</b>
0-17 years	623	1	30	30	30	90	33.0	12.8
18-24 years	250	1	30	30	30	60	32.8	11.3
25-40 years	341	1	30	30	30	60	32.6	11.6
41-64 years	*****	4	30	30	56	90	37.5	16.3
≥ 65 years	*****	7	30	30	30	60	31.8	9.2

**Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Distribution of Days Supplied by Dispensing							
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Tucatinib</b>	<b>7,376</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>120</b>	<b>30.0</b>	<b>8.0</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	8	8	25	30	30	21.0	11.5
25-40 years	*****	1	30	30	30	60	29.6	7.0
41-64 years	3,939	1	30	30	30	90	30.1	8.2
≥ 65 years	2,721	1	30	30	30	120	29.9	7.9
<b>Pemigatinib</b>	<b>1,780</b>	<b>1</b>	<b>14</b>	<b>21</b>	<b>21</b>	<b>63</b>	<b>18.1</b>	<b>4.7</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	3	14	14	21	28	16.6	4.0
41-64 years	*****	1	14	21	21	30	17.7	4.3
≥ 65 years	1,086	2	14	21	21	63	18.5	4.9
<b>Sacituzumab Govitecan Hziy</b>	<b>25,467</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>28</b>	<b>1.1</b>	<b>1.6</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	8,143	1	1	1	1	21	1.1	1.5
≥ 65 years	16,367	1	1	1	1	28	1.1	1.6

**Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Distribution of Days Supplied by Dispensing							
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Opicapone</b>	<b>9,831</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>30</b>	<b>150</b>	<b>36.1</b>	<b>21.1</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	7	30	30	30	83	30.8	10.6
41-64 years	*****	1	30	30	30	90	33.9	19.0
≥ 65 years	8,451	1	30	30	30	150	36.5	21.4

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 3a. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**

	Number of Patients by Cumulative Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Avapritinib	165	*****	*****	58	35.2%	75	45.5%	*****	*****	*****	*****
Teprotumumab Trbw	2,989	2,785	93.2%	*****	*****	156	5.2%	*****	*****	0	0.0%
Tazemetostat	212	47	22.2%	76	35.8%	75	35.4%	*****	*****	*****	*****
Lactitol	0	-	-	-	-	-	-	-	-	-	-
Bempedoic Acid	11,324	2,124	18.8%	2,923	25.8%	4,715	41.6%	1,535	13.60%	27	0.20%
Eptinezumab Jjmr	5,619	5,167	92.0%	159	2.80%	235	4.2%	58	1.00%	0	0.0%
Amisulpride	301	301	100.00%	0	0.00%	0	0.0%	0	0.0%	0	0.0%
Rimegepant	71,338	29,187	40.9%	20,589	28.9%	19,713	27.6%	*****	*****	*****	*****
Isatuximab	1,059	979	92.4%	60	5.7%	*****	*****	*****	*****	0	0.0%
Osilodrostat	164	27	16.5%	46	28.0%	62	37.8%	*****	*****	*****	*****
Ozanimod	923	*****	*****	216	23.4%	448	48.5%	*****	*****	0	0.0%
Selumetinib	203	*****	*****	38	18.7%	100	49.3%	40	19.7%	*****	*****
Tucatinib	1,317	254	19.3%	348	26.4%	560	42.5%	*****	*****	*****	*****
Pemigatinib	275	*****	*****	89	32.4%	114	41.5%	*****	*****	0	0.0%
Sacituzumab Govitecan Hziy	2,587	2,461	95.1%	*****	*****	*****	*****	*****	*****	0	0.0%
Opicapone	2,125	516	24.30%	528	24.80%	788	37.10%	293	13.80%	0	0.00%

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

**Table 3b. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**

	Distribution of Cumulative Treatment Episode Duration, Days							Standard Deviation
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	
Avapritinib	165	2	60	90	203	870	143.7	136.2
Teprotumumab Trbw	2,989	1	4	8	8	588	15.2	36.5
Tazemetostat	212	2	44	90	150	762	128.0	135.2
Lactitol	0	-	-	-	-	-	-	-
Bempedoic Acid	11,324	1	60	120	270	815	182.5	159.9
Eptinezumab Jjmr	5,619	1	1	2	5	721	18.4	66.4
Amisulpride	301	1	1	1	1	3	1.0	0.2
Rimegepant	71,338	1	26	48	120	794	87.1	99.5
Isatuximab	1,059	1	5	8	16	413	14.9	29.3
Osilodrostat	164	4	60	120	303	765	193.5	181.3
Ozanimod	923	2	67	152	301	685	197.9	158.0
Selumetinib	203	3	84	210	334	778	240.3	191.5
Tucatinib	1,317	1	60	120	236	759	168.0	156.0
Pemigatinib	275	1	36	84	164	722	117.4	113.4
Sacituzumab Govitecan Hziy	2,587	1	3	7	14	525	11.0	20.7
Opicapone	2,125	1	36	102	264	641	167.2	154.0

le

Table 3c. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex

	Number of Patients by Cumulative Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Avapritinib</b>	<b>165</b>	<b>****</b>	<b>****</b>	<b>58</b>	<b>100.0%</b>	<b>75</b>	<b>100.0%</b>	<b>****</b>	<b>****</b>	<b>****</b>	<b>****</b>
Female	81	****	****	32	55.2%	34	45.3%	****	****	****	****
Male	84	****	****	26	44.8%	41	54.7%	****	****	****	****
<b>Teprotumumab Trbw</b>	<b>2,989</b>	<b>2,785</b>	<b>100.0%</b>	<b>****</b>	<b>****</b>	<b>156</b>	<b>100.0%</b>	<b>****</b>	<b>****</b>	<b>0</b>	<b>NaN</b>
Female	2,313	2,161	77.6%	****	****	115	73.7%	****	****	0	NaN
Male	676	624	22.4%	****	****	41	26.3%	****	****	0	NaN
<b>Tazemetostat</b>	<b>212</b>	<b>47</b>	<b>100.0%</b>	<b>76</b>	<b>100.0%</b>	<b>75</b>	<b>100.0%</b>	<b>****</b>	<b>****</b>	<b>****</b>	<b>****</b>
Female	97	23	48.9%	30	39.5%	40	53.3%	****	****	****	****
Male	115	24	51.1%	46	60.5%	35	46.7%	****	****	****	****
<b>Lactitol</b>	<b>0</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
Female	0	-	-	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-	-	-
<b>Bempezoic Acid</b>	<b>11,324</b>	<b>2,124</b>	<b>100.00%</b>	<b>2,923</b>	<b>100.00%</b>	<b>4,715</b>	<b>100.00%</b>	<b>1,535</b>	<b>100.00%</b>	<b>27</b>	<b>100.00%</b>
Female	6,794	1,315	61.90%	1,791	61.30%	2,784	59.00%	888	57.90%	16	59.30%
Male	4,530	809	38.10%	1,132	38.70%	1,931	41.00%	647	42.10%	11	40.70%
<b>Eptinezumab Jjmr</b>	<b>5,619</b>	<b>5,167</b>	<b>100.00%</b>	<b>159</b>	<b>100.00%</b>	<b>235</b>	<b>100.00%</b>	<b>58</b>	<b>100.00%</b>	<b>0</b>	<b>NaN</b>
Female	4,665	4,302	83.30%	123	77.40%	193	82.10%	47	81.00%	0	NaN
Male	954	865	16.70%	36	22.60%	42	17.90%	11	19.00%	0	NaN
<b>Amisulpride</b>	<b>301</b>	<b>301</b>	<b>100.00%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	239	239	79.40%	0	NaN	0	NaN	0	NaN	0	NaN
Male	62	62	20.60%	0	NaN	0	NaN	0	NaN	0	NaN

**Table 3c. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

	Number of Patients by Cumulative Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Rimegepant</b>	<b>71,338</b>	<b>29,187</b>	<b>100.0%</b>	<b>20,589</b>	<b>100.0%</b>	<b>19,713</b>	<b>100.0%</b>	*****	*****	*****	*****
Female	61,031	24,566	84.2%	17,704	86.0%	17,164	87.1%	*****	*****	*****	*****
Male	10,307	4,621	15.8%	2,885	14.0%	2,549	12.9%	*****	*****	*****	*****
<b>Isatuximab</b>	<b>1,059</b>	<b>979</b>	<b>100.0%</b>	<b>60</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
Female	509	465	47.5%	34	56.7%	*****	*****	*****	*****	0	NaN
Male	550	514	52.5%	26	43.3%	*****	*****	*****	*****	0	NaN
<b>Osilodrostat</b>	<b>164</b>	<b>27</b>	<b>100.00%</b>	<b>46</b>	<b>100.0%</b>	<b>62</b>	<b>100.0%</b>	<b>28</b>	<b>100.0%</b>	*****	*****
Female	*****	*****	*****	*****	*****	49	79.0%	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	13	21.0%	*****	*****	*****	*****
<b>Ozanimod</b>	<b>923</b>	<b>103</b>	<b>100.00%</b>	<b>216</b>	<b>100.00%</b>	<b>448</b>	<b>100.00%</b>	<b>156</b>	<b>100.00%</b>	<b>0</b>	<b>NaN</b>
Female	648	72	69.90%	147	68.1%	313	69.9%	116	74.40%	0	NaN
Male	275	31	30.10%	69	31.9%	135	30.1%	40	25.60%	0	NaN
<b>Selumetinib</b>	<b>203</b>	*****	*****	<b>38</b>	<b>100.0%</b>	<b>100</b>	<b>100.0%</b>	<b>40</b>	<b>100.0%</b>	*****	*****
Female	102	*****	*****	18	47.4%	50	50.0%	19	47.5%	*****	*****
Male	101	*****	*****	20	52.6%	50	50.0%	21	52.5%	*****	*****
<b>Tucatinib</b>	<b>1,317</b>	<b>254</b>	<b>100.0%</b>	<b>348</b>	<b>100.0%</b>	<b>560</b>	<b>100.0%</b>	*****	*****	*****	*****
Female	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
<b>Pemigatinib</b>	<b>275</b>	*****	*****	<b>89</b>	<b>100.0%</b>	<b>114</b>	<b>100.0%</b>	*****	*****	<b>0</b>	<b>NaN</b>
Female	164	*****	*****	59	66.3%	70	61.4%	*****	*****	0	NaN
Male	111	*****	*****	30	33.7%	44	38.6%	*****	*****	0	NaN



**Table 3c. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

	Number of Patients by Cumulative Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Sacituzumab Govitecan Hziy</b>	<b>2,587</b>	<b>2,461</b>	<b>100.0%</b>	*****	*****	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
Female	*****	2,096	85.2%	*****	*****	*****	*****	*****	*****	0	NaN
Male	*****	365	14.8%	*****	*****	*****	*****	*****	*****	0	NaN
<b>Opicapone</b>	<b>2,125</b>	<b>516</b>	<b>100.00%</b>	<b>528</b>	<b>100.00%</b>	<b>788</b>	<b>100.00%</b>	<b>293</b>	<b>100.00%</b>	<b>0</b>	<b>NaN</b>
Female	827	232	45.00%	197	37.30%	297	37.70%	101	34.50%	0	NaN
Male	1,298	284	55.00%	331	62.70%	491	62.30%	192	65.50%	0	NaN

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented. Data presented by a dash or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 3d. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

	Distribution of Cumulative Treatment Episode Duration, Days							Standard Deviation
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Avapritinib</b>	<b>165</b>	<b>2</b>	<b>60</b>	<b>90</b>	<b>203</b>	<b>870</b>	<b>143.7</b>	<b>136.2</b>
Female	81	2	60	90	180	870	138.1	144.5
Male	84	4	60	106	218	699	149.0	128.4
<b>Teprotumumab Trbw</b>	<b>2,989</b>	<b>1</b>	<b>4</b>	<b>8</b>	<b>8</b>	<b>588</b>	<b>15.2</b>	<b>36.5</b>
Female	2,313	1	4	8	8	220	14.5	34.1
Male	676	1	4	8	8	588	17.3	43.8
<b>Tazemetostat</b>	<b>212</b>	<b>2</b>	<b>44</b>	<b>90</b>	<b>150</b>	<b>762</b>	<b>128.0</b>	<b>135.2</b>
Female	97	2	42	90	165	539	122.6	109.2
Male	115	4	47	88	146	762	132.5	154.2
<b>Lactitol</b>	<b>0</b>	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
<b>Bempeoic Acid</b>	<b>11,324</b>	<b>1</b>	<b>60</b>	<b>120</b>	<b>270</b>	<b>815</b>	<b>182.5</b>	<b>159.9</b>
Female	6,794	1	60	120	270	791	178.4	158.3
Male	4,530	1	60	138	271	815	188.7	162.1
<b>Eptinezumab Jjmr</b>	<b>5,619</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>5</b>	<b>721</b>	<b>18.4</b>	<b>66.4</b>
Female	4,665	1	1	2	5	721	18.1	66.1
Male	954	1	1	2	5	672	20.0	68.2
<b>Amisulpride</b>	<b>301</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>1.0</b>	<b>0.2</b>
Female	239	1	1	1	1	3	1.0	0.2
Male	62	1	1	1	1	2	1.0	0.1
<b>Rimegepant</b>	<b>71,338</b>	<b>1</b>	<b>26</b>	<b>48</b>	<b>120</b>	<b>794</b>	<b>87.1</b>	<b>99.5</b>
Female	61,031	1	27	50	120	782	88.1	100.0
Male	10,307	1	24	39	102	794	81.1	96.4

**Table 3d. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

	Distribution of Cumulative Treatment Episode Duration, Days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Isatuximab</b>	<b>1,059</b>	<b>1</b>	<b>5</b>	<b>8</b>	<b>16</b>	<b>413</b>	<b>14.9</b>	<b>29.3</b>
Female	509	1	5	8	16	413	15.4	31.9
Male	550	1	4	9	16	322	14.3	26.7
<b>Osilodrostat</b>	<b>164</b>	<b>4</b>	<b>60</b>	<b>120</b>	<b>303</b>	<b>765</b>	<b>193.5</b>	<b>181.3</b>
Female	*****	4	60	120	315	765	195.2	180.6
Male	*****	8	31	120	291	690	186.3	186.8
<b>Ozanimod</b>	<b>923</b>	<b>2</b>	<b>67</b>	<b>152</b>	<b>301</b>	<b>685</b>	<b>197.9</b>	<b>158.0</b>
Female	648	3	67	157	312	666	202.3	160.4
Male	275	2	65	137	277	685	187.4	152.1
<b>Selumetinib</b>	<b>203</b>	<b>3</b>	<b>84</b>	<b>210</b>	<b>334</b>	<b>778</b>	<b>240.3</b>	<b>191.5</b>
Female	102	5	64	210	334	778	234.7	188.2
Male	101	3	90	210	332	765	246.0	195.6
<b>Tucatinib</b>	<b>1,317</b>	<b>1</b>	<b>60</b>	<b>120</b>	<b>236</b>	<b>759</b>	<b>168.0</b>	<b>156.0</b>
Female	*****	1	60	120	240	759	169.2	156.4
Male	*****	3	30	75	150	584	105.4	117.6
<b>Pemigatinib</b>	<b>275</b>	<b>1</b>	<b>36</b>	<b>84</b>	<b>164</b>	<b>722</b>	<b>117.4</b>	<b>113.4</b>
Female	164	3	42	85	168	722	130.9	124.8
Male	111	1	21	70	127	410	97.5	91.0
<b>Sacituzumab Govitecan Hziy</b>	<b>2,587</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>14</b>	<b>525</b>	<b>11.0</b>	<b>20.7</b>
Female	*****	1	3	7	15	525	11.7	22.1
Male	*****	1	2	5	10	42	7.1	6.7
<b>Opicapone</b>	<b>2,125</b>	<b>1</b>	<b>36</b>	<b>102</b>	<b>264</b>	<b>641</b>	<b>167.2</b>	<b>154.0</b>
Female	827	2	30	90	240	625	158.6	152.0
Male	1,298	1	45	115	270	641	172.7	155.0

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

**Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Number of Patients by Cumulative Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Avapritinib</b>	<b>165</b>	*****	*****	<b>58</b>	<b>100.0%</b>	<b>75</b>	<b>100.0%</b>	*****	*****	*****	*****
0-17 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	62	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	90	*****	*****	32	55.2%	38	50.7%	*****	*****	0	0.0%
<b>Teprotumumab Trbw</b>	<b>2,989</b>	<b>2,785</b>	<b>100.0%</b>	*****	*****	<b>156</b>	<b>100.0%</b>	*****	*****	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
25-40 years	217	215	7.7%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	1,047	988	35.5%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	1,691	1,549	55.6%	34	72.3%	107	68.6%	*****	*****	0	NaN
<b>Tazemetostat</b>	<b>212</b>	<b>47</b>	<b>100.0%</b>	<b>76</b>	<b>100.0%</b>	<b>75</b>	<b>100.0%</b>	*****	*****	*****	*****
0-17 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	43	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	146	32	68.1%	54	71.1%	50	66.7%	*****	*****	0	0.0%

**Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Number of Patients by Cumulative Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
<b>Lactitol</b>	<b>0</b>	-	-	-	-	-	-	-	-	-	
0-17 years	0	-	-	-	-	-	-	-	-	-	
18-24 years	0	-	-	-	-	-	-	-	-	-	
25-40 years	0	-	-	-	-	-	-	-	-	-	
41-64 years	0	-	-	-	-	-	-	-	-	-	
≥ 65 years	0	-	-	-	-	-	-	-	-	-	
<b>Bempedoic Acid</b>	<b>11,324</b>	<b>2,124</b>	<b>100.0%</b>	<b>2,923</b>	<b>100.0%</b>	<b>4,715</b>	<b>100.0%</b>	<b>1,535</b>	<b>100.0%</b>	<b>27</b>	<b>100.0%</b>
0-17 years	*****	*****	0.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%
18-24 years	*****	*****	0.1%	0	0.0%	0	0.0%	*****	*****	0	0.0%
25-40 years	*****	*****	0.9%	36	1.2%	76	1.6%	*****	*****	0	0.0%
41-64 years	3,338	572	26.9%	862	29.5%	1,482	31.4%	419	27.3%	*****	*****
≥ 65 years	7,836	1,530	72.0%	2,025	69.3%	3,157	67.0%	1,100	71.7%	*****	*****
<b>Eptinezumab Jjmr</b>	<b>5,619</b>	<b>5,167</b>	<b>100.0%</b>	<b>159</b>	<b>100.0%</b>	<b>235</b>	<b>100.0%</b>	<b>58</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	0.2%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	3.2%	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	928	876	17.0%	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	2,663	2,413	46.7%	80	50.3%	130	55.3%	40	69.0%	0	NaN
≥ 65 years	1,847	1,704	33.0%	49	30.8%	80	34.0%	*****	*****	0	NaN

**Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Number of Patients by Cumulative Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Amisulpride</b>	<b>301</b>	*****	*****	<b>0</b>	NaN	<b>0</b>	NaN	<b>0</b>	NaN	<b>0</b>	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	80	80	26.6%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	158	158	52.5%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
<b>Rimegepant</b>	<b>71,338</b>	<b>29,187</b>	<b>100.0%</b>	<b>20,589</b>	<b>100.0%</b>	<b>19,713</b>	<b>100.0%</b>	*****	*****	*****	*****
0-17 years	356	161	*****	123	0.6%	68	0.3%	*****	*****	0	0.0%
18-24 years	3,660	1,683	*****	1,078	5.2%	842	4.3%	*****	*****	0	0.0%
25-40 years	17,365	6,831	23.4%	5,120	24.9%	4,964	25.2%	447	24.4%	*****	*****
41-64 years	37,752	14,468	49.6%	10,918	53.0%	11,233	57.0%	1,123	61.3%	*****	*****
≥ 65 years	12,205	6,044	20.7%	3,350	16.3%	2,606	13.2%	201	11.0%	*****	*****
<b>Isatuximab</b>	<b>1,059</b>	<b>979</b>	<b>100.0%</b>	<b>60</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	*****	*****	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	*****	*****	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	*****	*****	0	NaN
41-64 years	*****	*****	*****	11	18.3%	*****	*****	*****	*****	0	NaN
≥ 65 years	840	774	79.1%	49	81.7%	*****	*****	*****	*****	0	NaN

**Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Number of Patients by Cumulative Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Osilodrostat</b>	<b>164</b>	<b>27</b>	<b>100.0%</b>	<b>46</b>	<b>100.0%</b>	<b>62</b>	<b>100.0%</b>	<b>*****</b>	<b>100.0%</b>	<b>1</b>	<b>100.0%</b>
0-17 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	0	0.0%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	69	*****	*****	25	54.3%	28	45.2%	*****	*****	0	0.0%
≥ 65 years	60	16	59.3%	14	30.4%	18	29.0%	12	42.9%	0	0.0%
<b>Ozanimod</b>	<b>923</b>	<b>*****</b>	<b>*****</b>	<b>216</b>	<b>100.0%</b>	<b>448</b>	<b>100.0%</b>	<b>156</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
0-17 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	245	31	30.1%	55	25.5%	119	26.6%	40	25.6%	0	NaN
41-64 years	528	57	55.3%	132	61.1%	247	55.1%	92	59.0%	0	NaN
≥ 65 years	119	*****	10.7%	*****	*****	62	13.8%	*****	*****	0	NaN
<b>Selumetinib</b>	<b>203</b>	<b>*****</b>	<b>*****</b>	<b>38</b>	<b>100.0%</b>	<b>100</b>	<b>100.0%</b>	<b>40</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>
0-17 years	89	*****	*****	15	39.5%	49	49.0%	17	42.5%	*****	*****
18-24 years	32	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	41	*****	*****	*****	*****	20	20.0%	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	15	15.0%	*****	*****	0	0.0%
≥ 65 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%

**Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Number of Patients by Cumulative Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Tucatinib</b>	<b>1,317</b>	<b>254</b>	<b>100.0%</b>	<b>348</b>	<b>100.0%</b>	<b>560</b>	<b>100.0%</b>	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	58	10.4%	*****	*****	*****	*****
41-64 years	679	120	47.2%	169	48.6%	303	54.1%	85	56.3%	*****	*****
≥ 65 years	519	117	46.1%	148	42.5%	199	35.5%	*****	*****	*****	*****
<b>Pemigatinib</b>	<b>275</b>	*****	*****	<b>89</b>	<b>100.0%</b>	<b>114</b>	<b>100.0%</b>	*****	*****	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	177	36	59.0%	63	70.8%	72	63.2%	*****	*****	0	NaN
<b>Sacituzumab Govitecan Hziy</b>	<b>2,587</b>	<b>2,461</b>	<b>100.0%</b>	*****	*****	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	869	828	33.6%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	1,602	1,520	61.8%	76	65.5%	*****	*****	*****	*****	0	NaN



**Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Number of Patients by Cumulative Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Opicapone</b>	<b>2,125</b>	<b>516</b>	<b>100.0%</b>	<b>528</b>	<b>100.0%</b>	<b>788</b>	<b>100.0%</b>	<b>293</b>	<b>100.0%</b>	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	0	0.0%	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	1,854	*****	*****	455	86.2%	687	87.2%	251	85.7%	0	NaN

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

Distribution of Cumulative Treatment Episode Duration, Days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Avapritinib</b>	<b>165</b>	<b>2</b>	<b>60</b>	<b>90</b>	<b>203</b>	<b>870</b>	<b>143.7</b>	<b>136.2</b>
0-17 years	*****	180	180	180	180	180	180.0	NaN
18-24 years	*****	90	90	90	90	90	90.0	NaN
25-40 years	*****	18	46	120	154	356	138.9	118.3
41-64 years	62	2	60	121	263	870	172.3	164.3
≥ 65 years	90	13	60	90	173	699	124.7	114.6
<b>Teprotumumab Trbw</b>	<b>2,989</b>	<b>1</b>	<b>4</b>	<b>8</b>	<b>8</b>	<b>588</b>	<b>15.2</b>	<b>36.5</b>
0-17 years	*****	3	3	6	12	16	7.5	6.1
18-24 years	*****	1	5	8	8	168	12.3	29.6
25-40 years	217	1	3	7	8	168	6.8	11.7
41-64 years	1,047	1	4	8	8	290	13.5	32.1
≥ 65 years	1,691	1	4	8	8	588	17.3	40.9
<b>Tazemetostat</b>	<b>212</b>	<b>2</b>	<b>44</b>	<b>90</b>	<b>150</b>	<b>762</b>	<b>128.0</b>	<b>135.2</b>
0-17 years	*****	42	94	210	302	330	198.0	129.4
18-24 years	*****	14	37	60	221	382	129.0	170.1
25-40 years	15	16	30	52	120	210	75.6	58.7
41-64 years	43	4	39	90	180	762	137.9	147.3
≥ 65 years	146	2	51	90	150	684	128.5	136.4
<b>Lactitol</b>	<b>0</b>	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-

**Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

Distribution of Cumulative Treatment Episode Duration, Days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Bempedoic Acid</b>	<b>11,324</b>	<b>1</b>	<b>60</b>	<b>120</b>	<b>270</b>	<b>815</b>	<b>182.5</b>	<b>159.9</b>
0-17 years	*****	420	420	420	420	420	420.0	NaN
18-24 years	*****	3	3	30	30	30	21.0	15.6
25-40 years	*****	18	64	150	279	686	186.8	142.8
41-64 years	3,338	1	60	127	270	772	179.3	152.2
≥ 65 years	7,836	1	60	120	270	815	183.9	163.4
<b>Eptinezumab Jjmr</b>	<b>5,619</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>5</b>	<b>721</b>	<b>18.4</b>	<b>66.4</b>
0-17 years	*****	1	1	2	4	8	2.8	2.0
18-24 years	*****	1	1	2	3	168	6.1	18.9
25-40 years	928	1	1	2	4	528	11.7	46.5
41-64 years	2,663	1	1	2	5	672	22.1	75.6
≥ 65 years	1,847	1	1	3	5	721	17.5	63.3
<b>Amisulpride</b>	<b>301</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>1.0</b>	<b>0.2</b>
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	80	1	1	1	1	2	1.0	0.1
41-64 years	158	1	1	1	1	3	1.0	0.2
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
<b>Rimegepant</b>	<b>71,338</b>	<b>1</b>	<b>26</b>	<b>48</b>	<b>120</b>	<b>794</b>	<b>87.1</b>	<b>99.5</b>
0-17 years	*****	1	24	37	82	512	66.4	76.2
18-24 years	*****	1	24	38	90	689	73.3	85.0
25-40 years	17,365	1	28	54	120	759	89.2	100.3
41-64 years	37,752	1	29	56	120	782	92.7	103.6
≥ 65 years	12,205	1	20	32	90	794	71.5	87.2

**Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Distribution of Cumulative Treatment Episode Duration, Days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Isatuximab</b>	<b>1,059</b>	<b>1</b>	<b>5</b>	<b>8</b>	<b>16</b>	<b>413</b>	<b>14.9</b>	<b>29.3</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	8	8	9	13	16	10.3	3.9
41-64 years	*****	1	5	8	16	143	12.6	16.2
≥ 65 years	840	1	4	9	16	413	15.5	31.9
<b>Osilodrostat</b>	<b>164</b>	<b>4</b>	<b>60</b>	<b>120</b>	<b>303</b>	<b>765</b>	<b>193.5</b>	<b>181.3</b>
0-17 years	*****	132	132	132	132	132	132.0	NaN
18-24 years	*****	44	150	330	476	622	323.9	191.8
25-40 years	*****	10	60	102	347	765	238.8	227.1
41-64 years	69	4	60	120	270	716	175.4	155.7
≥ 65 years	60	8	30	98	247	656	179.8	181.0
<b>Ozanimod</b>	<b>923</b>	<b>2</b>	<b>67</b>	<b>152</b>	<b>301</b>	<b>685</b>	<b>197.9</b>	<b>158.0</b>
0-17 years	*****	240	240	240	240	240	240.0	NaN
18-24 years	*****	2	97	206	278	630	216.5	159.9
25-40 years	245	3	62	141	275	586	187.4	149.5
41-64 years	528	3	65	152	306	685	199.2	161.3
≥ 65 years	119	7	73	168	329	599	208.5	161.5
<b>Selumetinib</b>	<b>203</b>	<b>3</b>	<b>84</b>	<b>210</b>	<b>334</b>	<b>778</b>	<b>240.3</b>	<b>191.5</b>
0-17 years	89	4	92	208	326	778	231.2	177.7
18-24 years	*****	13	65	198	415	763	256.4	222.7
25-40 years	41	3	90	245	360	765	271.5	210.6
41-64 years	*****	9	64	210	320	702	232.1	188.5
≥ 65 years	*****	60	60	139	225	300	150.9	92.2

**Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

Distribution of Cumulative Treatment Episode Duration, Days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Tucatinib</b>	<b>1,317</b>	<b>1</b>	<b>60</b>	<b>120</b>	<b>236</b>	<b>759</b>	<b>168.0</b>	<b>156.0</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	8	8	32	55	55	31.5	33.2
25-40 years	*****	1	60	146	233	749	180.2	156.5
41-64 years	679	2	60	120	240	759	174.7	158.1
≥ 65 years	519	4	46	90	210	735	157.0	152.8
<b>Pemigatinib</b>	<b>275</b>	<b>1</b>	<b>36</b>	<b>84</b>	<b>164</b>	<b>722</b>	<b>117.4</b>	<b>113.4</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	9	29	112	249	329	141.2	124.0
41-64 years	*****	1	28	84	182	455	121.9	111.7
≥ 65 years	177	3	38	77	142	722	113.6	113.9
<b>Sacituzumab Govitecan Hziy</b>	<b>2,587</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>14</b>	<b>525</b>	<b>11.0</b>	<b>20.7</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	2	2	2	1.5	0.7
25-40 years	*****	1	3	6	9	46	8.4	8.3
41-64 years	869	1	3	7	13	298	10.4	15.4
≥ 65 years	1,602	1	3	7	15	525	11.5	23.6
<b>Opicapone</b>	<b>2,125</b>	<b>1</b>	<b>36</b>	<b>102</b>	<b>264</b>	<b>641</b>	<b>167.2</b>	<b>154.0</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	60	60	102	157	474	159.0	158.8
41-64 years	*****	1	47	106	265	641	172.5	159.2
≥ 65 years	1,854	1	31	101	264	640	166.5	153.3

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**

	Number of Treatment Episodes by Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
Avapritinib	349	179	51.3%	107	30.7%	*****	*****	*****	*****	0	0.0%
Teprotumumab Trbw	17,185	16,911	98.4%	182	1.1%	*****	*****	*****	*****	0	0.0%
Tazemetostat	437	254	58.1%	118	27.0%	*****	*****	*****	*****	0	0.0%
Lactitol	0	-	-	-	-	-	-	-	-	-	-
Bempedoic Acid	25,112	11,577	46.1%	8,668	34.5%	4,348	17.3%	503	2.00%	16	0.10%
Eptinezumab Jjmr	15,196	14,500	95.4%	501	3.3%	*****	1.20%	*****	*****	0	0.0%
Amisulpride	306	306	100.00%	0	0.00%	0	0.0%	0	0.0%	0	0.0%
Rimegepant	207,166	172,576	83.3%	25,848	12.5%	8,296	4.0%	*****	*****	*****	*****
Isatuximab	11,363	11,334	99.7%	18	0.2%	*****	*****	*****	*****	0	0.0%
Osilodrostat	362	177	48.9%	101	27.9%	70	19.3%	*****	*****	*****	*****
Ozanimod	2,072	899	43.40%	633	30.60%	476	23.00%	64	3.10%	0	0.00%
Selumetinib	497	266	53.5%	102	20.5%	104	20.9%	*****	*****	*****	*****
Tucatinib	3,047	1,628	53.4%	853	28.0%	513	16.8%	*****	*****	*****	*****
Pemigatinib	944	673	71.3%	211	22.4%	*****	*****	*****	*****	0	0.0%
Sacituzumab Govitecan Hziy	25,276	25,249	99.9%	*****	*****	*****	*****	0	0.0%	0	0.0%
Opicapone	4,194	2,035	48.50%	1,235	29.40%	797	19.00%	127	3.00%	0	0.00%

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

**Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**

Distribution of Treatment Episode Durations, Days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Avapritinib	349	1	30	30	90	480	67.9	66.7
Teprotumumab Trbw	17,185	1	1	1	1	588	2.6	12.7
Tazemetostat	437	2	30	30	61	510	62.1	63.4
Lactitol	0	-	-	-	-	-	-	-
Bempedoic Acid	25,112	1	30	60	90	815	82.3	88.9
Eptinezumab Jjmr	15,196	1	1	1	1	630	6.8	29.8
Amisulpride	306	1	1	1	1	1	1.0	0.0
Rimegepant	207,166	1	8	24	30	757	30.0	40.8
Isatuximab	11,363	1	1	1	1	413	1.4	7.1
Osilodrostat	362	1	30	32	90	765	87.7	115.8
Ozanimod	2,072	1	30	40	97	666	88.1	102.3
Selumetinib	497	1	30	30	99	743	98.2	131.7
Tucatinib	3,047	1	30	30	90	759	72.6	86.4
Pemigatinib	944	1	14	21	35	431	34.2	45.2
Sacituzumab Govitecan Hziy	25,276	1	1	1	1	294	1.1	3.6
Opicapone	4,194	1	30	38	90	641	84.7	98.9

Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

**Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

	Number of Treatment Episodes by Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Avapritinib</b>	<b>349</b>	<b>179</b>	<b>100.0%</b>	<b>107</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
Female	172	84	46.9%	60	56.1%	*****	*****	*****	*****	0	NaN
Male	177	95	53.1%	47	43.9%	*****	*****	*****	*****	0	NaN
<b>Teprotumumab Trbw</b>	<b>17,185</b>	<b>16,911</b>	<b>100.0%</b>	<b>182</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
Female	13,270	13,072	77.3%	127	69.8%	*****	*****	*****	*****	0	NaN
Male	3,915	3,839	22.7%	55	30.2%	*****	*****	*****	*****	0	NaN
<b>Tazemetostat</b>	<b>437</b>	<b>254</b>	<b>100.0%</b>	<b>118</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
Female	210	129	50.8%	57	48.3%	*****	*****	*****	*****	0	NaN
Male	227	125	49.2%	61	51.7%	*****	*****	*****	*****	0	NaN
<b>Lactitol</b>	<b>0</b>	-	-	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-	-	-
<b>Bempedoic Acid</b>	<b>25,112</b>	<b>11,577</b>	<b>100.0%</b>	<b>8,668</b>	<b>100.0%</b>	<b>4,348</b>	<b>100.0%</b>	<b>503</b>	<b>100.00%</b>	*****	*****
Female	15,024	7,029	60.7%	5,169	59.6%	2,528	58.1%	289	57.50%	*****	*****
Male	10,088	4,548	39.3%	3,499	40.4%	1,820	41.9%	214	42.50%	*****	*****
<b>Eptinezumab Jjmr</b>	<b>15,196</b>	<b>14,500</b>	<b>100.0%</b>	<b>501</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
Female	12,703	12,149	83.8%	400	79.8%	*****	*****	*****	*****	0	NaN
Male	2,493	2,351	16.2%	101	20.2%	*****	*****	*****	*****	0	NaN
<b>Amisulpride</b>	<b>306</b>	<b>306</b>	<b>100.00%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	243	243	79.40%	0	NaN	0	NaN	0	NaN	0	NaN
Male	63	63	20.60%	0	NaN	0	NaN	0	NaN	0	NaN



**Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

	Number of Treatment Episodes by Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Rimegepant</b>	<b>207,166</b>	<b>172,576</b>	<b>100.0%</b>	<b>25,848</b>	<b>100.0%</b>	<b>8,296</b>	<b>100.0%</b>	*****	*****	*****	*****
Female	179,654	149,845	86.8%	22,217	86.0%	7,214	87.0%	*****	*****	*****	*****
Male	27,512	22,731	13.2%	3,631	14.0%	1,082	13.0%	*****	*****	*****	*****
<b>Isatuximab</b>	<b>11,363</b>	<b>11,334</b>	<b>100.0%</b>	<b>18</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
Female	5,490	5,475	48.3%	*****	*****	*****	*****	*****	*****	0	NaN
Male	5,873	5,859	51.7%	*****	*****	*****	*****	*****	*****	0	NaN
<b>Osilodrostat</b>	<b>362</b>	<b>177</b>	<b>100.0%</b>	<b>101</b>	<b>100.0%</b>	<b>70</b>	<b>100.0%</b>	*****	*****	*****	*****
Female	307	152	85.9%	87	86.1%	57	81.4%	*****	*****	*****	*****
Male	55	25	14.1%	14	13.9%	13	18.6%	*****	*****	0	NaN
<b>Ozanimod</b>	<b>2,072</b>	<b>899</b>	<b>100.00%</b>	<b>633</b>	<b>100.00%</b>	<b>476</b>	<b>100.00%</b>	<b>64</b>	<b>100.00%</b>	<b>0</b>	<b>NaN</b>
Female	1,480	643	71.50%	442	69.80%	345	72.50%	50	78.10%	0	NaN
Male	592	256	28.50%	191	30.20%	131	27.50%	14	21.90%	0	NaN
<b>Selumetinib</b>	<b>497</b>	<b>266</b>	<b>100.0%</b>	<b>102</b>	<b>100.0%</b>	<b>104</b>	<b>100.0%</b>	*****	*****	*****	*****
Female	259	138	51.9%	62	60.8%	47	45.2%	*****	*****	*****	*****
Male	238	128	48.1%	40	39.2%	57	54.8%	*****	*****	*****	*****
<b>Tucatinib</b>	<b>3,047</b>	<b>1,628</b>	<b>100.0%</b>	<b>853</b>	<b>100.0%</b>	<b>513</b>	<b>100.0%</b>	*****	*****	*****	*****
Female	2,997	1,600	98.3%	837	98.1%	*****	*****	*****	*****	*****	*****
Male	50	28	1.7%	16	1.9%	*****	*****	*****	*****	*****	*****
<b>Pemigatinib</b>	<b>944</b>	<b>673</b>	<b>100.0%</b>	<b>211</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
Female	587	401	59.6%	146	69.2%	*****	*****	*****	*****	0	NaN
Male	357	272	40.4%	65	30.8%	*****	*****	*****	*****	0	NaN

**Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

	Number of Treatment Episodes by Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Sacituzumab Govitecan Hziy</b>	<b>25,276</b>	<b>25,249</b>	<b>100.0%</b>	*****	*****	*****	*****	0	NaN	0	NaN
Female	22,702	22,675	89.8%	*****	*****	*****	*****	0	NaN	0	NaN
Male	2,574	2,574	10.2%	*****	*****	*****	*****	0	NaN	0	NaN
<b>Opicapone</b>	<b>4,194</b>	<b>2,035</b>	<b>100.00%</b>	<b>1,235</b>	<b>100.00%</b>	<b>797</b>	<b>100.00%</b>	<b>127</b>	<b>100.00%</b>	<b>0</b>	<b>NaN</b>
Female	1,527	756	37.10%	424	34.30%	301	37.80%	46	36.20%	0	NaN
Male	2,667	1,279	62.90%	811	65.70%	496	62.20%	81	63.80%	0	NaN

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

Distribution of Treatment Episode Durations, Days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Avapritinib</b>	<b>349</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>480</b>	<b>67.9</b>	<b>66.7</b>
Female	172	2	30	39	68	480	65.0	63.4
Male	177	1	30	30	90	390	70.7	69.8
<b>Teprotumumab Trbw</b>	<b>17,185</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>588</b>	<b>2.6</b>	<b>12.7</b>
Female	13,270	1	1	1	1	168	2.5	11.8
Male	3,915	1	1	1	1	588	3.0	15.4
<b>Tazemetostat</b>	<b>437</b>	<b>2</b>	<b>30</b>	<b>30</b>	<b>61</b>	<b>510</b>	<b>62.1</b>	<b>63.4</b>
Female	210	2	30	30	60	420	56.6	53.7
Male	227	4	30	30	88	510	67.1	71.0
<b>Lactitol</b>	<b>0</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
<b>Bempeoic Acid</b>	<b>25,112</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>90</b>	<b>815</b>	<b>82.3</b>	<b>88.9</b>
Female	15,024	1	30	57	90	791	80.7	87.1
Male	10,088	1	30	60	90	815	84.7	91.5
<b>Eptinezumab Jjmr</b>	<b>15,196</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>630</b>	<b>6.8</b>	<b>29.8</b>
Female	12,703	1	1	1	1	630	6.6	29.6
Male	2,493	1	1	1	1	477	7.7	30.7
<b>Amisulpride</b>	<b>306</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1.0</b>	<b>0.0</b>
Female	243	1	1	1	1	1	1.0	0.0
Male	63	1	1	1	1	1	1.0	0.0
<b>Rimegepant</b>	<b>207,166</b>	<b>1</b>	<b>8</b>	<b>24</b>	<b>30</b>	<b>757</b>	<b>30.0</b>	<b>40.8</b>
Female	179,654	1	8	24	30	757	29.9	40.7
Male	27,512	1	8	25	30	724	30.4	41.4

**Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

	Distribution of Treatment Episode Durations, Days							Standard Deviation
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	
<b>Isatuximab</b>	<b>11,363</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>413</b>	<b>1.4</b>	<b>7.1</b>
Female	5,490	1	1	1	1	413	1.4	7.8
Male	5,873	1	1	1	1	294	1.3	6.3
<b>Osilodrostat</b>	<b>362</b>	<b>1</b>	<b>30</b>	<b>32</b>	<b>90</b>	<b>765</b>	<b>87.7</b>	<b>115.8</b>
Female	307	1	30	31	90	765	84.6	113.1
Male	55	3	30	39	120	666	105.0	129.5
<b>Ozanimod</b>	<b>2,072</b>	<b>1</b>	<b>30</b>	<b>40</b>	<b>97</b>	<b>666</b>	<b>88.1</b>	<b>102.3</b>
Female	1,480	1	30	42	97	666	88.6	102.6
Male	592	1	30	39	90	623	87.1	101.5
<b>Selumetinib</b>	<b>497</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>99</b>	<b>743</b>	<b>98.2</b>	<b>131.7</b>
Female	259	5	30	30	90	731	92.4	125.3
Male	238	1	30	30	120	743	104.4	138.3
<b>Tucatinib</b>	<b>3,047</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>759</b>	<b>72.6</b>	<b>86.4</b>
Female	2,997	1	30	30	90	759	72.9	86.9
Male	50	3	30	30	60	212	52.7	40.1
<b>Pemigatinib</b>	<b>944</b>	<b>1</b>	<b>14</b>	<b>21</b>	<b>35</b>	<b>431</b>	<b>34.2</b>	<b>45.2</b>
Female	587	2	14	21	42	431	36.6	48.9
Male	357	1	14	14	28	280	30.3	38.0
<b>Sacituzumab Govitecan Hziy</b>	<b>25,276</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>294</b>	<b>1.1</b>	<b>3.6</b>
Female	22,702	1	1	1	1	294	1.1	3.8
Male	2,574	1	1	1	1	21	1.0	0.6
<b>Opicapone</b>	<b>4,194</b>	<b>1</b>	<b>30</b>	<b>38</b>	<b>90</b>	<b>641</b>	<b>84.7</b>	<b>98.9</b>
Female	1,527	1	30	34	90	625	85.9	101.0
Male	2,667	1	30	42	90	641	84.1	97.7

Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

**Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Number of Treatment Episodes by Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Avapritinib</b>	<b>349</b>	<b>179</b>	<b>100.0%</b>	<b>107</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
0-17 years	*****	0	0.00%	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	139	*****	*****	*****	*****	30	49.2%	*****	*****	0	NaN
≥ 65 years	184	97	54.2%	61	57.0%	*****	*****	*****	*****	0	NaN
<b>Teprotumumab Trbw</b>	<b>17,185</b>	<b>16,911</b>	<b>100.0%</b>	<b>182</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
0-17 years	15	15	0.1%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	183	181	1.1%	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	1,256	1,254	7.4%	*****	*****	*****	*****	0	0.00%	0	NaN
41-64 years	6,188	6,107	36.1%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	9,543	9,354	55.3%	121	66.5%	67	73.6%	*****	*****	0	NaN
<b>Tazemetostat</b>	<b>437</b>	<b>254</b>	<b>100.0%</b>	<b>118</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	0.8%	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	*****	*****	3.9%	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	25	13	5.1%	*****	9.3%	*****	*****	0	0.0%	0	NaN
41-64 years	100	63	24.8%	22	18.6%	*****	*****	0	0.0%	0	NaN
≥ 65 years	291	166	65.4%	80	67.8%	43	68.3%	*****	*****	0	NaN
<b>Lactitol</b>	<b>0</b>	-	-	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-	-	-

**Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Number of Treatment Episodes by Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Bempedoic Acid</b>	<b>25,112</b>	<b>11,577</b>	<b>100.0%</b>	<b>8,668</b>	<b>100.0%</b>	<b>4,348</b>	<b>100.0%</b>	<b>503</b>	<b>100.00%</b>	<b>16</b>	<b>100.00%</b>
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	364	168	1.5%	*****	*****	67	1.5%	*****	*****	0	0.0%
41-64 years	7,498	3,508	30.3%	2,598	30.0%	1,249	28.7%	*****	*****	*****	*****
≥ 65 years	17,236	7,890	68.2%	5,940	68.5%	3,032	69.7%	359	71.4%	*****	*****
<b>Eptinezumab Jjmr</b>	<b>15,196</b>	<b>14,500</b>	<b>100.0%</b>	<b>501</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
0-17 years	*****	30	0.2%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	412	2.8%	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	2,489	2,417	16.7%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	7,127	6,738	46.5%	265	52.9%	115	62.5%	*****	*****	0	NaN
≥ 65 years	5,132	4,903	33.8%	172	34.3%	*****	*****	*****	*****	0	NaN
<b>Amisulpride</b>	<b>306</b>	<b>306</b>	<b>100.00%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	81	81	26.5%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	162	162	52.9%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	45	45	14.7%	0	NaN	0	NaN	0	NaN	0	NaN
<b>Rimegepant</b>	<b>207,166</b>	<b>172,576</b>	<b>100.0%</b>	<b>25,848</b>	<b>100.0%</b>	<b>8,296</b>	<b>100.0%</b>	*****	*****	*****	*****
0-17 years	3	713	0.4%	94	0.4%	27	0.3%	0	0.0%	0	0.0%
18-24 years	15	7,828	4.5%	1,121	4.3%	294	3.5%	*****	*****	0	0.0%
25-40 years	51,764	43,241	25.1%	6,404	24.8%	1,998	24.1%	120	27.1%	*****	*****
41-64 years	116,019	96,466	55.9%	14,487	56.0%	4,803	57.9%	262	59.1%	*****	*****
≥ 65 years	29,293	24,328	14.1%	3,742	14.5%	1,174	14.2%	48	10.80%	*****	*****

**Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Number of Treatment Episodes by Duration										
	1-30 Days			31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Isatuximab</b>	<b>11,363</b>	<b>11,334</b>	<b>100.0%</b>	<b>18</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	41	41	0.4%	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	2,310	2,305	20.3%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	9,012	8,988	79.3%	*****	*****	*****	*****	*****	*****	0	NaN
<b>Osilodrostat</b>	<b>362</b>	<b>177</b>	<b>100.0%</b>	<b>101</b>	<b>100.0%</b>	<b>70</b>	<b>100.0%</b>	*****	*****	*****	*****
0-17 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	11	6.2%	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	61	27	15.3%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	143	74	41.8%	37	36.6%	27	38.6%	*****	*****	0	0.0%
≥ 65 years	131	65	36.7%	39	38.6%	21	30.0%	*****	*****	0	0.0%
<b>Ozanimod</b>	<b>2,072</b>	<b>899</b>	<b>100.00%</b>	<b>633</b>	<b>100.00%</b>	<b>476</b>	<b>100.00%</b>	<b>64</b>	<b>100.00%</b>	<b>0</b>	<b>NaN</b>
0-17 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	NaN
18-24 years	*****	34	3.8%	17	2.7%	*****	*****	*****	*****	0	NaN
25-40 years	577	281	31.3%	166	26.2%	114	23.9%	16	25.0%	0	NaN
41-64 years	1,164	488	54.3%	362	57.2%	277	58.2%	37	57.8%	0	NaN
≥ 65 years	260	96	10.7%	88	13.9%	69	14.5%	*****	*****	0	NaN
<b>Selumetinib</b>	<b>497</b>	<b>266</b>	<b>100.0%</b>	<b>102</b>	<b>100.0%</b>	<b>104</b>	<b>100.0%</b>	*****	*****	*****	*****
0-17 years	226	126	47.4%	45	44.1%	44	42.3%	11	47.8%	0	0.0%
18-24 years	84	40	15.0%	19	18.6%	22	21.2%	*****	*****	0	0.0%
25-40 years	109	65	24.4%	16	15.7%	22	21.2%	*****	*****	*****	*****
41-64 years	63	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	15	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%

**Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Number of Treatment Episodes by Duration										
	1-30 Days			31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Tucatinib</b>	<b>3,047</b>	<b>1,628</b>	<b>100.0%</b>	<b>853</b>	<b>100.0%</b>	<b>513</b>	<b>100.0%</b>	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	43	8.4%	*****	*****	0	0.0%
41-64 years	1,550	825	50.7%	408	47.8%	284	55.4%	31	62.0%	*****	*****
≥ 65 years	1,188	635	39.0%	351	41.1%	186	36.3%	*****	*****	*****	*****
<b>Pemigatinib</b>	<b>944</b>	<b>673</b>	<b>100.0%</b>	<b>211</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	32	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	270	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	642	461	68.5%	149	70.6%	32	54.2%	0	0.0%	0	NaN
<b>Sacituzumab Govitecan Hziy</b>	<b>25,276</b>	<b>25,249</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	8,094	8,086	32.0%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	16,225	16,206	64.2%	*****	*****	*****	*****	0	NaN	0	NaN
<b>Opicapone</b>	<b>4,194</b>	<b>2,035</b>	<b>100.0%</b>	<b>1,235</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	12	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	578	*****	*****	*****	*****	*****	*****	17	13.4%	0	NaN
≥ 65 years	3,604	1,744	85.7%	1,049	84.9%	701	88.0%	110	86.6%	0	NaN

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.



**Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

Distribution of Treatment Episode Durations, Days									
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation	
<b>Avapritinib</b>	<b>349</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>480</b>	<b>67.9</b>	<b>66.7</b>	
0-17 years	*****	60	60	90	120	120	90.0	42.4	
18-24 years	*****	30	30	30	30	30	30.0	0.0	
25-40 years	*****	18	30	56	90	154	72.8	47.7	
41-64 years	139	2	30	30	90	480	76.8	83.9	
≥ 65 years	184	1	30	30	73	390	61.0	52.4	
<b>Teprotumumab Trbw</b>	<b>17,185</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>588</b>	<b>2.6</b>	<b>12.7</b>	
0-17 years	15	1	1	1	1	16	2.0	3.9	
18-24 years	183	1	1	1	1	105	2.0	9.0	
25-40 years	1,256	1	1	1	1	168	1.2	4.9	
41-64 years	6,188	1	1	1	1	168	2.3	10.0	
≥ 65 years	9,543	1	1	1	1	588	3.1	14.9	
<b>Tazemetostat</b>	<b>437</b>	<b>2</b>	<b>30</b>	<b>30</b>	<b>61</b>	<b>510</b>	<b>62.1</b>	<b>63.4</b>	
0-17 years	*****	30	36	60	163	244	99.0	84.0	
18-24 years	*****	14	30	30	30	120	39.7	27.4	
25-40 years	25	12	30	30	60	150	45.4	29.2	
41-64 years	100	4	30	30	64	312	59.3	61.5	
≥ 65 years	291	2	30	30	81	510	64.4	66.3	
<b>Lactitol</b>	<b>0</b>	-	-	-	-	-	-	-	
0-17 years	0	-	-	-	-	-	-	-	
18-24 years	0	-	-	-	-	-	-	-	
25-40 years	0	-	-	-	-	-	-	-	
41-64 years	0	-	-	-	-	-	-	-	
≥ 65 years	0	-	-	-	-	-	-	-	

**Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

Distribution of Treatment Episode Durations, Days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Bempezoic Acid</b>	<b>25,112</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>90</b>	<b>815</b>	<b>82.3</b>	<b>88.9</b>
0-17 years	*****	30	30	30	60	60	38.2	14.0
18-24 years	*****	3	3	30	30	30	21.0	15.6
25-40 years	364	2	30	60	90	407	74.9	68.8
41-64 years	7,498	1	30	56	90	737	79.8	84.1
≥ 65 years	17,236	1	30	60	90	815	83.6	91.3
<b>Eptinezumab Jjmr</b>	<b>15,196</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>630</b>	<b>6.8</b>	<b>29.8</b>
0-17 years	30	1	1	1	1	2	1.0	0.2
18-24 years	418	1	1	1	1	84	2.5	9.2
25-40 years	2,489	1	1	1	1	290	4.4	19.5
41-64 years	7,127	1	1	1	1	630	8.3	34.6
≥ 65 years	5,132	1	1	1	1	626	6.3	27.8
<b>Amisulpride</b>	<b>306</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1.0</b>	<b>0.0</b>
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	81	1	1	1	1	1	1.0	0.0
41-64 years	162	1	1	1	1	1	1.0	0.0
≥ 65 years	45	1	1	1	1	1	1.0	0.0
<b>Rimegepant</b>	<b>207,166</b>	<b>1</b>	<b>8</b>	<b>24</b>	<b>30</b>	<b>757</b>	<b>30.0</b>	<b>40.8</b>
0-17 years	834	1	8	27	30	274	28.3	31.7
18-24 years	9,256	1	8	28	30	676	29.0	35.5
25-40 years	51,764	1	8	25	30	757	29.9	40.8
41-64 years	116,019	1	8	24	30	746	30.2	41.6
≥ 65 years	29,293	1	8	24	30	735	29.8	39.3

**Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Distribution of Treatment Episode Durations, Days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Isatuximab</b>	<b>11,363</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>413</b>	<b>1.4</b>	<b>7.1</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	41	1	1	1	1	1	1.0	0.0
41-64 years	2,310	1	1	1	1	112	1.2	3.4
≥ 65 years	9,012	1	1	1	1	413	1.4	7.8
<b>Osilodrostat</b>	<b>362</b>	<b>1</b>	<b>30</b>	<b>32</b>	<b>90</b>	<b>765</b>	<b>87.7</b>	<b>115.8</b>
0-17 years	*****	132	132	132	132	132	132.0	NaN
18-24 years	*****	22	30	60	116	330	87.2	81.7
25-40 years	61	1	30	56	102	765	105.7	147.2
41-64 years	143	1	30	30	90	716	84.6	111.0
≥ 65 years	131	1	30	31	90	626	82.4	110.8
<b>Ozanimod</b>	<b>2,072</b>	<b>1</b>	<b>30</b>	<b>40</b>	<b>97</b>	<b>666</b>	<b>88.1</b>	<b>102.3</b>
0-17 years	*****	240	240	240	240	240	240.0	NaN
18-24 years	*****	2	30	37	97	623	92.8	123.8
25-40 years	577	1	30	36	90	584	79.6	93.9
41-64 years	1,164	1	30	47	106	666	90.4	104.3
≥ 65 years	260	1	30	60	120	577	95.4	103.9
<b>Selumetinib</b>	<b>497</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>99</b>	<b>743</b>	<b>98.2</b>	<b>131.7</b>
0-17 years	226	4	30	30	90	718	91.1	127.0
18-24 years	84	1	30	41	125	651	97.7	115.9
25-40 years	109	3	30	30	116	743	102.1	145.1
41-64 years	63	7	30	60	150	702	121.6	155.0
≥ 65 years	15	30	30	60	90	210	80.5	58.1

**Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

Distribution of Treatment Episode Durations, Days									
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation	
<b>Tucatinib</b>	<b>3,047</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>90</b>	<b>759</b>	<b>72.6</b>	<b>86.4</b>	
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	8	8	32	55	55	31.5	33.2	
25-40 years	*****	1	30	30	60	678	68.7	82.0	
41-64 years	1,550	1	30	30	90	759	76.5	92.5	
≥ 65 years	1,188	1	30	30	65	735	68.6	78.8	
<b>Pemigatinib</b>	<b>944</b>	<b>1</b>	<b>14</b>	<b>21</b>	<b>35</b>	<b>431</b>	<b>34.2</b>	<b>45.2</b>	
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	32	9	14	14	39	294	52.9	79.2	
41-64 years	270	1	14	20	42	431	38.8	55.8	
≥ 65 years	642	2	14	21	35	323	31.3	36.9	
<b>Sacituzumab Govitecan Hziy</b>	<b>25,276</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>294</b>	<b>1.1</b>	<b>3.6</b>	
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0	
25-40 years	*****	1	1	1	1	1	1.0	0.0	
41-64 years	8,094	1	1	1	1	214	1.1	3.4	
≥ 65 years	16,225	1	1	1	1	294	1.1	3.7	
<b>Opicapone</b>	<b>4,194</b>	<b>1</b>	<b>30</b>	<b>38</b>	<b>90</b>	<b>641</b>	<b>84.7</b>	<b>98.9</b>	
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	12	30	30	60	102	270	79.5	70.9	
41-64 years	578	1	30	37	90	641	79.1	95.1	
≥ 65 years	3,604	1	30	38	90	640	85.7	99.6	

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**

	Number of Patients by First Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Avapritinib	165	82	49.7%	51	30.9%	*****	*****	*****	*****	0	0.0%
Teprotumumab Trbw	2,989	2,887	96.6%	54	1.8%	*****	*****	*****	*****	0	0.0%
Tazemetostat	212	115	54.2%	63	29.7%	*****	*****	*****	*****	0	0.0%
Lactitol	0	-	-	-	-	-	-	-	-	-	-
Bempedoic Acid	11,324	4,741	41.90%	3,904	34.50%	2,287	20.20%	376	3.30%	16	0.10%
Eptinezumab Jjmr	5,619	5,249	93.4%	258	4.6%	*****	*****	*****	*****	0	0.0%
Amisulpride	301	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Rimegepant	71,338	57,916	81.2%	9,499	13.3%	3,641	5.1%	*****	*****	*****	*****
Isatuximab	1,059	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
Osilodrostat	164	64	39.0%	52	31.7%	37	22.6%	*****	*****	*****	*****
Ozanimod	923	332	36.00%	297	32.20%	250	27.10%	44	4.80%	0	0.00%
Selumetinib	203	87	42.9%	43	21.2%	53	26.1%	*****	*****	*****	*****
Tucatinib	1,317	650	49.4%	372	28.2%	266	20.2%	*****	*****	*****	*****
Pemigatinib	275	152	55.3%	97	35.3%	*****	*****	*****	*****	0	0.0%
Sacituzumab Govitecan Hziy	2,587	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
Opicapone	2,125	1,012	47.60%	560	26.40%	449	21.10%	104	4.90%	0	0.00%

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

**Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**

Distribution of First Treatment Episode Duration, Days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Avapritinib	165	2	30	32	90	390	72.6	71.9
Teprotumumab Trbw	2,989	1	1	1	1	588	5.2	23.1
Tazemetostat	212	2	30	30	81	420	63.1	59.6
Lactitol	0	-	-	-	-	-	-	-
Bempezoic Acid	11,324	1	30	60	90	815	96.3	105.5
Eptinezumab Jjmr	5,619	1	1	1	1	630	9.6	38.1
Amisulpride	301	1	1	1	1	1	1.0	0.0
Rimegepant	71,338	1	8	30	30	757	34.4	48.3
Isatuximab	1,059	1	1	1	1	413	2.6	16.4
Osilodrostat	164	4	30	60	120	765	113.2	142.8
Ozanimod	923	2	30	48	127	666	101.2	117.8
Selumetinib	203	3	30	60	180	743	133.2	163.6
Tucatinib	1,317	1	30	38	90	759	81.9	98.3
Pemigatinib	275	1	21	21	42	431	44.2	53.1
Sacituzumab Govitecan Hziy	2,587	1	1	1	1	168	1.4	5.6
Opicapone	2,125	1	30	49	116	641	98.4	116.1

Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex

	Number of Patients by First Treatment Episode Duration										
	1-30 Days			31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Avapritinib</b>	<b>165</b>	<b>82</b>	<b>100.0%</b>	<b>51</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
Female	81	40	48.8%	28	54.9%	*****	*****	*****	*****	0	NaN
Male	84	42	51.2%	23	45.1%	*****	*****	*****	*****	0	NaN
<b>Teprotumumab Trbw</b>	<b>2,989</b>	<b>2,887</b>	<b>100.0%</b>	<b>54</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
Female	2,313	2,240	77.6%	37	68.5%	*****	*****	*****	*****	0	NaN
Male	676	647	22.4%	17	31.5%	*****	*****	*****	*****	0	NaN
<b>Tazemetostat</b>	<b>212</b>	<b>115</b>	<b>100.0%</b>	<b>63</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
Female	97	58	50.4%	26	41.3%	*****	*****	*****	*****	0	NaN
Male	115	57	49.6%	37	58.7%	*****	*****	*****	*****	0	NaN
<b>Lactitol</b>	<b>0</b>	-	-	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-	-	-
<b>Bempepoic Acid</b>	<b>11,324</b>	<b>4,741</b>	<b>100.0%</b>	<b>3,904</b>	<b>100.0%</b>	<b>2,287</b>	<b>100.0%</b>	*****	*****	*****	*****
Female	6,794	2,886	60.9%	2,340	59.9%	1,347	58.9%	*****	*****	*****	*****
Male	4,530	1,855	39.1%	1,564	40.1%	940	41.1%	*****	*****	*****	*****
<b>Eptinezumab Jjmr</b>	<b>5,619</b>	<b>5,249</b>	<b>100.0%</b>	<b>258</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
Female	4,665	4,375	83.3%	201	77.9%	*****	*****	*****	*****	0	NaN
Male	954	874	16.7%	57	22.1%	*****	*****	*****	*****	0	NaN
<b>Amisulpride</b>	<b>301</b>	<b>301</b>	<b>100.00%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	239	239	79.40%	0	NaN	0	NaN	0	NaN	0	NaN
Male	62	62	20.60%	0	NaN	0	NaN	0	NaN	0	NaN
<b>Rimegepant</b>	<b>71,338</b>	<b>57,916</b>	<b>100.0%</b>	<b>9,499</b>	<b>100.0%</b>	<b>3,641</b>	<b>100.0%</b>	*****	*****	*****	*****
Female	61,031	49,599	85.6%	8,034	84.6%	3,161	86.8%	*****	*****	*****	*****
Male	10,307	8,317	14.4%	1,465	15.4%	480	13.2%	*****	*****	*****	*****

**Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

	Number of Patients by First Treatment Episode Duration										
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Isatuximab</b>	<b>1,059</b>	*****	*****	*****	*****	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
Female	509	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Male	550	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
<b>Osilodrostat</b>	<b>164</b>	<b>64</b>	<b>100.0%</b>	<b>52</b>	<b>100.0%</b>	<b>37</b>	<b>100.0%</b>	*****	*****	*****	*****
Female	133	48	75.0%	*****	*****	*****	*****	*****	*****	*****	*****
Male	31	16	25.0%	*****	*****	*****	*****	*****	*****	*****	*****
<b>Ozanimod</b>	<b>923</b>	<b>332</b>	<b>100.00%</b>	<b>297</b>	<b>100.00%</b>	<b>250</b>	<b>100.00%</b>	<b>44</b>	<b>100.00%</b>	<b>0</b>	<b>NaN</b>
Female	648	234	70.5%	199	67.0%	180	72.00%	*****	*****	0	NaN
Male	275	98	29.5%	98	33.0%	70	28.00%	*****	*****	0	NaN
<b>Selumetinib</b>	<b>203</b>	<b>87</b>	<b>100.0%</b>	<b>43</b>	<b>100.0%</b>	<b>53</b>	<b>100.0%</b>	*****	*****	*****	*****
Female	102	44	50.6%	22	51.2%	26	49.1%	*****	*****	*****	*****
Male	101	43	49.4%	21	48.8%	27	50.9%	*****	*****	*****	*****
<b>Tucatinib</b>	<b>1,317</b>	<b>650</b>	<b>100.0%</b>	<b>372</b>	<b>100.0%</b>	<b>266</b>	<b>100.0%</b>	*****	*****	*****	*****
Female	1,292	636	97.8%	*****	*****	*****	*****	*****	*****	*****	*****
Male	25	14	2.2%	*****	*****	*****	*****	*****	*****	*****	*****
<b>Pemigatinib</b>	<b>275</b>	<b>152</b>	<b>100.0%</b>	<b>97</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
Female	164	79	52.0%	70	72.2%	*****	*****	*****	*****	0	NaN
Male	111	73	48.0%	27	27.8%	*****	*****	*****	*****	0	NaN
<b>Sacituzumab Govitecan Hziy</b>	<b>2,587</b>	*****	*****	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	2,217	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	370	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
<b>Opicapone</b>	<b>2,125</b>	<b>1,012</b>	<b>100.00%</b>	<b>560</b>	<b>100.00%</b>	<b>449</b>	<b>100.00%</b>	<b>104</b>	<b>100.00%</b>	<b>0</b>	<b>NaN</b>
Female	827	404	39.90%	214	38.20%	174	38.80%	35	33.70%	0	NaN
Male	1,298	608	60.10%	346	61.80%	275	61.20%	69	66.30%	0	NaN

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.



**Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

Distribution of First Treatment Episode Duration, Days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Avapritinib</b>	<b>165</b>	<b>2</b>	<b>30</b>	<b>32</b>	<b>90</b>	<b>390</b>	<b>72.6</b>	<b>71.9</b>
Female	81	2	30	32	63	300	64.1	57.1
Male	84	4	30	31	90	390	80.8	83.3
<b>Teprotumumab Trbw</b>	<b>2,989</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>588</b>	<b>5.2</b>	<b>23.1</b>
Female	2,313	1	1	1	1	168	4.9	20.3
Male	676	1	1	1	1	588	6.4	30.9
<b>Tazemetostat</b>	<b>212</b>	<b>2</b>	<b>30</b>	<b>30</b>	<b>81</b>	<b>420</b>	<b>63.1</b>	<b>59.6</b>
Female	97	2	30	30	67	420	59.1	58.0
Male	115	4	30	34	88	330	66.6	61.0
<b>Lactitol</b>	<b>0</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
<b>Bempedoic Acid</b>	<b>11,324</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>90</b>	<b>815</b>	<b>96.3</b>	<b>105.5</b>
Female	6,794	1	30	60	90	791	93.9	102.4
Male	4,530	1	30	60	90	815	100.0	110.0
<b>Eptinezumab Jjmr</b>	<b>5,619</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>630</b>	<b>9.6</b>	<b>38.1</b>
Female	4,665	1	1	1	1	630	9.3	38.1
Male	954	1	1	1	1	477	11.1	38.2
<b>Amisulpride</b>	<b>301</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1.0</b>	<b>0.0</b>
Female	239	1	1	1	1	1	1.0	0.0
Male	62	1	1	1	1	1	1.0	0.0
<b>Rimegepant</b>	<b>71,338</b>	<b>1</b>	<b>8</b>	<b>30</b>	<b>30</b>	<b>757</b>	<b>34.4</b>	<b>48.3</b>
Female	61,031	1	8	30	30	757	34.4	48.2
Male	10,307	1	8	30	30	724	34.4	48.9

**Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

Distribution of First Treatment Episode Duration, Days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Isatuximab</b>	<b>1,059</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>413</b>	<b>2.6</b>	<b>16.4</b>
Female	509	1	1	1	1	413	2.7	19.2
Male	550	1	1	1	1	224	2.5	13.4
<b>Osilodrostat</b>	<b>164</b>	<b>4</b>	<b>30</b>	<b>60</b>	<b>120</b>	<b>765</b>	<b>113.2</b>	<b>142.8</b>
Female	133	4	30	60	120	765	114.1	141.4
Male	31	8	30	30	120	666	109.5	150.7
<b>Ozanimod</b>	<b>923</b>	<b>2</b>	<b>30</b>	<b>48</b>	<b>127</b>	<b>666</b>	<b>101.2</b>	<b>117.8</b>
Female	648	3	30	48	132	666	103.2	120.2
Male	275	2	30	53	120	598	96.4	111.9
<b>Selumetinib</b>	<b>203</b>	<b>3</b>	<b>30</b>	<b>60</b>	<b>180</b>	<b>743</b>	<b>133.2</b>	<b>163.6</b>
Female	102	5	30	60	169	639	127.0	151.0
Male	101	3	30	60	205	743	139.5	176.0
<b>Tucatinib</b>	<b>1,317</b>	<b>1</b>	<b>30</b>	<b>38</b>	<b>90</b>	<b>759</b>	<b>81.9</b>	<b>98.3</b>
Female	1,292	1	30	38	90	759	82.4	99.0
Male	25	3	30	30	60	212	52.8	44.1
<b>Pemigatinib</b>	<b>275</b>	<b>1</b>	<b>21</b>	<b>21</b>	<b>42</b>	<b>431</b>	<b>44.2</b>	<b>53.1</b>
Female	164	3	21	35	58	431	47.8	56.3
Male	111	1	14	21	35	280	39.0	47.8
<b>Sacituzumab Govitecan Hziy</b>	<b>2,587</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>168</b>	<b>1.4</b>	<b>5.6</b>
Female	2,217	1	1	1	1	168	1.4	6.1
Male	370	1	1	1	1	21	1.1	1.0
<b>Opicapone</b>	<b>2,125</b>	<b>1</b>	<b>30</b>	<b>49</b>	<b>116</b>	<b>641</b>	<b>98.4</b>	<b>116.1</b>
Female	827	2	30	38	94	625	95.8	113.7
Male	1,298	1	30	52	120	641	100.1	117.6

Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group

	Number of Patients by First Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Avapritinib</b>	<b>165</b>	<b>82</b>	<b>100.0%</b>	<b>51</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
0-17 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	62	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	90	48	58.5%	28	54.9%	13	41.9%	*****	*****	0	NaN
<b>Teprotumumab Trbw</b>	<b>2,989</b>	<b>2,887</b>	<b>100.0%</b>	<b>54</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	217	215	7.4%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	1,047	1,026	35.5%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	1,691	1,613	55.9%	41	75.9%	36	76.6%	*****	*****	0	NaN
<b>Tazemetostat</b>	<b>212</b>	<b>115</b>	<b>100.0%</b>	<b>63</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	43	26	22.6%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	146	78	67.8%	43	68.3%	24	72.7%	*****	*****	0	NaN
<b>Lactitol</b>	<b>0</b>	-	-	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-	-	-

**Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Number of Patients by First Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Bempedoic Acid</b>	<b>11,324</b>	<b>4,741</b>	<b>100.00%</b>	<b>3,904</b>	<b>100.00%</b>	<b>2,287</b>	<b>100.00%</b>	<b>376</b>	<b>100.00%</b>	<b>16</b>	<b>100.00%</b>
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	48	1.2%	38	1.7%	*****	*****	0	0.0%
41-64 years	3,338	1,392	29.4%	1,164	29.8%	677	29.6%	*****	*****	*****	*****
≥ 65 years	7,836	3,287	69.3%	2,692	69.0%	1,572	68.7%	270	71.8%	*****	*****
<b>Eptinezumab Jjmr</b>	<b>5,619</b>	<b>5,249</b>	<b>100.0%</b>	<b>258</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN</b>
0-17 years	11	11	0.2%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	170	167	3.2%	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	928	889	16.9%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	2,663	2,467	47.0%	127	49.2%	62	60.2%	*****	*****	0	NaN
≥ 65 years	1,847	1,715	32.7%	97	37.6%	*****	*****	*****	*****	0	NaN
<b>Amisulpride</b>	<b>301</b>	<b>301</b>	<b>100.00%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	80	80	26.6%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	158	158	52.5%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	45	45	15.0%	0	NaN	0	NaN	0	NaN	0	NaN
<b>Rimegepant</b>	<b>71,338</b>	<b>57,916</b>	<b>100.0%</b>	<b>9,499</b>	<b>100.0%</b>	<b>3,641</b>	<b>100.0%</b>	<b>279</b>	<b>100.0%</b>	<b>3</b>	<b>100.0%</b>
0-17 years	356	298	0.5%	40	0.4%	18	0.5%	0	0.0%	0	0.0%
18-24 years	3,660	3,023	5.2%	478	5.0%	149	4.1%	*****	*****	0	0.0%
25-40 years	17,365	14,104	24.4%	2,311	24.3%	870	23.9%	79	28.3%	*****	*****
41-64 years	37,752	30,485	52.6%	5,071	53.4%	2,038	56.0%	157	56.3%	*****	*****
≥ 65 years	12,205	10,006	17.3%	1,599	16.8%	566	15.5%	*****	*****	*****	*****

**Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Number of Patients by First Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Isatuximab</b>	<b>1,059</b>	<b>1,050</b>	<b>100.0%</b>	*****	*****	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	840	833	79.3%	*****	*****	*****	*****	*****	*****	0	NaN
<b>Osilodrostat</b>	<b>164</b>	<b>64</b>	<b>100.0%</b>	<b>52</b>	<b>100.0%</b>	<b>37</b>	<b>100.0%</b>	*****	*****	*****	*****
0-17 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	69	*****	39.1%	24	46.2%	15	40.5%	*****	*****	0	0.0%
≥ 65 years	60	30	46.9%	16	30.8%	*****	*****	*****	*****	0	0.0%
<b>Ozanimod</b>	<b>923</b>	<b>332</b>	<b>100.00%</b>	<b>297</b>	<b>100.00%</b>	<b>250</b>	<b>100.00%</b>	<b>44</b>	<b>100.00%</b>	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	0.0%	0	0.0%	*****	*****	0	0.0%	0	NaN
18-24 years	*****	*****	4.2%	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	245	97	29.2%	78	26.3%	57	22.8%	13	29.5%	0	NaN
41-64 years	528	186	56.0%	170	57.2%	147	58.8%	25	56.8%	0	NaN
≥ 65 years	119	35	10.5%	*****	*****	37	14.8%	*****	*****	0	NaN
<b>Selumetinib</b>	<b>203</b>	<b>87</b>	<b>100.0%</b>	<b>43</b>	<b>100.0%</b>	<b>53</b>	<b>100.0%</b>	*****	*****	*****	*****
0-17 years	89	37	42.5%	20	46.5%	22	41.5%	*****	*****	0	0.0%
18-24 years	32	14	16.1%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	41	21	24.1%	*****	*****	12	22.6%	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%

**Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Number of Patients by First Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<b>Tucatinib</b>	<b>1,317</b>	<b>650</b>	<b>100.0%</b>	<b>372</b>	<b>100.0%</b>	<b>266</b>	<b>100.0%</b>	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	25	9.4%	*****	*****	0	0.0%
41-64 years	679	318	48.9%	179	48.1%	160	60.2%	20	76.9%	*****	*****
≥ 65 years	519	272	41.8%	161	43.3%	81	30.5%	*****	*****	*****	*****
<b>Pemigatinib</b>	<b>275</b>	<b>152</b>	<b>100.0%</b>	<b>97</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	12	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	86	*****	*****	*****	*****	13	52.0%	*****	*****	0	NaN
≥ 65 years	177	99	65.1%	69	71.1%	*****	*****	0	0.0%	0	NaN
<b>Sacituzumab Govitecan Hziy</b>	<b>2,587</b>	*****	*****	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	869	866	33.6%	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	1,602	1,599	62.0%	0	0.0%	*****	*****	0	NaN	0	NaN
<b>Opicapone</b>	<b>2,125</b>	<b>1,012</b>	<b>100.00%</b>	<b>560</b>	<b>100.00%</b>	<b>449</b>	<b>100.00%</b>	<b>104</b>	<b>100.00%</b>	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	14	13.5%	0	NaN
≥ 65 years	1,854	890	87.9%	478	85.4%	396	88.2%	90	86.5%	0	NaN

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

Distribution of First Treatment Episode Duration, Days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Avapritinib</b>	<b>165</b>	<b>2</b>	<b>30</b>	<b>32</b>	<b>90</b>	<b>390</b>	<b>72.6</b>	<b>71.9</b>
0-17 years	*****	120	120	120	120	120	120.0	NaN
18-24 years	*****	30	30	30	30	30	30.0	NaN
25-40 years	*****	18	30	54	150	154	82.4	58.3
41-64 years	62	2	30	38	90	330	81.9	88.9
≥ 65 years	90	13	30	30	90	390	64.9	59.6
<b>Teprotumumab Trbw</b>	<b>2,989</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>588</b>	<b>5.2</b>	<b>23.1</b>
0-17 years	*****	1	1	1	9	16	4.8	7.5
18-24 years	*****	1	1	1	1	63	3.7	11.8
25-40 years	217	1	1	1	1	168	2.0	11.7
41-64 years	1,047	1	1	1	1	168	3.7	16.1
≥ 65 years	1,691	1	1	1	1	588	6.6	27.6
<b>Tazemetostat</b>	<b>212</b>	<b>2</b>	<b>30</b>	<b>30</b>	<b>81</b>	<b>420</b>	<b>63.1</b>	<b>59.6</b>
0-17 years	*****	30	30	36	126	210	78.0	88.2
18-24 years	*****	14	22	45	90	120	56.0	46.7
25-40 years	*****	16	30	34	60	70	41.7	16.9
41-64 years	43	4	30	30	90	312	66.0	69.7
≥ 65 years	146	2	30	30	88	420	64.3	58.9
<b>Lactitol</b>	<b>0</b>	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-

**Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

Distribution of First Treatment Episode Duration, Days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Bempedoic Acid</b>	<b>11,324</b>	<b>1</b>	<b>30</b>	<b>60</b>	<b>90</b>	<b>815</b>	<b>96.3</b>	<b>105.5</b>
0-17 years	*****	30	30	30	30	30	30.0	NaN
18-24 years	*****	3	3	30	30	30	21.0	15.6
25-40 years	*****	18	30	61	120	407	94.5	86.4
41-64 years	3,338	1	30	60	90	737	93.4	98.4
≥ 65 years	7,836	1	30	60	90	815	97.7	108.7
<b>Eptinezumab Jjmr</b>	<b>5,619</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>630</b>	<b>9.6</b>	<b>38.1</b>
0-17 years	*****	1	1	1	1	2	1.1	0.3
18-24 years	*****	1	1	1	1	84	2.9	10.1
25-40 years	928	1	1	1	1	290	6.2	25.6
41-64 years	2,663	1	1	1	1	630	11.3	43.4
≥ 65 years	1,847	1	1	1	1	626	9.6	36.9
<b>Amisulpride</b>	<b>301</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1.0</b>	<b>0.0</b>
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	80	1	1	1	1	1	1.0	0.0
41-64 years	158	1	1	1	1	1	1.0	0.0
≥ 65 years	45	1	1	1	1	1	1.0	0.0
<b>Rimegepant</b>	<b>71,338</b>	<b>1</b>	<b>8</b>	<b>30</b>	<b>30</b>	<b>757</b>	<b>34.4</b>	<b>48.3</b>
0-17 years	*****	1	11	30	30	274	32.4	37.3
18-24 years	*****	1	8	30	30	676	32.3	41.4
25-40 years	17,365	1	8	30	30	757	34.7	49.4
41-64 years	37,752	1	8	30	30	746	35.0	49.6
≥ 65 years	12,205	1	8	30	30	735	32.8	44.5



**Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

Distribution of First Treatment Episode Duration, Days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Isatuximab</b>	<b>1,059</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>413</b>	<b>2.6</b>	<b>16.4</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	112	1.9	8.6
≥ 65 years	840	1	1	1	1	413	2.8	17.9
<b>Osilodrostat</b>	<b>164</b>	<b>4</b>	<b>30</b>	<b>60</b>	<b>120</b>	<b>765</b>	<b>113.2</b>	<b>142.8</b>
0-17 years	*****	132	132	132	132	132	132.0	NaN
18-24 years	*****	30	44	90	315	330	145.6	127.0
25-40 years	*****	10	30	75	180	765	145.6	191.7
41-64 years	69	4	30	60	120	716	110.8	138.9
≥ 65 years	60	8	30	31	90	600	97.4	124.1
<b>Ozanimod</b>	<b>923</b>	<b>2</b>	<b>30</b>	<b>48</b>	<b>127</b>	<b>666</b>	<b>101.2</b>	<b>117.8</b>
0-17 years	*****	240	240	240	240	240	240.0	NaN
18-24 years	*****	2	30	37	97	547	92.8	126.5
25-40 years	245	3	30	43	120	584	97.5	117.2
41-64 years	528	3	30	57	148	666	103.2	118.8
≥ 65 years	119	7	30	60	120	577	100.5	113.2
<b>Selumetinib</b>	<b>203</b>	<b>3</b>	<b>30</b>	<b>60</b>	<b>180</b>	<b>743</b>	<b>133.2</b>	<b>163.6</b>
0-17 years	89	4	30	60	149	716	132.5	164.1
18-24 years	32	7	30	50	138	651	109.8	141.2
25-40 years	41	3	30	30	180	743	132.4	168.0
41-64 years	*****	9	30	90	270	702	175.6	190.5
≥ 65 years	*****	30	30	60	75	157	64.6	42.8

**Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

Distribution of First Treatment Episode Duration, Days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Tucatinib</b>	<b>1,317</b>	<b>1</b>	<b>30</b>	<b>38</b>	<b>90</b>	<b>759</b>	<b>81.9</b>	<b>98.3</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	8	8	32	55	55	31.5	33.2
25-40 years	*****	1	30	30	90	678	81.9	96.8
41-64 years	679	2	30	60	120	759	92.6	111.7
≥ 65 years	519	4	30	30	60	735	68.1	76.0
<b>Pemigatinib</b>	<b>275</b>	<b>1</b>	<b>21</b>	<b>21</b>	<b>42</b>	<b>431</b>	<b>44.2</b>	<b>53.1</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	12	9	18	32	112	294	75.6	91.6
41-64 years	86	1	21	21	63	431	58.3	75.9
≥ 65 years	177	3	21	21	42	177	35.3	29.1
<b>Sacituzumab Govitecan Hziy</b>	<b>2,587</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>168</b>	<b>1.4</b>	<b>5.6</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	869	1	1	1	1	84	1.4	4.6
≥ 65 years	1,602	1	1	1	1	168	1.4	6.3
<b>Opicapone</b>	<b>2,125</b>	<b>1</b>	<b>30</b>	<b>49</b>	<b>116</b>	<b>641</b>	<b>98.4</b>	<b>116.1</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	72	120	270	98.8	90.5
41-64 years	*****	1	30	53	90	641	96.3	115.8
≥ 65 years	1,854	1	30	46	120	640	98.7	116.2

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**

**Number of Treatment Episodes by Duration (Excluding First Treatment Episode)**

	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Avapritinib	184	97	52.7%	56	30.4%	****	****	****	****	0	0.0%
Teprotumumab Trbw	14,196	14,024	98.80%	128	0.90%	44	0.30%	0	0.00%	0	0.00%
Tazemetostat	225	139	61.8%	55	24.4%	****	****	****	****	0	0.0%
Lactitol	0	-	-	-	-	-	-	-	-	-	-
Bempedoic Acid	13,788	6,836	49.60%	4,764	34.60%	2,061	14.90%	127	0.90%	0	0.00%
Eptinezumab Jjmr	9,577	9,251	96.6%	243	2.5%	****	****	****	****	0	0.0%
Amisulpride	****	****	100.00%	0	0.00%	0	0.0%	0	0.0%	0	0.0%
Rimegepant	135,828	114,660	84.40%	16,349	12.00%	4,655	3.40%	164	0.10%	0	0.00%
Isatuximab	10,304	10,284	99.8%	****	****	****	****	0	0.0%	0	0.0%
Osilodrostat	198	113	57.1%	49	24.7%	****	****	****	****	0	0.0%
Ozanimod	1,149	567	49.30%	336	29.20%	226	19.70%	20	1.70%	0	0.00%
Selumetinib	294	179	60.9%	59	20.1%	****	****	****	****	****	****
Tucatinib	1,730	978	56.50%	481	27.80%	247	14.30%	24	1.40%	0	0.00%
Pemigatinib	669	521	77.90%	114	17.00%	34	5.10%	0	0.00%	0	0.00%
Sacituzumab Govitecan Hziy	22,689	22,668	99.90%	****	****	****	****	0	0.00%	0	0.00%
Opicapone	2,069	1,023	49.4%	675	32.6%	****	****	****	****	0	0.0%

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

**Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**

Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Avapritinib	184	1	30	30	87	480	63.7	61.5
Teprotumumab Trbw	14,196	1	1	1	1	168	2.1	9.0
Tazemetostat	225	4	30	30	60	510	61.1	67.0
Lactitol	0	-	-	-	-	-	-	-
Bempeoic Acid	13,788	1	30	33	90	652	70.8	70.4
Eptinezumab Jjmr	9,577	1	1	1	1	569	5.1	23.4
Amisulpride	*****	1	1	1	1	1	1.0	0.0
Rimegepant	135,828	1	8	17	30	723	27.7	36.1
Isatuximab	10,304	1	1	1	1	294	1.3	5.2
Osilodrostat	198	1	30	30	80	626	66.5	82.0
Ozanimod	1,149	1	30	34	90	623	77.7	86.5
Selumetinib	294	1	30	30	65	731	73.9	97.3
Tucatinib	1,730	1	30	30	60	675	65.6	75.3
Pemigatinib	669	2	14	14	21	323	30.1	40.8
Sacituzumab Govitecan Hziy	22,689	1	1	1	1	294	1.1	3.2
Opicapone	2,069	1	30	31	90	570	70.7	74.9

Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Avapritinib</b>	<b>184</b>	<b>97</b>	<b>100.0%</b>	<b>56</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
Female	91	44	45.4%	32	57.1%	*****	*****	*****	*****	0	NaN
Male	93	53	54.6%	24	42.9%	*****	*****	*****	*****	0	NaN
<b>Teprotumumab Trbw</b>	<b>14,196</b>	<b>14,024</b>	<b>100.00%</b>	<b>128</b>	<b>100.00%</b>	<b>44</b>	<b>100.00%</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	10,957	10,832	77.2%	90	70.30%	*****	*****	0	NaN	0	NaN
Male	3,239	3,192	22.8%	38	29.70%	*****	*****	0	NaN	0	NaN
<b>Tazemetostat</b>	<b>225</b>	<b>139</b>	<b>100.0%</b>	<b>55</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
Female	113	71	51.1%	31	56.4%	*****	*****	*****	*****	0	NaN
Male	112	68	48.9%	24	43.6%	*****	*****	*****	*****	0	NaN
<b>Lactitol</b>	<b>0</b>	-	-	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-	-	-
<b>Bempedoic Acid</b>	<b>13,788</b>	<b>6,836</b>	<b>100.00%</b>	<b>4,764</b>	<b>100.00%</b>	<b>2,061</b>	<b>100.00%</b>	<b>127</b>	<b>100.00%</b>	<b>0</b>	<b>NaN</b>
Female	8,230	4,143	60.60%	2,829	59.40%	1,181	57.30%	77	60.60%	0	NaN
Male	5,558	2,693	39.40%	1,935	40.60%	880	42.70%	50	39.40%	0	NaN
<b>Eptinezumab Jjmr</b>	<b>9,577</b>	<b>9,251</b>	<b>100.0%</b>	<b>243</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
Female	8,038	7,774	84.0%	199	81.9%	*****	*****	*****	*****	0	NaN
Male	1,539	1,477	16.0%	44	18.1%	*****	*****	*****	*****	0	NaN
<b>Amisulpride</b>	*****	*****	*****	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
<b>Rimegepant</b>	<b>135,828</b>	<b>114,660</b>	<b>100.00%</b>	<b>16,349</b>	<b>100.00%</b>	<b>4,655</b>	<b>100.00%</b>	<b>164</b>	<b>100.00%</b>	<b>0</b>	<b>NaN</b>
Female	118,623	100,246	87.40%	14,183	86.80%	4,053	87.10%	141	86.00%	0	NaN
Male	17,205	14,414	12.60%	2,166	13.20%	602	12.90%	23	14.00%	0	NaN

**Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Isatuximab</b>	<b>10,304</b>	<b>10,284</b>	<b>100.0%</b>	*****	*****	*****	*****	0	NaN	0	NaN
Female	4,981	4,971	48.3%	*****	*****	*****	*****	0	NaN	0	NaN
Male	5,323	5,313	51.7%	*****	*****	*****	*****	0	NaN	0	NaN
<b>Osilodrostat</b>	<b>198</b>	<b>113</b>	<b>100.0%</b>	<b>49</b>	<b>100.0%</b>	*****	*****	*****	*****	0	NaN
Female	174	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Male	24	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
<b>Ozanimod</b>	<b>1,149</b>	<b>567</b>	<b>100.00%</b>	<b>336</b>	<b>100.00%</b>	<b>226</b>	<b>100.00%</b>	<b>20</b>	<b>100.00%</b>	<b>0</b>	<b>NaN</b>
Female	832	409	72.1%	243	72.3%	165	73.00%	*****	*****	0	NaN
Male	317	158	27.9%	93	27.7%	61	27.00%	*****	*****	0	NaN
<b>Selumetinib</b>	<b>294</b>	<b>179</b>	<b>100.0%</b>	<b>59</b>	<b>100.0%</b>	*****	*****	*****	*****	*****	*****
Female	157	94	52.5%	40	67.8%	21	41.20%	*****	*****	*****	*****
Male	137	85	47.5%	19	32.2%	30	58.80%	*****	*****	*****	*****
<b>Tucatinib</b>	<b>1,730</b>	<b>978</b>	<b>100.0%</b>	<b>481</b>	<b>100.0%</b>	*****	*****	*****	*****	0	NaN
Female	1,705	964	98.6%	*****	*****	*****	*****	*****	*****	0	NaN
Male	25	14	1.4%	*****	*****	*****	*****	*****	*****	0	NaN
<b>Pemigatinib</b>	<b>669</b>	<b>521</b>	<b>100.0%</b>	<b>114</b>	<b>100.00%</b>	*****	*****	0	NaN	0	NaN
Female	423	322	61.8%	76	66.70%	*****	*****	0	NaN	0	NaN
Male	246	199	38.2%	38	33.30%	*****	*****	0	NaN	0	NaN
<b>Sacituzumab Govitecan Hziy</b>	<b>22,689</b>	<b>22,668</b>	<b>100.0%</b>	*****	*****	*****	*****	0	NaN	0	NaN
Female	20,485	20,464	90.3%	*****	*****	*****	*****	0	NaN	0	NaN
Male	2,204	2,204	9.7%	*****	*****	*****	*****	0	NaN	0	NaN
<b>Opicapone</b>	<b>2,069</b>	<b>1,023</b>	<b>100.00%</b>	<b>675</b>	<b>100.00%</b>	<b>348</b>	<b>100.00%</b>	<b>23</b>	<b>100.00%</b>	<b>0</b>	<b>NaN</b>
Female	700	352	34.40%	210	31.10%	127	36.50%	11	47.80%	0	NaN
Male	1,369	671	65.60%	465	68.90%	221	63.50%	12	52.20%	0	NaN

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

**Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days**

	<b>Total Number of Episodes</b>	<b>Minimum</b>	<b>Q1</b>	<b>Median</b>	<b>Q3</b>	<b>Maximum</b>	<b>Mean</b>	<b>Standard Deviation</b>
<b>Avapritinib</b>	<b>184</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>87</b>	<b>480</b>	<b>63.7</b>	<b>61.5</b>
Female	91	10	30	59	74	480	65.9	68.8
Male	93	1	30	30	90	240	61.6	53.7
<b>Teprotumumab Trbw</b>	<b>14,196</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>168</b>	<b>2.1</b>	<b>9.0</b>
Female	10,957	1	1	1	1	168	2.0	9.0
Male	3,239	1	1	1	1	147	2.3	9.2
<b>Tazemetostat</b>	<b>225</b>	<b>4</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>510</b>	<b>61.1</b>	<b>67.0</b>
Female	113	7	30	30	60	270	54.5	49.9
Male	112	4	30	30	60	510	67.6	80.3
<b>Lactitol</b>	<b>0</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
<b>Bempedoic Acid</b>	<b>13,788</b>	<b>1</b>	<b>30</b>	<b>33</b>	<b>90</b>	<b>652</b>	<b>70.8</b>	<b>70.4</b>
Female	8,230	1	30	30	90	630	69.8	70.2
Male	5,558	1	30	44	90	652	72.3	70.6
<b>Eptinezumab Jjmr</b>	<b>9,577</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>569</b>	<b>5.1</b>	<b>23.4</b>
Female	8,038	1	1	1	1	569	5.1	23.1
Male	1,539	1	1	1	1	354	5.6	24.8
<b>Amisulpride</b>	<b>*****</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1.0</b>	<b>0.0</b>
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	1	1.0	NaN
<b>Rimegepant</b>	<b>135,828</b>	<b>1</b>	<b>8</b>	<b>17</b>	<b>30</b>	<b>723</b>	<b>27.7</b>	<b>36.1</b>
Female	118,623	1	8	17	30	723	27.6	36.1
Male	17,205	1	8	18	30	659	28.0	35.9

**Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

**Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days**

	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Isatuximab</b>	<b>10,304</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>294</b>	<b>1.3</b>	<b>5.2</b>
Female	4,981	1	1	1	1	183	1.3	5.4
Male	5,323	1	1	1	1	294	1.2	5.0
<b>Osilodrostat</b>	<b>198</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>80</b>	<b>626</b>	<b>66.5</b>	<b>82.0</b>
Female	174	1	28	30	67	626	62.0	78.7
Male	24	3	30	60	150	330	99.2	98.5
<b>Ozanimod</b>	<b>1,149</b>	<b>1</b>	<b>30</b>	<b>34</b>	<b>90</b>	<b>623</b>	<b>77.7</b>	<b>86.5</b>
Female	832	1	30	36	90	564	77.2	84.7
Male	317	1	30	32	90	623	79.0	90.9
<b>Selumetinib</b>	<b>294</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>65</b>	<b>731</b>	<b>73.9</b>	<b>97.3</b>
Female	157	5	30	30	60	731	70.0	99.6
Male	137	1	30	30	90	544	78.5	94.8
<b>Tucatinib</b>	<b>1,730</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>675</b>	<b>65.6</b>	<b>75.3</b>
Female	1,705	1	30	30	60	675	65.7	75.7
Male	25	14	30	30	60	150	52.6	36.6
<b>Pemigatinib</b>	<b>669</b>	<b>2</b>	<b>14</b>	<b>14</b>	<b>21</b>	<b>323</b>	<b>30.1</b>	<b>40.8</b>
Female	423	2	14	14	28	323	32.2	45.1
Male	246	2	14	14	21	277	26.4	31.9
<b>Sacituzumab Govitecan Hziy</b>	<b>22,689</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>294</b>	<b>1.1</b>	<b>3.2</b>
Female	20,485	1	1	1	1	294	1.1	3.4
Male	2,204	1	1	1	1	21	1.0	0.4
<b>Opicapone</b>	<b>2,069</b>	<b>1</b>	<b>30</b>	<b>31</b>	<b>90</b>	<b>570</b>	<b>70.7</b>	<b>74.9</b>
Female	700	1	30	30	90	570	74.2	82.2
Male	1,369	1	30	35	90	568	68.9	70.8

\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.



**Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	1-30 Days			31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Avapritinib</b>	<b>184</b>	<b>97</b>	<b>100.0%</b>	<b>56</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
0-17 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	77	*****	43.3%	17	30.4%	17	56.7%	*****	*****	0	NaN
≥ 65 years	94	49	50.5%	33	58.9%	*****	*****	0	0.0%	0	NaN
<b>Teprotumumab Trbw</b>	<b>14,196</b>	<b>14,024</b>	<b>100.0%</b>	<b>128</b>	<b>100.00%</b>	*****	*****	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	11	11	0.1%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	153	152	1.1%	0	0.0%	*****	*****	0	NaN	0	NaN
25-40 years	1,039	1,039	7.4%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	5,141	5,081	36.2%	48	37.5%	*****	*****	0	NaN	0	NaN
≥ 65 years	7,852	7,741	55.2%	80	62.5%	31	70.5%	0	NaN	0	NaN
<b>Tazemetostat</b>	<b>225</b>	<b>139</b>	<b>100.0%</b>	<b>55</b>	<b>100.0%</b>	*****	*****	*****	*****	<b>0</b>	<b>NaN</b>
0-17 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	57	37	26.6%	*****	21.8%	*****	*****	0	0.0%	0	NaN
≥ 65 years	145	88	63.3%	37	67.3%	19	63.3%	*****	*****	0	NaN
<b>Lactitol</b>	<b>0</b>	-	-	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-	-	-

**Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	1-30 Days			31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Bempedoic Acid</b>	<b>13,788</b>	<b>6,836</b>	<b>100.0%</b>	<b>4,764</b>	<b>100.0%</b>	<b>2,061</b>	<b>100.00%</b>	<b>127</b>	<b>100.00%</b>	<b>0</b>	<b>NaN</b>
0-17 years	*****	*****	*****	*****	*****	0	0.00%	0	0.00%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.00%	0	0.00%	0	NaN
25-40 years	*****	*****	*****	*****	*****	29	1.40%	0	0.00%	0	NaN
41-64 years	4,160	2,116	31.0%	1,434	30.1%	572	27.80%	38	29.90%	0	NaN
≥ 65 years	9,400	4,603	67.3%	3,248	68.2%	1,460	70.80%	89	70.10%	0	NaN
<b>Eptinezumab Jjmr</b>	<b>9,577</b>	<b>9,251</b>	<b>100.0%</b>	<b>243</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN</b>
0-17 years	19	19	0.2%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	248	245	2.6%	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	1,561	1,528	16.5%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	4,464	4,271	46.2%	138	56.8%	53	65.4%	*****	*****	0	NaN
≥ 65 years	3,285	3,188	34.5%	75	30.9%	*****	*****	0	0.0%	0	NaN
<b>Amisulpride</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
<b>Rimegepant</b>	<b>135,828</b>	<b>114,660</b>	<b>100.00%</b>	<b>16,349</b>	<b>100.00%</b>	<b>4,655</b>	<b>100.00%</b>	<b>164</b>	<b>100.00%</b>	<b>0</b>	<b>NaN</b>
0-17 years	478	415	0.4%	54	0.30%	*****	*****	0	0.0%	0	NaN
18-24 years	5,596	4,805	4.2%	643	3.90%	*****	*****	*****	*****	0	NaN
25-40 years	34,399	29,137	25.4%	4,093	25.00%	1,128	24.2%	41	25.0%	0	NaN
41-64 years	78,267	65,981	57.5%	9,416	57.60%	2,765	59.4%	105	64.0%	0	NaN
≥ 65 years	17,088	14,322	12.5%	2,143	13.10%	608	13.1%	*****	*****	0	NaN

**Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	1-30 Days			31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Isatuximab</b>	<b>10,304</b>	<b>10,284</b>	<b>100.0%</b>	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	37	37	0.4%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	2,095	2,092	20.3%	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	8,172	8,155	79.3%	*****	*****	*****	*****	0	NaN	0	NaN
<b>Osilodrostat</b>	<b>198</b>	<b>113</b>	<b>100.0%</b>	<b>49</b>	<b>100.0%</b>	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	19	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	34	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	74	49	43.4%	13	26.5%	12	36.4%	0	0.0%	0	NaN
≥ 65 years	71	35	31.0%	23	46.9%	11	33.3%	*****	*****	0	NaN
<b>Ozanimod</b>	<b>1,149</b>	<b>567</b>	<b>100.0%</b>	<b>336</b>	<b>100.0%</b>	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	40	20	3.5%	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	332	184	32.5%	88	26.2%	57	25.2%	*****	*****	0	NaN
41-64 years	636	302	53.3%	192	57.1%	130	57.5%	*****	*****	0	NaN
≥ 65 years	141	61	10.8%	*****	*****	*****	*****	*****	*****	0	NaN
<b>Selumetinib</b>	<b>294</b>	<b>179</b>	<b>100.0%</b>	<b>59</b>	<b>100.0%</b>	*****	*****	*****	*****	*****	*****
0-17 years	137	89	49.7%	25	42.4%	22	43.1%	*****	*****	0	0.0%
18-24 years	52	26	14.5%	11	18.6%	14	27.5%	*****	*****	0	0.0%
25-40 years	68	44	24.6%	11	18.6%	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%

**Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	1-30 Days			31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<b>Tucatinib</b>	<b>1,730</b>	<b>978</b>	<b>100.00%</b>	<b>481</b>	<b>100.00%</b>	<b>247</b>	<b>100.00%</b>	<b>24</b>	<b>100.00%</b>	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.00%	0	0.00%	0	0.00%	0	0.0%	0	NaN
18-24 years	0	0	0.00%	0	0.00%	0	0.00%	0	0.0%	0	NaN
25-40 years	190	108	11.00%	62	12.90%	18	7.30%	*****	*****	0	NaN
41-64 years	871	507	51.80%	229	47.60%	124	50.20%	*****	*****	0	NaN
≥ 65 years	669	363	37.10%	190	39.50%	105	42.50%	11	45.8%	0	NaN
<b>Pemigatinib</b>	<b>669</b>	<b>521</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	20	17	3.3%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	184	142	27.3%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	465	362	69.5%	80	70.2%	23	67.6%	0	NaN	0	NaN
<b>Sacituzumab Govitecan Hziy</b>	<b>22,689</b>	<b>22,668</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN</b>	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	7,225	7,220	31.9%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	14,623	14,607	64.4%	*****	*****	*****	*****	0	NaN	0	NaN
<b>Opicapone</b>	<b>2,069</b>	<b>1,023</b>	<b>100.0%</b>	<b>675</b>	<b>100.0%</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>*****</b>	<b>0</b>	<b>NaN</b>
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	1,750	854	83.5%	571	84.6%	305	87.6%	*****	*****	0	NaN

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Avapritinib</b>	<b>184</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>87</b>	<b>480</b>	<b>63.7</b>	<b>61.5</b>
0-17 years	*****	60	60	60	60	60	60.0	NaN
18-24 years	*****	30	30	30	30	30	30.0	0.0
25-40 years	*****	30	30	58	90	116	62.2	32.3
41-64 years	77	3	30	30	90	480	72.8	80.1
≥ 65 years	94	1	30	30	60	240	57.2	44.4
<b>Teprotumumab Trbw</b>	<b>14,196</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>168</b>	<b>2.1</b>	<b>9.0</b>
0-17 years	11	1	1	1	1	1	1.0	0.0
18-24 years	153	1	1	1	1	105	1.7	8.4
25-40 years	1,039	1	1	1	1	2	1.0	0.1
41-64 years	5,141	1	1	1	1	147	2.0	8.2
≥ 65 years	7,852	1	1	1	1	168	2.3	10.1
<b>Tazemetostat</b>	<b>225</b>	<b>4</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>510</b>	<b>61.1</b>	<b>67.0</b>
0-17 years	*****	60	60	88	180	244	120.0	86.8
18-24 years	*****	22	30	30	30	60	32.4	10.7
25-40 years	*****	12	30	30	60	150	50.8	42.2
41-64 years	57	7	30	30	60	300	54.3	54.7
≥ 65 years	145	4	30	30	60	510	64.6	73.2
<b>Lactitol</b>	<b>0</b>	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-

**Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Bempedoic Acid</b>	<b>13,788</b>	<b>1</b>	<b>30</b>	<b>33</b>	<b>90</b>	<b>652</b>	<b>70.8</b>	<b>70.4</b>
0-17 years	*****	30	30	30	60	60	39.0	14.5
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	2	30	30	90	330	61.8	49.9
41-64 years	4,160	1	30	30	90	652	69.0	68.6
≥ 65 years	9,400	1	30	37	90	652	71.8	71.6
<b>Eptinezumab Jjmr</b>	<b>9,577</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>569</b>	<b>5.1</b>	<b>23.4</b>
0-17 years	19	1	1	1	1	1	1.0	0.0
18-24 years	248	1	1	1	1	84	2.2	8.5
25-40 years	1,561	1	1	1	1	168	3.3	14.5
41-64 years	4,464	1	1	1	1	569	6.5	27.9
≥ 65 years	3,285	1	1	1	1	317	4.4	20.7
<b>Amisulpride</b>	<b>*****</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1.0</b>	<b>0.0</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	NaN
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<b>Rimegepant</b>	<b>135,828</b>	<b>1</b>	<b>8</b>	<b>17</b>	<b>30</b>	<b>723</b>	<b>27.7</b>	<b>36.1</b>
0-17 years	478	1	8	22	30	261	25.3	26.4
18-24 years	5,596	1	8	24	30	570	26.8	30.8
25-40 years	34,399	1	8	18	30	693	27.5	35.4
41-64 years	78,267	1	8	16	30	723	27.8	36.9
≥ 65 years	17,088	1	8	17	30	690	27.6	35.0

**Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Isatuximab</b>	<b>10,304</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>294</b>	<b>1.3</b>	<b>5.2</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	37	1	1	1	1	1	1.0	0.0
41-64 years	2,095	1	1	1	1	56	1.1	2.2
≥ 65 years	8,172	1	1	1	1	294	1.3	5.8
<b>Osilodrostat</b>	<b>198</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>80</b>	<b>626</b>	<b>66.5</b>	<b>82.0</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	19	22	30	30	90	180	65.7	45.5
25-40 years	34	1	30	30	90	389	74.1	90.2
41-64 years	74	1	28	30	56	300	60.3	69.1
≥ 65 years	71	1	26	31	80	626	69.6	97.4
<b>Ozanimod</b>	<b>1,149</b>	<b>1</b>	<b>30</b>	<b>34</b>	<b>90</b>	<b>623</b>	<b>77.7</b>	<b>86.5</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	40	8	30	38	90	623	92.8	123.3
25-40 years	332	1	30	30	87	493	66.3	69.4
41-64 years	636	1	30	40	90	618	79.7	89.1
≥ 65 years	141	1	30	60	90	472	91.2	95.6
<b>Selumetinib</b>	<b>294</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>65</b>	<b>731</b>	<b>73.9</b>	<b>97.3</b>
0-17 years	137	5	30	30	60	718	64.2	85.9
18-24 years	52	1	30	35	125	411	90.2	97.9
25-40 years	68	4	30	30	75	731	83.9	127.2
41-64 years	*****	7	30	30	80	308	62.1	66.0
≥ 65 years	*****	30	30	90	180	210	98.6	70.8

**Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Tucatinib</b>	<b>1,730</b>	<b>1</b>	<b>30</b>	<b>30</b>	<b>60</b>	<b>675</b>	<b>65.6</b>	<b>75.3</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	190	2	30	30	60	510	60.5	70.4
41-64 years	871	1	30	30	60	655	64.0	71.7
≥ 65 years	669	1	30	30	71	675	69.0	80.9
<b>Pemigatinib</b>	<b>669</b>	<b>2</b>	<b>14</b>	<b>14</b>	<b>21</b>	<b>323</b>	<b>30.1</b>	<b>40.8</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	20	14	14	14	14	287	39.4	69.8
41-64 years	184	2	14	14	25	304	29.8	40.4
≥ 65 years	465	2	14	14	21	323	29.8	39.4
<b>Sacituzumab Govitecan Hziy</b>	<b>22,689</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>294</b>	<b>1.1</b>	<b>3.2</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	7,225	1	1	1	1	214	1.1	3.2
≥ 65 years	14,623	1	1	1	1	294	1.1	3.3
<b>Opicapone</b>	<b>2,069</b>	<b>1</b>	<b>30</b>	<b>31</b>	<b>90</b>	<b>570</b>	<b>70.7</b>	<b>74.9</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	45	67	144	60.2	44.3
41-64 years	*****	2	30	30	64	550	64.5	70.1
≥ 65 years	1,750	1	30	36	90	570	71.8	75.8

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.



**Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**

**Distribution of Treatment Episode Gap Durations, Days**

	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Avapritinib	184	1	3	7	15	480	17.7	43.3
Teprotumumab Trbw	14,196	1	20	20	20	609	25.3	30.4
Tazemetostat	225	1	2	5	13	242	16.3	32.1
Lactitol	0	-	-	-	-	-	-	-
Bempezoic Acid	13,788	1	3	7	21	609	21.1	40.5
Eptinezumab Jjmr	9,577	1	83	90	94	557	90.8	33.9
Amisulpride	5	9	35	55	180	287	113.2	117.3
Rimegepant	135,828	1	9	23	48	775	40.5	56.0
Isatuximab	10,304	1	8	13	13	308	13.1	10.1
Osilodrostat	198	1	3	8	30	238	23.0	35.8
Ozanimod	1,149	1	3	6	14	535	14.1	31.5
Selumetinib	294	1	4	8	21	543	23.4	55.0
Tucatinib	1,730	1	3	7	18	464	18.2	36.0
Pemigatinib	669	1	4	7	9	235	10.7	20.1
Sacituzumab Govitecan Hziy	22,689	1	6	13	13	386	11.6	9.3
Opicapone	2,069	1	2	6	16	537	17.3	38.6

Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

**Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

Distribution of Treatment Episode Gap Durations, Days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Avapritinib</b>	<b>184</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>15</b>	<b>480</b>	<b>17.7</b>	<b>43.3</b>
Female	91	1	3	6	13	480	18.9	56.9
Male	93	1	3	7	25	162	16.6	23.6
<b>Teprotumumab Trbw</b>	<b>14,196</b>	<b>1</b>	<b>20</b>	<b>20</b>	<b>20</b>	<b>609</b>	<b>25.3</b>	<b>30.4</b>
Female	10,957	1	20	20	20	609	25.4	31.0
Male	3,239	1	20	20	20	411	25.1	28.3
<b>Tazemetostat</b>	<b>225</b>	<b>1</b>	<b>2</b>	<b>5</b>	<b>13</b>	<b>242</b>	<b>16.3</b>	<b>32.1</b>
Female	113	1	3	5	13	242	15.5	30.1
Male	112	1	2	4	14	232	17.1	34.1
<b>Lactitol</b>	<b>0</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
<b>Bempedoic Acid</b>	<b>13,788</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>21</b>	<b>609</b>	<b>21.1</b>	<b>40.5</b>
Female	8,230	1	3	7	22	579	22.1	41.7
Male	5,558	1	3	7	20	609	19.7	38.4
<b>Eptinezumab Jjmr</b>	<b>9,577</b>	<b>1</b>	<b>83</b>	<b>90</b>	<b>94</b>	<b>557</b>	<b>90.8</b>	<b>33.9</b>
Female	8,038	1	83	90	94	557	91.1	34.4
Male	1,539	1	83	90	92	432	89.3	31.1
<b>Amisulpride</b>	<b>5</b>	<b>9</b>	<b>35</b>	<b>55</b>	<b>180</b>	<b>287</b>	<b>113.2</b>	<b>117.3</b>
Female	4	9	22	108	234	287	127.8	130.1
Male	1	55	55	55	55	55	55.0	NaN
<b>Rimegepant</b>	<b>135,828</b>	<b>1</b>	<b>9</b>	<b>23</b>	<b>48</b>	<b>775</b>	<b>40.5</b>	<b>56.0</b>
Female	118,623	1	10	23	48	775	40.6	55.8
Male	17,205	1	8	21	47	686	40.1	57.4
<b>Isatuximab</b>	<b>10,304</b>	<b>1</b>	<b>8</b>	<b>13</b>	<b>13</b>	<b>308</b>	<b>13.1</b>	<b>10.1</b>
Female	4,981	1	8	13	13	228	13.1	9.6
Male	5,323	1	8	13	13	308	13.0	10.6

**Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

Distribution of Treatment Episode Gap Durations, Days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Osilodrostat</b>	<b>198</b>	<b>1</b>	<b>3</b>	<b>8</b>	<b>30</b>	<b>238</b>	<b>23.0</b>	<b>35.8</b>
Female	174	1	3	8	28	137	20.3	27.2
Male	24	1	5	12	41	238	42.5	70.5
<b>Ozanimod</b>	<b>1,149</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>14</b>	<b>535</b>	<b>14.1</b>	<b>31.5</b>
Female	832	1	3	6	14	363	14.2	26.8
Male	317	1	3	5	12	535	13.6	41.4
<b>Selumetinib</b>	<b>294</b>	<b>1</b>	<b>4</b>	<b>8</b>	<b>21</b>	<b>543</b>	<b>23.4</b>	<b>55.0</b>
Female	157	1	3	7	25	543	25.8	64.8
Male	137	1	4	9	21	310	20.6	41.0
<b>Tucatinib</b>	<b>1,730</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>18</b>	<b>464</b>	<b>18.2</b>	<b>36.0</b>
Female	1,705	1	3	7	18	464	18.0	35.5
Male	25	1	3	6	24	292	29.0	61.5
<b>Pemigatinib</b>	<b>669</b>	<b>1</b>	<b>4</b>	<b>7</b>	<b>9</b>	<b>235</b>	<b>10.7</b>	<b>20.1</b>
Female	423	1	4	7	11	223	11.3	19.7
Male	246	1	4	7	8	235	9.5	20.8
<b>Sacituzumab Govitecan Hziy</b>	<b>22,689</b>	<b>1</b>	<b>6</b>	<b>13</b>	<b>13</b>	<b>386</b>	<b>11.6</b>	<b>9.3</b>
Female	20,485	1	6	13	13	386	11.6	9.4
Male	2,204	4	6	13	13	121	11.5	8.0
<b>Opicapone</b>	<b>2,069</b>	<b>1</b>	<b>2</b>	<b>6</b>	<b>16</b>	<b>537</b>	<b>17.3</b>	<b>38.6</b>
Female	700	1	2	6	17	537	17.0	39.3
Male	1,369	1	2	6	16	509	17.4	38.2

Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

Distribution of Treatment Episode Gap Durations, Days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Avapritinib</b>	<b>184</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>15</b>	<b>480</b>	<b>17.7</b>	<b>43.3</b>
0-17 years	1	6	6	6	6	6	6.0	NaN
18-24 years	2	5	5	26	46	46	25.5	29.0
25-40 years	10	1	3	4	7	36	7.2	10.3
41-64 years	77	1	3	7	12	85	12.5	16.6
≥ 65 years	94	1	3	7	25	480	23.1	58.1
<b>Teprotumumab Trbw</b>	<b>14,196</b>	<b>1</b>	<b>20</b>	<b>20</b>	<b>20</b>	<b>609</b>	<b>25.3</b>	<b>30.4</b>
0-17 years	11	18	20	20	22	27	21.0	2.5
18-24 years	153	4	20	20	21	318	25.4	28.7
25-40 years	1,039	2	20	20	21	440	25.6	26.5
41-64 years	5,141	1	20	20	21	573	25.9	31.7
≥ 65 years	7,852	1	20	20	20	609	24.9	30.1
<b>Tazemetostat</b>	<b>225</b>	<b>1</b>	<b>2</b>	<b>5</b>	<b>13</b>	<b>242</b>	<b>16.3</b>	<b>32.1</b>
0-17 years	4	1	2	3	3	3	2.3	1.0
18-24 years	9	1	5	8	13	54	13.9	16.8
25-40 years	10	1	3	8	10	122	19.9	37.1
41-64 years	57	1	2	3	12	242	16.1	38.1
≥ 65 years	145	1	3	5	14	232	16.7	30.5
<b>Lactitol</b>	<b>0</b>	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-

**Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

Distribution of Treatment Episode Gap Durations, Days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Bempedoic Acid</b>	<b>13,788</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>21</b>	<b>609</b>	<b>21.1</b>	<b>40.5</b>
0-17 years	10	1	1	3	5	13	4.2	4.1
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	218	1	3	7	20	203	18.1	28.7
41-64 years	4,160	1	3	7	20	502	20.5	38.8
≥ 65 years	9,400	1	3	7	21	609	21.5	41.4
<b>Eptinezumab Jjmr</b>	<b>9,577</b>	<b>1</b>	<b>83</b>	<b>90</b>	<b>94</b>	<b>557</b>	<b>90.8</b>	<b>33.9</b>
0-17 years	19	77	83	90	97	265	99.1	41.0
18-24 years	248	1	85	90	97	187	92.5	26.7
25-40 years	1,561	1	83	90	94	407	90.0	32.8
41-64 years	4,464	1	83	90	94	557	90.7	37.3
≥ 65 years	3,285	1	83	90	93	489	91.1	29.7
<b>Amisulpride</b>	<b>5</b>	<b>9</b>	<b>35</b>	<b>55</b>	<b>180</b>	<b>287</b>	<b>113.2</b>	<b>117.3</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	1	55	55	55	55	55	55.0	NaN
41-64 years	4	9	22	108	234	287	127.8	130.1
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<b>Rimegepant</b>	<b>135,828</b>	<b>1</b>	<b>9</b>	<b>23</b>	<b>48</b>	<b>775</b>	<b>40.5</b>	<b>56.0</b>
0-17 years	478	1	9	24	53	585	46.3	70.8
18-24 years	5,596	1	10	26	57	775	45.8	60.9
25-40 years	34,399	1	10	23	47	662	39.3	53.4
41-64 years	78,267	1	9	22	47	726	39.8	55.1
≥ 65 years	17,088	1	9	22	52	710	44.1	62.6

**Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

Distribution of Treatment Episode Gap Durations, Days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Isatuximab</b>	<b>10,304</b>	<b>1</b>	<b>8</b>	<b>13</b>	<b>13</b>	<b>308</b>	<b>13.1</b>	<b>10.1</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	37	6	6	13	13	63	13.2	10.9
41-64 years	2,095	1	12	13	13	97	13.3	8.1
≥ 65 years	8,172	1	7	13	13	308	13.0	10.6
<b>Osilodrostat</b>	<b>198</b>	<b>1</b>	<b>3</b>	<b>8</b>	<b>30</b>	<b>238</b>	<b>23.0</b>	<b>35.8</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	19	1	3	7	42	96	21.1	28.0
25-40 years	34	1	4	7	26	124	19.7	26.9
41-64 years	74	1	4	14	44	238	29.9	39.6
≥ 65 years	71	1	2	5	16	223	17.9	36.7
<b>Ozanimod</b>	<b>1,149</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>14</b>	<b>535</b>	<b>14.1</b>	<b>31.5</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	40	1	3	9	16	62	12.1	13.1
25-40 years	332	1	3	6	14	449	13.7	30.7
41-64 years	636	1	3	5	12	535	14.3	34.9
≥ 65 years	141	1	3	7	17	111	14.1	18.4
<b>Selumetinib</b>	<b>294</b>	<b>1</b>	<b>4</b>	<b>8</b>	<b>21</b>	<b>543</b>	<b>23.4</b>	<b>55.0</b>
0-17 years	137	1	4	8	19	543	21.2	51.0
18-24 years	52	1	4	8	18	503	29.1	77.4
25-40 years	68	1	4	7	23	310	21.5	46.8
41-64 years	30	1	4	12	25	224	26.3	47.8
≥ 65 years	7	1	4	27	31	120	31.0	41.3

**Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

Distribution of Treatment Episode Gap Durations, Days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Tucatinib</b>	<b>1,730</b>	<b>1</b>	<b>3</b>	<b>7</b>	<b>18</b>	<b>464</b>	<b>18.2</b>	<b>36.0</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	190	1	3	7	17	326	17.0	32.3
41-64 years	871	1	3	7	19	464	19.7	39.5
≥ 65 years	669	1	3	8	17	373	16.7	32.1
<b>Pemigatinib</b>	<b>669</b>	<b>1</b>	<b>4</b>	<b>7</b>	<b>9</b>	<b>235</b>	<b>10.7</b>	<b>20.1</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	20	1	5	7	9	66	9.9	14.4
41-64 years	184	1	5	7	10	235	13.3	29.9
≥ 65 years	465	1	4	7	9	182	9.6	14.8
<b>Sacituzumab Govitecan Hziy</b>	<b>22,689</b>	<b>1</b>	<b>6</b>	<b>13</b>	<b>13</b>	<b>386</b>	<b>11.6</b>	<b>9.3</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	1	13	13	13	13	13	13.0	NaN
25-40 years	840	4	6	12	13	137	11.6	9.0
41-64 years	7,225	1	6	13	13	223	11.9	8.8
≥ 65 years	14,623	1	6	13	13	386	11.4	9.5
<b>Opicapone</b>	<b>2,069</b>	<b>1</b>	<b>2</b>	<b>6</b>	<b>16</b>	<b>537</b>	<b>17.3</b>	<b>38.6</b>
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	6	1	1	2	2	9	2.8	3.1
41-64 years	313	1	2	4	12	356	14.8	38.3
≥ 65 years	1,750	1	2	6	17	537	17.8	38.7

Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**

	Distribution of First Treatment Episode Gap Duration, Days							Standard Deviation
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	
Avapritinib	86	1	3	9	27	87	16.4	19.0
Teprotumumab Trbw	2,696	1	20	20	20	609	23.5	26.4
Tazemetostat	106	1	3	6	17	232	19.7	34.3
Lactitol	0	.	.	.	.	.	.	.
Bempeoic Acid	5,502	1	3	8	26	609	26.0	49.8
Eptinezumab Jjmr	3,666	1	83	90	95	557	92.2	39.2
Amisulpride	4	9	22	45	171	287	96.5	128.4
Rimegepant	40,448	1	10	27	63	775	52.2	72.8
Isatuximab	961	1	6	6	8	308	9.0	13.5
Osilodrostat	67	1	4	12	40	137	23.6	26.1
Ozanimod	472	1	3	7	16	535	18.8	45.3
Selumetinib	106	1	4	9	29	543	28.9	64.1
Tucatinib	665	1	4	8	20	353	20.3	37.1
Pemigatinib	162	1	2	6	12	235	13.3	30.8
Sacituzumab Govitecan Hziy	2,345	1	6	6	13	142	10.3	9.1
Opicapone	905	1	2	7	19	537	21.3	49.1

Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.



**Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

Distribution of First Treatment Episode Gap Duration, Days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Avapritinib</b>	86	1	3	9	27	87	16.4	19.0
Female	41	1	3	7	19	85	15.0	17.9
Male	45	1	4	10	27	87	17.7	20.1
<b>Teprotumumab Trbw</b>	2,696	1	20	20	20	609	23.5	26.4
Female	2,081	1	20	20	20	609	23.9	27.9
Male	615	1	20	20	20	379	22.4	20.5
<b>Tazemetostat</b>	106	1	3	6	17	232	19.7	34.3
Female	51	1	3	8	14	122	16.0	24.7
Male	55	1	3	5	28	232	23.1	41.1
<b>Lactitol</b>	0	.	.	.	.	.	.	.
Female	0	.	.	.	.	.	.	.
Male	0	.	.	.	.	.	.	.
<b>Bempedoic Acid</b>	5,502	1	3	8	26	609	26.0	49.8
Female	3,277	1	3	9	26	579	26.9	50.3
Male	2,225	1	3	8	24	609	24.7	49.0
<b>Eptinezumab Jjmr</b>	3,666	1	83	90	95	557	92.2	39.2
Female	3,068	1	83	90	95	557	92.4	39.8
Male	598	1	83	90	94	432	91.3	36.3
<b>Amisulpride</b>	4	9	22	45	171	287	96.5	128.4
Female	3	9	9	35	287	287	110.3	153.5
Male	1	55	55	55	55	55	55.0	NaN
<b>Rimegepant</b>	40,448	1	10	27	63	775	52.2	72.8
Female	35,100	1	10	27	63	775	52.3	72.7
Male	5,348	1	9	24	62	686	51.8	73.7

**Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Sex**

Distribution of First Treatment Episode Gap Duration, Days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Isatuximab</b>	961	1	6	6	8	308	9.0	13.5
Female	462	3	6	6	10	191	9.5	12.7
Male	499	1	6	6	7	308	8.5	14.1
<b>Osilodrostat</b>	67	1	4	12	40	137	23.6	26.1
Female	55	1	4	12	40	137	23.9	26.8
Male	12	3	5	12	41	69	22.6	23.2
<b>Ozanimod</b>	472	1	3	7	16	535	18.8	45.3
Female	338	1	3	7	16	363	18.3	37.1
Male	134	1	3	6	16	535	19.8	61.6
<b>Selumetinib</b>	106	1	4	9	29	543	28.9	64.1
Female	52	1	4	12	30	543	37.6	83.3
Male	54	1	4	8	17	224	20.6	36.1
<b>Tucatinib</b>	665	1	4	8	20	353	20.3	37.1
Female	656	1	4	8	20	353	20.3	37.3
Male	9	1	5	6	24	54	15.4	17.1
<b>Pemigatinib</b>	162	1	2	6	12	235	13.3	30.8
Female	102	1	3	6	12	210	11.8	24.4
Male	60	1	2	5	11	235	16.0	39.6
<b>Sacituzumab Govitecan Hziy</b>	2,345	1	6	6	13	142	10.3	9.1
Female	2,025	1	6	6	13	142	10.2	8.8
Male	320	4	6	6	13	117	10.8	11.2
<b>Opicapone</b>	905	1	2	7	19	537	21.3	49.1
Female	321	1	3	7	19	537	20.5	51.0
Male	584	1	2	6	20	509	21.8	48.1

Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Distribution of First Treatment Episode Gap Duration, Days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Avapritinib</b>	86	1	3	9	27	87	16.4	19.0
0-17 years	1	6	6	6	6	6	6.0	NaN
18-24 years	1	46	46	46	46	46	46.0	NaN
25-40 years	4	3	4	5	7	8	5.0	2.2
41-64 years	36	1	3	7	23	85	15.5	20.5
≥ 65 years	44	1	4	11	30	87	17.7	18.3
<b>Teprotumumab Trbw</b>	2,696	1	20	20	20	609	23.5	26.4
0-17 years	3	20	20	20	20	20	20.0	0.0
18-24 years	27	4	20	20	21	24	20.0	3.5
25-40 years	194	14	20	20	21	397	25.4	31.0
41-64 years	959	1	20	20	21	491	24.1	26.6
≥ 65 years	1,513	1	20	20	20	609	23.0	25.9
<b>Tazemetostat</b>	106	1	3	6	17	232	19.7	34.3
0-17 years	3	1	1	2	3	3	2.0	1.0
18-24 years	2	5	5	30	54	54	29.5	34.6
25-40 years	7	1	3	8	34	122	25.6	44.0
41-64 years	21	1	1	3	12	107	17.7	32.1
≥ 65 years	73	1	3	8	25	232	20.2	35.0
<b>Lactitol</b>	0	.	.	.	.	.	.	.
0-17 years	0	.	.	.	.	.	.	.
18-24 years	0	.	.	.	.	.	.	.
25-40 years	0	.	.	.	.	.	.	.
41-64 years	0	.	.	.	.	.	.	.
≥ 65 years	0	.	.	.	.	.	.	.

**Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Distribution of First Treatment Episode Gap Duration, Days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Bempedoic Acid</b>	5,502	1	3	8	26	609	26.0	49.8
0-17 years	1	1	1	1	1	1	1.0	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	78	1	5	9	31	203	25.2	36.0
41-64 years	1,679	1	3	8	26	502	25.3	47.9
≥ 65 years	3,744	1	3	8	25	609	26.4	50.9
<b>Eptinezumab Jjmr</b>	3,666	1	83	90	95	557	92.2	39.2
0-17 years	7	79	83	90	97	110	90.6	10.6
18-24 years	106	12	85	91	97	187	95.3	24.8
25-40 years	592	1	83	90	97	370	92.3	34.9
41-64 years	1,725	1	83	90	96	557	92.7	43.9
≥ 65 years	1,236	1	83	90	94	468	91.3	35.3
<b>Amisulpride</b>	4	9	22	45	171	287	96.5	128.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	1	55	55	55	55	55	55.0	NaN
41-64 years	3	9	9	35	287	287	110.3	153.5
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<b>Rimegepant</b>	40,448	1	10	27	63	775	52.2	72.8
0-17 years	180	1	9	27	63	585	57.6	89.5
18-24 years	1,875	1	10	30	73	775	56.1	74.1
25-40 years	10,150	1	10	26	60	662	49.4	68.1
41-64 years	22,472	1	10	26	61	726	51.7	72.8
≥ 65 years	5,771	1	10	27	71	710	57.7	79.5

**Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Distribution of First Treatment Episode Gap Duration, Days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Isatuximab</b>	961	1	6	6	8	308	9.0	13.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	4	6	6	6	13	19	9.3	6.5
41-64 years	197	1	6	6	13	56	9.4	7.4
≥ 65 years	760	2	6	6	7	308	8.9	14.7
<b>Osilodrostat</b>	67	1	4	12	40	137	23.6	26.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	3	4	4	42	47	47	31.0	23.5
25-40 years	11	1	3	8	24	95	21.2	29.0
41-64 years	29	2	8	19	37	137	28.2	30.7
≥ 65 years	24	1	5	11	37	61	18.3	17.9
<b>Ozanimod</b>	472	1	3	7	16	535	18.8	45.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	18	1	2	9	15	62	11.1	14.3
25-40 years	125	1	3	7	16	449	16.7	44.3
41-64 years	263	1	3	6	16	535	20.5	51.1
≥ 65 years	66	1	4	9	18	111	17.9	23.0
<b>Selumetinib</b>	106	1	4	9	29	543	28.9	64.1
0-17 years	49	1	4	8	22	543	28.6	78.9
18-24 years	17	2	3	12	17	96	19.2	25.0
25-40 years	24	1	5	10	21	226	24.2	47.2
41-64 years	11	1	4	25	67	224	51.6	73.0
≥ 65 years	5	4	5	29	31	120	37.8	47.7

**Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022, by Age Group**

	Distribution of First Treatment Episode Gap Duration, Days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<b>Tucatinib</b>	665	1	4	8	20	353	20.3	37.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	74	1	3	8	19	132	19.9	31.3
41-64 years	333	1	4	8	20	279	21.1	38.4
≥ 65 years	258	1	4	8	19	353	19.3	37.0
<b>Pemigatinib</b>	162	1	2	6	12	235	13.3	30.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	4	1	2	7	39	66	20.3	30.9
41-64 years	47	1	3	8	16	235	22.4	47.7
≥ 65 years	111	1	2	5	9	182	9.2	19.0
<b>Sacituzumab Govitecan Hziy</b>	2,345	1	6	6	13	142	10.3	9.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	1	13	13	13	13	13	13.0	NaN
25-40 years	104	5	6	6	13	60	10.6	8.5
41-64 years	784	1	6	6	13	118	11.1	9.5
≥ 65 years	1,456	1	6	6	13	142	9.8	8.9
<b>Opicapone</b>	905	1	2	7	19	537	21.3	49.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	3	1	1	2	9	9	4.0	4.4
41-64 years	111	1	2	6	19	356	23.6	59.6
≥ 65 years	791	1	2	7	19	537	21.1	47.6

Data presented by a dash, asterisk, or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

**Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022<sup>1</sup>**

	Censoring Reason												
	End of exposure episode <sup>2</sup>		Occurrence of request-defined censoring criteria <sup>3</sup>		Evidence of death <sup>4</sup>		Disenrollment <sup>5</sup>		End of data partner data <sup>6</sup>		End of query period <sup>7</sup>		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Avapritinib	349	339	97.1%	0	0.0%	*****	*****	58	16.6%	*****	*****	0	0.0%
Teprotumumab Trbw	17,185	17,183	100.0%	0	0.0%	*****	*****	73	0.4%	*****	*****	0	0.0%
Tazemetostat	437	425	97.30%	0	0.00%	11	2.50%	75	17.20%	64	14.60%	0	0.00%
Lactitol	0	.	.	.	.	.	.	.	.	.	.	.	.
Bempedoic Acid	25,112	24,724	98.50%	0	0.00%	53	0.20%	4,720	18.80%	4,377	17.40%	0	0.00%
Eptinezumab Jjmr	15,196	15,188	99.9%	0	0.0%	*****	*****	224	1.5%	211	1.4%	0	0.0%
Amisulpride	306	*****	*****	0	0.0%	0	0.0%	*****	*****	*****	*****	0	0.0%
Rimegepant	207,166	204,104	98.50%	0	0.00%	59	0.00%	17,805	8.60%	16,929	8.20%	0	0.00%
Isatuximab	11,363	11,358	100.0%	0	0.0%	*****	*****	*****	*****	41	0.4%	0	0.0%
Osilodrostat	362	352	97.2%	0	0.0%	*****	*****	89	24.6%	*****	*****	0	0.0%
Ozanimod	2,072	1,992	96.1%	0	0.0%	*****	*****	579	27.9%	*****	*****	0	0.0%
Selumetinib	497	474	95.4%	0	0.0%	*****	*****	99	19.9%	*****	*****	0	0.0%
Tucatinib	3,047	2,966	97.30%	0	0.00%	67	2.20%	427	14.00%	335	11.00%	0	0.00%
Pemigatinib	944	928	98.30%	0	0.00%	15	1.60%	72	7.60%	57	6.00%	0	0.00%
Sacituzumab Govitecan Hziy	25,276	25,275	100.0%	0	0.0%	*****	*****	*****	*****	93	0.4%	0	0.0%
Opicapone	4,194	4,120	98.20%	0	0.00%	42	1.00%	897	21.40%	868	20.70%	0	0.00%

<sup>1</sup>An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

<sup>2</sup>Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

<sup>3</sup>Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

<sup>4</sup>Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

<sup>5</sup>Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

<sup>6</sup>Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

<sup>7</sup>Represents episodes censored due to user-specified study end date.

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash or period represent missing information. Data are not presented in shaded cells due to their inability to be calculated. This table may not use all data representations.

**Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**

	Amisulpride		Avapritinib		Teprotumumab Trbw		Bempedoic Acid	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>								
Enrolled at any point during the query period	158,200,645	N/A	158,200,645	N/A	158,200,645	N/A	158,200,645	N/A
Had required coverage type (medical and/or drug coverage)	98,737,790	59,462,855	98,737,790	59,462,855	98,737,790	59,462,855	98,737,790	59,462,855
Enrolled during specified age range	98,737,043	747	98,737,043	747	98,737,043	747	98,737,043	747
Had requestable medical charts	98,737,043	0	98,737,043	0	98,737,043	0	98,737,043	0
Met demographic requirements (sex, race, and Hispanic origin)	98,159,617	577,426	98,159,617	577,426	98,159,617	577,426	98,159,617	577,426
<b>Members with a valid index event</b>								
Had any cohort-defining claim during the query period	345	98,159,272	189	98,159,428	3,223	98,156,394	12,564	98,147,053
Claim recorded during specified age range	345	0	189	0	3,223	0	12,564	0
Episode defining index claim recorded during the query period	345	0	189	0	3,223	0	12,564	0
Met exposure incidence criteria	345	0	189	0	3,223	0	12,564	0
<b>Members with required pre-index history</b>								
Had sufficient pre-index continuous enrollment	301	44	165	24	2,989	234	11,324	1,240
Met inclusion and exclusion criteria	301	0	165	0	2,989	0	11,324	0
<b>Members with required post-index follow-up</b>								
Had sufficient post-index continuous enrollment	301	0	165	0	2,989	0	11,324	0
<b>Final cohort</b>								
Number of members	301	N/A	165	N/A	2,989	N/A	11,324	N/A
Number of episodes	301	N/A	165	N/A	2,989	N/A	11,324	N/A



**Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**

	Tazemetostat		Eptinezumab Jjmr		Lactitol		Isatuximab	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>								
Enrolled at any point during the query period	158,200,645	N/A	158,200,645	N/A	158,200,645	N/A	158,200,645	N/A
Had required coverage type (medical and/or drug coverage)	98,737,790	59,462,855	98,737,790	59,462,855	98,737,790	59,462,855	98,737,790	59,462,855
Enrolled during specified age range	98,737,043	747	98,737,043	747	98,737,043	747	98,737,043	747
Had requestable medical charts	98,737,043	0	98,737,043	0	98,737,043	0	98,737,043	0
Met demographic requirements (sex, race, and Hispanic origin)	98,159,617	577,426	98,159,617	577,426	98,159,617	577,426	98,159,617	577,426
<b>Members with a valid index event</b>								
Had any cohort-defining claim during the query period	228	98,159,389	6,186	98,153,431	12,564	98,147,053	228	98,159,389
Claim recorded during specified age range	228	0	6,186	0	12,564	0	228	0
Episode defining index claim recorded during the query period	228	0	6,186	0	12,564	0	228	0
Met exposure incidence criteria	228	0	6,186	0	12,564	0	228	0
<b>Members with required pre-index history</b>								
Had sufficient pre-index continuous enrollment	212	16	5,619	567	11,324	1,240	212	16
Met inclusion and exclusion criteria	212	0	5,619	0	11,324	0	212	0
<b>Members with required post-index follow-up</b>								
Had sufficient post-index continuous enrollment	212	0	5,619	0	11,324	0	212	0
<b>Final cohort</b>								
Number of members	212	N/A	5,619	N/A	11,324	N/A	212	N/A
Number of episodes	212	N/A	5,619	N/A	11,324	N/A	212	N/A

**Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**

	Opicapone		Osilodrostat		Rimegepant		Ozanimod	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>								
Enrolled at any point during the query period	158,200,645	N/A	158,200,645	N/A	158,200,645	N/A	158,200,645	N/A
Had required coverage type (medical and/or drug coverage)	98,737,790	59,462,855	98,737,790	59,462,855	98,737,790	59,462,855	98,737,790	59,462,855
Enrolled during specified age range	98,737,043	747	98,737,043	747	98,737,043	747	98,737,043	747
Had requestable medical charts	98,737,043	0	98,737,043	0	98,737,043	0	98,737,043	0
Met demographic requirements (sex, race, and Hispanic origin)	98,159,617	577,426	98,159,617	577,426	98,159,617	577,426	98,159,617	577,426
<b>Members with a valid index event</b>								
Had any cohort-defining claim during the query period	6,186	98,153,431	192	98,159,425	81,263	98,078,354	1,095	98,158,522
Claim recorded during specified age range	6,186	0	192	0	81,263	0	1,095	0
Episode defining index claim recorded during the query period	6,186	0	192	0	81,263	0	1,095	0
Met exposure incidence criteria	6,186	0	192	0	81,263	0	1,095	0
<b>Members with required pre-index history</b>								
Had sufficient pre-index continuous enrollment	5,619	567	164	28	71,338	9,925	923	172
Met inclusion and exclusion criteria	5,619	0	164	0	71,338	0	923	0
<b>Members with required post-index follow-up</b>								
Had sufficient post-index continuous enrollment	5,619	0	164	0	71,338	0	923	0
<b>Final cohort</b>								
Number of members	5,619	N/A	164	N/A	71,338	N/A	923	N/A
Number of episodes	5,619	N/A	164	N/A	71,338	N/A	923	N/A

**Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**

	Pemigatinib		Sacituzumab Govitecan		Selumetinib		Tucatinib	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
<b>Members meeting enrollment and demographic requirements</b>								
Enrolled at any point during the query period	158,200,645	N/A	158,200,645	N/A	158,200,645	N/A	158,200,645	N/A
Had required coverage type (medical and/or drug coverage)	98,737,790	59,462,855	98,737,790	59,462,855	98,737,790	59,462,855	98,737,790	59,462,855
Enrolled during specified age range	98,737,043	747	98,737,043	747	98,737,043	747	98,737,043	747
Had requestable medical charts	98,737,043	0	98,737,043	0	98,737,043	0	98,737,043	0
Met demographic requirements (sex, race, and Hispanic origin)	98,159,617	577,426	98,159,617	577,426	98,159,617	577,426	98,159,617	577,426
<b>Members with a valid index event</b>								
Had any cohort-defining claim during the query period	314	98,159,303	2,874	98,156,743	224	98,159,393	1,520	98,158,097
Claim recorded during specified age range	314	0	2,874	0	224	0	1,520	0
Episode defining index claim recorded during the query period	314	0	2,874	0	224	0	1,520	0
Met exposure incidence criteria	314	0	2,874	0	224	0	1,520	0
<b>Members with required pre-index history</b>								
Had sufficient pre-index continuous enrollment	275	39	2,587	287	203	21	1,317	203
Met inclusion and exclusion criteria	275	0	2,587	0	203	0	1,317	0
<b>Members with required post-index follow-up</b>								
Had sufficient post-index continuous enrollment	275	0	2,587	0	203	0	1,317	0
<b>Final cohort</b>								
Number of members	275	N/A	2,587	N/A	203	N/A	1,317	N/A
Number of episodes	275	N/A	2,587	N/A	203	N/A	1,317	N/A

N/A: Not Applicable


**Figure 1a. Patient Entry into Study by Month for Avapritinib in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**

---

*\*\*\*\*Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

\*The FDA approval date for this drug was on January 9, 2020, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020>

**Figure 1b. Patient Entry into Study by Month for Teprotumumab Trbw in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**



\*The FDA approval date for this drug was on January 21, 2020, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020>


**Figure 1c. Patient Entry into Study by Month for Tazemetostat in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**

---

*\*\*\*\*Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*


\*The FDA approval date for this drug was on January 23, 2020, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020>

**Figure 1d. Patient Entry into Study by Month for Bempedoic Acid in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**



\*The FDA approval date for this drug was on February 21, 2020, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020>


**Figure 1e. Patient Entry into Study by Month for Eptinezumab Jjmr in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**



\*The FDA approval date for this drug was on February 21, 2020, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020>



Figure 1f. Patient Entry into Study by Month for lactitolin the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022



\*The FDA approval date for this drug was on April 24, 2020, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020>


**Figure 1g. Patient Entry into Study by Month for Amisulpride in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**

---

*\*\*\*\*Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

\*The FDA approval date for this drug was on February 26, 2020, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020>

**Figure 1h. Patient Entry into Study by Month for Rimegepant in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**



\*The FDA approval date for this drug was on February 27, 2020, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020>

**Figure 1i. Patient Entry into Study by Month for Isatuximab in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**

---

*\*\*\*\*Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

\*The FDA approval date for this drug was on March 2, 2020, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020>


**Figure 1j. Patient Entry into Study by Month for Osilodrostat in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**

---

*\*\*\*\*Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

\*The FDA approval date for this drug was on March 6, 2020, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020>

**Figure 1k. Patient Entry into Study by Month for Ozanimod in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**



\*The FDA approval date for this drug was on March 25, 2020, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020>


**Figure 1l. Patient Entry into Study by Month for Selumetinib in the SDD from January 1, 2020 to August 31, 2022**

---

*\*\*\*\*Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

\*The FDA approval date for this drug was on April 10, 2020, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020>

**Figure 1m. Patient Entry into Study by Month for Tucatinib in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**



\*The FDA approval date for this drug was on April 17, 2020, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020>




**Figure 1n. Patient Entry into Study by Month for Pemigatinib in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**

---

*\*\*\*\*Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*


\*The FDA approval date for this drug was on April 17, 2020, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020>

**Figure 1o. Patient Entry into Study by Month for Sacituzumab Govitecan Hziy in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**



\*The FDA approval date for this drug was on April 22, 2020, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020>

**Figure 1p. Patient Entry into Study by Month for Opicapone in the Sentinel Distributed Database (SDD) from January 1, 2020 to August 31, 2022**



\*The FDA approval date for this drug was on April 24, 2020, as listed on the FDA website: <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020>

**Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (January 17, 2023)**

Masked DP ID	DP Start Date	DP End Date <sup>1</sup>
DP01	01/01/2004	05/31/2021
DP02	01/01/2005	07/31/2022
DP03	01/01/2008	04/30/2022
DP04	01/01/2006	06/30/2022
DP05	01/01/2000	07/31/2022
DP06	01/01/2000	12/31/2020
DP07	01/01/2000	05/31/2022
DP08	01/01/2000	08/31/2022
DP09	01/01/2000	08/31/2022
DP10	01/01/2000	05/31/2021
DP11	01/01/2007	05/31/2022
DP12	01/01/2014	12/31/2018
DP13	01/01/2008	06/30/2022
DP14	01/01/2010	06/30/2022

<sup>1</sup>End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

**Appendix B. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request**

<b>Non-Proprietary Name</b>	<b>Proprietary Name</b>
<b>Avapritinib</b>	
Avapritinib	Ayvakit
<b>Teprotumumab Trbw</b>	
Teprotumumab-Trbw	Tepezza
<b>Tazemetostat</b>	
Tazemetostat Hydrobromide	Tazverik
<b>Bempedoic</b>	
Bempedoic Acid	Nexletol
bempedoic acid	Nexletol
<b>Eptinezumab Jjmr</b>	
Eptinezumab-Jjmr	Vyepti
<b>Amisulpride</b>	
Amisulpride	Barhemsys
<b>Lactitol</b>	
Lactitol	Pizensy
<b>Rimegepant</b>	
Rimegepant Sulfate	Nurtec ODT
<b>Isatuximab</b>	
Isatuximab-lrfc	Sarclisa
<b>Osilodrostat</b>	
Osilodrostat Phosphate	Isturisa
<b>Ozanimod</b>	
Ozanimod Hydrochloride	Zeposia
Ozanimod Hydrochloride	Zeposia Starter Kit
Ozanimod Hydrochloride	Zeposia Starter Pack
<b>Selumetinib</b>	
Selumetinib Sulfate/Vitamin E TPGS	Koselugo
<b>Tucatinib</b>	
Tucatinib	Tukysa
<b>Pemigatinib</b>	
Pemigatinib	Pemazyre
<b>Sacituzumab Govitecan Hziy</b>	
Sacituzumab Govitecan-Hziy	Trodelyv
<b>Opicapone</b>	
Opicapone	Ongentys

**Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS) and Codes Used to Define Exposures in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
<b>Teprotumumab Trbw</b>			
J3241	Injection, Teprotumumab-Trbw, 10 mg	HC	J32
<b>Eptinezumab Jjmr</b>			
J3032	Injection, Eptinezumab-Jjmr, 1 mg	Procedure	HCPCS
<b>Isatuximab</b>			
J9227	Injection, Isatuximab-Irfc, 10 mg	Procedure	HCPCS
<b>Sacituzumab Govitecan Hziy</b>			
C9066	Injection, Sacituzumab Govitecan-Hziy, 2.5 mg	Procedure	HCPCS
J9317	Injection, Sacituzumab Govitecan-Hziy, 2.5 mg	Procedure	HCPCS

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
<b>Acquired Hypothyroidism</b>			
244.0	Postsurgical hypothyroidism	Diagnosis	ICD-9-CM
244.1	Other postablative hypothyroidism	Diagnosis	ICD-9-CM
244.2	Iodine hypothyroidism	Diagnosis	ICD-9-CM
244.3	Other iatrogenic hypothyroidism	Diagnosis	ICD-9-CM
244.8	Other specified acquired hypothyroidism	Diagnosis	ICD-9-CM
244.9	Unspecified hypothyroidism	Diagnosis	ICD-9-CM
E00.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CM
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CM
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CM
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CM
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CM
E03.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
<b>Alcohol Abuse</b>			
291.0	Alcohol withdrawal delirium	Diagnosis	ICD-9-CM
291.1	Alcohol-induced persisting amnesic disorder	Diagnosis	ICD-9-CM
291.2	Alcohol-induced persisting dementia	Diagnosis	ICD-9-CM
291.3	Alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
291.4	Idiosyncratic alcohol intoxication	Diagnosis	ICD-9-CM
291.5	Alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
291.8	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.81	Alcohol withdrawal	Diagnosis	ICD-9-CM
291.82	Alcohol induced sleep disorders	Diagnosis	ICD-9-CM
291.89	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.9	Unspecified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
303.00	Acute alcoholic intoxication, unspecified	Diagnosis	ICD-9-CM
303.01	Acute alcoholic intoxication, continuous	Diagnosis	ICD-9-CM
303.02	Acute alcoholic intoxication, episodic	Diagnosis	ICD-9-CM
303.90	Other and unspecified alcohol dependence, unspecified	Diagnosis	ICD-9-CM
303.91	Other and unspecified alcohol dependence, continuous	Diagnosis	ICD-9-CM
303.92	Other and unspecified alcohol dependence, episodic	Diagnosis	ICD-9-CM
305.00	Nondependent alcohol abuse, unspecified	Diagnosis	ICD-9-CM
305.01	Nondependent alcohol abuse, continuous	Diagnosis	ICD-9-CM
305.02	Nondependent alcohol abuse, episodic	Diagnosis	ICD-9-CM
357.5	Alcoholic polyneuropathy	Diagnosis	ICD-9-CM
425.5	Alcoholic cardiomyopathy	Diagnosis	ICD-9-CM
535.30	Alcoholic gastritis without mention of hemorrhage	Diagnosis	ICD-9-CM
535.31	Alcoholic gastritis with hemorrhage	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
571.0	Alcoholic fatty liver	Diagnosis	ICD-9-CM
571.1	Acute alcoholic hepatitis	Diagnosis	ICD-9-CM
571.2	Alcoholic cirrhosis of liver	Diagnosis	ICD-9-CM
571.3	Unspecified alcoholic liver damage	Diagnosis	ICD-9-CM
760.71	Noxious influences affecting fetus or newborn via placenta or breast milk, alcohol	Diagnosis	ICD-9-CM
94.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.61	Alcohol rehabilitation	Procedure	ICD-9-CM
94.62	Alcohol detoxification	Procedure	ICD-9-CM
94.63	Alcohol rehabilitation and detoxification	Procedure	ICD-9-CM
94.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
94.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
94.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
980.0	Toxic effect of ethyl alcohol	Diagnosis	ICD-9-CM
E860.0	Accidental poisoning by alcoholic beverages	Diagnosis	ICD-9-CM
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.130	Alcohol abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.131	Alcohol abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F10.132	Alcohol abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.139	Alcohol abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnesic disorder	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.930	Alcohol use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.931	Alcohol use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F10.932	Alcohol use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.939	Alcohol use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
R78.0	Finding of alcohol in blood	Diagnosis	ICD-10-CM
V65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
V79.1	Screening for alcoholism	Diagnosis	ICD-9-CM
Z65.8	Other specified problems related to psychosocial circumstances	Diagnosis	ICD-10-CM
Z71.41	Alcohol abuse counseling and surveillance of alcoholic	Diagnosis	ICD-10-CM
<b>Alzheimers</b>			
290.0	Senile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.10	Presenile dementia, uncomplicated	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
290.11	Presenile dementia with delirium	Diagnosis	ICD-9-CM
290.12	Presenile dementia with delusional features	Diagnosis	ICD-9-CM
290.13	Presenile dementia with depressive features	Diagnosis	ICD-9-CM
290.20	Senile dementia with delusional features	Diagnosis	ICD-9-CM
290.21	Senile dementia with depressive features	Diagnosis	ICD-9-CM
290.3	Senile dementia with delirium	Diagnosis	ICD-9-CM
290.40	Vascular dementia, uncomplicated	Diagnosis	ICD-9-CM
290.41	Vascular dementia, with delirium	Diagnosis	ICD-9-CM
290.42	Vascular dementia, with delusions	Diagnosis	ICD-9-CM
290.43	Vascular dementia, with depressed mood	Diagnosis	ICD-9-CM
294.0	Amnestic disorder in conditions classified elsewhere	Diagnosis	ICD-9-CM
294.10	Dementia in conditions classified elsewhere without behavioral disturbance	Diagnosis	ICD-9-CM
294.11	Dementia in conditions classified elsewhere with behavioral disturbance	Diagnosis	ICD-9-CM
294.20	Dementia, unspecified, without behavioral disturbance	Diagnosis	ICD-9-CM
294.21	Dementia, unspecified, with behavioral disturbance	Diagnosis	ICD-9-CM
294.8	Other persistent mental disorders due to conditions classified elsewhere	Diagnosis	ICD-9-CM
331.0	Alzheimer's disease	Diagnosis	ICD-9-CM
331.11	Pick's disease	Diagnosis	ICD-9-CM
331.19	Other frontotemporal dementia	Diagnosis	ICD-9-CM
331.2	Senile degeneration of brain	Diagnosis	ICD-9-CM
331.7	Cerebral degeneration in diseases classified elsewhere	Diagnosis	ICD-9-CM
797	Senility without mention of psychosis	Diagnosis	ICD-9-CM
F01.50	Vascular dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F01.51	Vascular dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F02.80	Dementia in other diseases classified elsewhere without behavioral disturbance	Diagnosis	ICD-10-CM
F02.81	Dementia in other diseases classified elsewhere with behavioral disturbance	Diagnosis	ICD-10-CM
F03.90	Unspecified dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F03.91	Unspecified dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F04	Amnestic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
F06.1	Catatonic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F06.8	Other specified mental disorders due to known physiological condition	Diagnosis	ICD-10-CM
G13.8	Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere	Diagnosis	ICD-10-CM
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal dementia	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM
R41.81	Age-related cognitive decline	Diagnosis	ICD-10-CM
R54	Age-related physical debility	Diagnosis	ICD-10-CM

**Acute Myocardial Infraction**

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.11	Acute myocardial infarction of other anterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.21	Acute myocardial infarction of inferolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.41	Acute myocardial infarction of other inferior wall, initial episode of care	Diagnosis	ICD-9-CM
410.51	Acute myocardial infarction of other lateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	Diagnosis	ICD-9-CM
410.71	Acute myocardial infarction, subendocardial infarction, initial episode of care	Diagnosis	ICD-9-CM
410.81	Acute myocardial infarction of other specified sites, initial episode of care	Diagnosis	ICD-9-CM
410.91	Acute myocardial infarction, unspecified site, initial episode of care	Diagnosis	ICD-9-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
<b>Anemia</b>			
280.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
280.1	Iron deficiency anemia secondary to inadequate dietary iron intake	Diagnosis	ICD-9-CM
280.8	Other specified iron deficiency anemias	Diagnosis	ICD-9-CM
280.9	Unspecified iron deficiency anemia	Diagnosis	ICD-9-CM
281.0	Pernicious anemia	Diagnosis	ICD-9-CM
281.1	Other vitamin B12 deficiency anemia	Diagnosis	ICD-9-CM
281.2	Folate-deficiency anemia	Diagnosis	ICD-9-CM
281.3	Other specified megaloblastic anemias not elsewhere classified	Diagnosis	ICD-9-CM
281.4	Protein-deficiency anemia	Diagnosis	ICD-9-CM
281.8	Anemia associated with other specified nutritional deficiency	Diagnosis	ICD-9-CM
281.9	Unspecified deficiency anemia	Diagnosis	ICD-9-CM
282.0	Hereditary spherocytosis	Diagnosis	ICD-9-CM
282.1	Hereditary elliptocytosis	Diagnosis	ICD-9-CM
282.2	Anemias due to disorders of glutathione metabolism	Diagnosis	ICD-9-CM
282.3	Other hemolytic anemias due to enzyme deficiency	Diagnosis	ICD-9-CM
282.40	Thalassemia, unspecified	Diagnosis	ICD-9-CM
282.41	Sickle-cell thalassemia without crisis	Diagnosis	ICD-9-CM
282.42	Sickle-cell thalassemia with crisis	Diagnosis	ICD-9-CM
282.43	Alpha thalassemia	Diagnosis	ICD-9-CM
282.44	Beta thalassemia	Diagnosis	ICD-9-CM
282.45	Delta-beta thalassemia	Diagnosis	ICD-9-CM
282.46	Thalassemia minor	Diagnosis	ICD-9-CM
282.47	Hemoglobin E-beta thalassemia	Diagnosis	ICD-9-CM
282.49	Other thalassemia	Diagnosis	ICD-9-CM
282.5	Sickle-cell trait	Diagnosis	ICD-9-CM
282.60	Sickle-cell disease, unspecified	Diagnosis	ICD-9-CM
282.61	Hb-SS disease without crisis	Diagnosis	ICD-9-CM
282.62	Hb-SS disease with crisis	Diagnosis	ICD-9-CM
282.63	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-9-CM
282.64	Sickle-cell/Hb-C disease with crisis	Diagnosis	ICD-9-CM
282.68	Other sickle-cell disease without crisis	Diagnosis	ICD-9-CM
282.69	Other sickle-cell disease with crisis	Diagnosis	ICD-9-CM
282.7	Other hemoglobinopathies	Diagnosis	ICD-9-CM
282.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-9-CM
282.9	Unspecified hereditary hemolytic anemia	Diagnosis	ICD-9-CM
283.0	Autoimmune hemolytic anemias	Diagnosis	ICD-9-CM
283.10	Unspecified non-autoimmune hemolytic anemia	Diagnosis	ICD-9-CM
283.11	Hemolytic-uremic syndrome	Diagnosis	ICD-9-CM
283.19	Other non-autoimmune hemolytic anemias	Diagnosis	ICD-9-CM
283.2	Hemoglobinuria due to hemolysis from external causes	Diagnosis	ICD-9-CM
283.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-9-CM
284.01	Constitutional red blood cell aplasia	Diagnosis	ICD-9-CM
284.09	Other constitutional aplastic anemia	Diagnosis	ICD-9-CM
284.11	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-9-CM
284.12	Other drug induced pancytopenia	Diagnosis	ICD-9-CM
284.19	Other pancytopenia	Diagnosis	ICD-9-CM
284.2	Myelophthisis	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
284.81	Red cell aplasia (acquired) (adult) (with thymoma)	Diagnosis	ICD-9-CM
284.89	Other specified aplastic anemias	Diagnosis	ICD-9-CM
284.9	Unspecified aplastic anemia	Diagnosis	ICD-9-CM
285.0	Sideroblastic anemia	Diagnosis	ICD-9-CM
285.1	Acute posthemorrhagic anemia	Diagnosis	ICD-9-CM
285.21	Anemia in chronic kidney disease	Diagnosis	ICD-9-CM
285.22	Anemia in neoplastic disease	Diagnosis	ICD-9-CM
285.29	Anemia of other chronic disease	Diagnosis	ICD-9-CM
285.3	Antineoplastic chemotherapy induced anemia	Diagnosis	ICD-9-CM
285.8	Other specified anemias	Diagnosis	ICD-9-CM
285.9	Unspecified anemia	Diagnosis	ICD-9-CM
C94.6	Myelodysplastic disease, not elsewhere classified	Diagnosis	ICD-10-CM
D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM
D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D47.4	Osteomyelofibrosis	Diagnosis	ICD-10-CM
D50.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-10-CM
D50.1	Sideropenic dysphagia	Diagnosis	ICD-10-CM
D50.8	Other iron deficiency anemias	Diagnosis	ICD-10-CM
D50.9	Iron deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D51.0	Vitamin B12 deficiency anemia due to intrinsic factor deficiency	Diagnosis	ICD-10-CM
D51.1	Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuria	Diagnosis	ICD-10-CM
D51.2	Transcobalamin II deficiency	Diagnosis	ICD-10-CM
D51.3	Other dietary vitamin B12 deficiency anemia	Diagnosis	ICD-10-CM
D51.8	Other vitamin B12 deficiency anemias	Diagnosis	ICD-10-CM
D51.9	Vitamin B12 deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D52.0	Dietary folate deficiency anemia	Diagnosis	ICD-10-CM
D52.1	Drug-induced folate deficiency anemia	Diagnosis	ICD-10-CM
D52.8	Other folate deficiency anemias	Diagnosis	ICD-10-CM
D52.9	Folate deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D53.0	Protein deficiency anemia	Diagnosis	ICD-10-CM
D53.1	Other megaloblastic anemias, not elsewhere classified	Diagnosis	ICD-10-CM
D53.2	Scorbutic anemia	Diagnosis	ICD-10-CM
D53.8	Other specified nutritional anemias	Diagnosis	ICD-10-CM
D53.9	Nutritional anemia, unspecified	Diagnosis	ICD-10-CM
D55.0	Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency	Diagnosis	ICD-10-CM
D55.1	Anemia due to other disorders of glutathione metabolism	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
D55.2	Anemia due to disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.21	Anemia due to pyruvate kinase deficiency	Diagnosis	ICD-10-CM
D55.29	Anemia due to other disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.3	Anemia due to disorders of nucleotide metabolism	Diagnosis	ICD-10-CM
D55.8	Other anemias due to enzyme disorders	Diagnosis	ICD-10-CM
D55.9	Anemia due to enzyme disorder, unspecified	Diagnosis	ICD-10-CM
D56.0	Alpha thalassemia	Diagnosis	ICD-10-CM
D56.1	Beta thalassemia	Diagnosis	ICD-10-CM
D56.2	Delta-beta thalassemia	Diagnosis	ICD-10-CM
D56.3	Thalassemia minor	Diagnosis	ICD-10-CM
D56.4	Hereditary persistence of fetal hemoglobin [HPFH]	Diagnosis	ICD-10-CM
D56.5	Hemoglobin E-beta thalassemia	Diagnosis	ICD-10-CM
D56.8	Other thalassemias	Diagnosis	ICD-10-CM
D56.9	Thalassemia, unspecified	Diagnosis	ICD-10-CM
D57.00	Hb-SS disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.01	Hb-SS disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.03	Hb-SS disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.09	Hb-SS disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.1	Sickle-cell disease without crisis	Diagnosis	ICD-10-CM
D57.20	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-10-CM
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.212	Sickle-cell/Hb-C disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.218	Sickle-cell/Hb-C disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.219	Sickle-cell/Hb-C disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.3	Sickle-cell trait	Diagnosis	ICD-10-CM
D57.40	Sickle-cell thalassemia without crisis	Diagnosis	ICD-10-CM
D57.411	Sickle-cell thalassemia with acute chest syndrome	Diagnosis	ICD-10-CM
D57.412	Sickle-cell thalassemia with splenic sequestration	Diagnosis	ICD-10-CM
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.418	Sickle-cell thalassemia, unspecified, with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.419	Sickle-cell thalassemia with crisis, unspecified	Diagnosis	ICD-10-CM
D57.42	Sickle-cell thalassemia beta zero without crisis	Diagnosis	ICD-10-CM
D57.431	Sickle-cell thalassemia beta zero with acute chest syndrome	Diagnosis	ICD-10-CM
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration	Diagnosis	ICD-10-CM
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.438	Sickle-cell thalassemia beta zero with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.439	Sickle-cell thalassemia beta zero with crisis, unspecified	Diagnosis	ICD-10-CM
D57.44	Sickle-cell thalassemia beta plus without crisis	Diagnosis	ICD-10-CM
D57.451	Sickle-cell thalassemia beta plus with acute chest syndrome	Diagnosis	ICD-10-CM
D57.452	Sickle-cell thalassemia beta plus with splenic sequestration	Diagnosis	ICD-10-CM
D57.453	Sickle-cell thalassemia beta plus with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.458	Sickle-cell thalassemia beta plus with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.459	Sickle-cell thalassemia beta plus with crisis, unspecified	Diagnosis	ICD-10-CM
D57.80	Other sickle-cell disorders without crisis	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
D57.811	Other sickle-cell disorders with acute chest syndrome	Diagnosis	ICD-10-CM
D57.812	Other sickle-cell disorders with splenic sequestration	Diagnosis	ICD-10-CM
D57.813	Other sickle-cell disorders with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.818	Other sickle-cell disorders with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.819	Other sickle-cell disorders with crisis, unspecified	Diagnosis	ICD-10-CM
D58.0	Hereditary spherocytosis	Diagnosis	ICD-10-CM
D58.1	Hereditary elliptocytosis	Diagnosis	ICD-10-CM
D58.2	Other hemoglobinopathies	Diagnosis	ICD-10-CM
D58.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-10-CM
D58.9	Hereditary hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.0	Drug-induced autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.1	Other autoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.10	Autoimmune hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.11	Warm autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.12	Cold autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.13	Mixed type autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.19	Other autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.2	Drug-induced nonautoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.4	Other nonautoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.5	Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]	Diagnosis	ICD-10-CM
D59.6	Hemoglobinuria due to hemolysis from other external causes	Diagnosis	ICD-10-CM
D59.8	Other acquired hemolytic anemias	Diagnosis	ICD-10-CM
D59.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D60.0	Chronic acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.1	Transient acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.8	Other acquired pure red cell aplasias	Diagnosis	ICD-10-CM
D60.9	Acquired pure red cell aplasia, unspecified	Diagnosis	ICD-10-CM
D61.01	Constitutional (pure) red blood cell aplasia	Diagnosis	ICD-10-CM
D61.09	Other constitutional aplastic anemia	Diagnosis	ICD-10-CM
D61.1	Drug-induced aplastic anemia	Diagnosis	ICD-10-CM
D61.2	Aplastic anemia due to other external agents	Diagnosis	ICD-10-CM
D61.3	Idiopathic aplastic anemia	Diagnosis	ICD-10-CM
D61.810	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-10-CM
D61.811	Other drug-induced pancytopenia	Diagnosis	ICD-10-CM
D61.818	Other pancytopenia	Diagnosis	ICD-10-CM
D61.82	Myelophthisis	Diagnosis	ICD-10-CM
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes	Diagnosis	ICD-10-CM
D61.9	Aplastic anemia, unspecified	Diagnosis	ICD-10-CM
D62	Acute posthemorrhagic anemia	Diagnosis	ICD-10-CM
D63.0	Anemia in neoplastic disease	Diagnosis	ICD-10-CM
D63.1	Anemia in chronic kidney disease	Diagnosis	ICD-10-CM
D63.8	Anemia in other chronic diseases classified elsewhere	Diagnosis	ICD-10-CM
D64.0	Hereditary sideroblastic anemia	Diagnosis	ICD-10-CM
D64.1	Secondary sideroblastic anemia due to disease	Diagnosis	ICD-10-CM
D64.2	Secondary sideroblastic anemia due to drugs and toxins	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
D64.3	Other sideroblastic anemias	Diagnosis	ICD-10-CM
D64.4	Congenital dyserythropoietic anemia	Diagnosis	ICD-10-CM
D64.81	Anemia due to antineoplastic chemotherapy	Diagnosis	ICD-10-CM
D64.89	Other specified anemias	Diagnosis	ICD-10-CM
D64.9	Anemia, unspecified	Diagnosis	ICD-10-CM
D75.81	Myelofibrosis	Diagnosis	ICD-10-CM
<b>Asthma</b>			
493.00	Extrinsic asthma, unspecified	Diagnosis	ICD-9-CM
493.01	Extrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.02	Extrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.10	Intrinsic asthma, unspecified	Diagnosis	ICD-9-CM
493.11	Intrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.12	Intrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.20	Chronic obstructive asthma, unspecified	Diagnosis	ICD-9-CM
493.21	Chronic obstructive asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.22	Chronic obstructive asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.81	Exercise induced bronchospasm	Diagnosis	ICD-9-CM
493.82	Cough variant asthma	Diagnosis	ICD-9-CM
493.90	Asthma, unspecified, unspecified status	Diagnosis	ICD-9-CM
493.91	Asthma, unspecified with status asthmaticus	Diagnosis	ICD-9-CM
493.92	Asthma, unspecified, with (acute) exacerbation	Diagnosis	ICD-9-CM
J45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.990	Exercise induced bronchospasm	Diagnosis	ICD-10-CM
J45.991	Cough variant asthma	Diagnosis	ICD-10-CM
J45.998	Other asthma	Diagnosis	ICD-10-CM
J82.83	Eosinophilic asthma	Diagnosis	ICD-10-CM
<b>Atrial Fibrillation</b>			
427.31	Atrial fibrillation	Diagnosis	ICD-9-CM
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
<b>Benign Prostatic Hyperplasia</b>			
600.00	Hypertrophy (benign) of prostate without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.01	Hypertrophy (benign) of prostate with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.10	Nodular prostate without urinary obstruction	Diagnosis	ICD-9-CM
600.11	Nodular prostate with urinary obstruction	Diagnosis	ICD-9-CM
600.20	Benign localized hyperplasia of prostate without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.21	Benign localized hyperplasia of prostate with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.3	Cyst of prostate	Diagnosis	ICD-9-CM
600.90	Hyperplasia of prostate, unspecified, without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.91	Hyperplasia of prostate, unspecified, with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
N40.0	Benign prostatic hyperplasia without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.1	Benign prostatic hyperplasia with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.2	Nodular prostate without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.3	Nodular prostate with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N42.83	Cyst of prostate	Diagnosis	ICD-10-CM
<b>Breast Cancer</b>			
174.0	Malignant neoplasm of nipple and areola of female breast	Diagnosis	ICD-9-CM
174.1	Malignant neoplasm of central portion of female breast	Diagnosis	ICD-9-CM
174.2	Malignant neoplasm of upper-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.3	Malignant neoplasm of lower-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.4	Malignant neoplasm of upper-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.5	Malignant neoplasm of lower-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.6	Malignant neoplasm of axillary tail of female breast	Diagnosis	ICD-9-CM
174.8	Malignant neoplasm of other specified sites of female breast	Diagnosis	ICD-9-CM
174.9	Malignant neoplasm of breast (female), unspecified site	Diagnosis	ICD-9-CM
175.0	Malignant neoplasm of nipple and areola of male breast	Diagnosis	ICD-9-CM
175.9	Malignant neoplasm of other and unspecified sites of male breast	Diagnosis	ICD-9-CM
233.0	Carcinoma in situ of breast	Diagnosis	ICD-9-CM
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
V10.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-9-CM
Z17.0	Estrogen receptor positive status [ER+]	Diagnosis	ICD-10-CM
Z17.1	Estrogen receptor negative status [ER-]	Diagnosis	ICD-10-CM
Z19.1	Hormone sensitive malignancy status	Diagnosis	ICD-10-CM
Z19.2	Hormone resistant malignancy status	Diagnosis	ICD-10-CM
Z85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CM
Z86.000	Personal history of in-situ neoplasm of breast	Diagnosis	ICD-10-CM
<b>Cardiac Arrest</b>			
V12.53	Personal history of sudden cardiac arrest	Diagnosis	ICD-9-CM
Z86.74	Personal history of sudden cardiac arrest	Diagnosis	ICD-10-CM
<b>Chronic Kidney Disease</b>			
016.00	Tuberculosis of kidney, confirmation unspecified	Diagnosis	ICD-9-CM
016.01	Tuberculosis of kidney, bacteriological or histological examination not done	Diagnosis	ICD-9-CM
016.02	Tuberculosis of kidney, bacteriological or histological examination unknown (at present)	Diagnosis	ICD-9-CM
016.03	Tuberculosis of kidney, tubercle bacilli found (in sputum) by microscopy	Diagnosis	ICD-9-CM
016.04	Tuberculosis of kidney, tubercle bacilli not found (in sputum) by microscopy, but found by bacterial culture	Diagnosis	ICD-9-CM
016.05	Tuberculosis of kidney, tubercle bacilli not found by bacteriological examination, but tuberculosis confirmed histologically	Diagnosis	ICD-9-CM
016.06	Tuberculosis of kidney, tubercle bacilli not found by bacteriological or histological examination, but tuberculosis confirmed by other methods [inoculation of animals]	Diagnosis	ICD-9-CM
095.4	Syphilis of kidney	Diagnosis	ICD-9-CM
189.0	Malignant neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
189.9	Malignant neoplasm of urinary organ, site unspecified	Diagnosis	ICD-9-CM
223.0	Benign neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
236.91	Neoplasm of uncertain behavior of kidney and ureter	Diagnosis	ICD-9-CM
249.40	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
271.4	Renal glycosuria	Diagnosis	ICD-9-CM
274.10	Gouty nephropathy, unspecified	Diagnosis	ICD-9-CM
283.11	Hemolytic-uremic syndrome	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
440.1	Atherosclerosis of renal artery	Diagnosis	ICD-9-CM
442.1	Aneurysm of renal artery	Diagnosis	ICD-9-CM
572.4	Hepatorenal syndrome	Diagnosis	ICD-9-CM
580.0	Acute glomerulonephritis with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
580.4	Acute glomerulonephritis with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
580.81	Acute glomerulonephritis with other specified pathological lesion in kidney in disease classified elsewhere	Diagnosis	ICD-9-CM
580.89	Other acute glomerulonephritis with other specified pathological lesion in kidney	Diagnosis	ICD-9-CM
580.9	Acute glomerulonephritis with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
581.0	Nephrotic syndrome with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
581.1	Nephrotic syndrome with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
581.2	Nephrotic syndrome with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
581.3	Nephrotic syndrome with lesion of minimal change glomerulonephritis	Diagnosis	ICD-9-CM
581.81	Nephrotic syndrome with other specified pathological lesion in kidney in diseases classified elsewhere	Diagnosis	ICD-9-CM
581.89	Other nephrotic syndrome with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
581.9	Nephrotic syndrome with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
582.0	Chronic glomerulonephritis with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
582.1	Chronic glomerulonephritis with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
582.2	Chronic glomerulonephritis with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
582.4	Chronic glomerulonephritis with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
582.81	Chronic glomerulonephritis with other specified pathological lesion in kidney in diseases classified elsewhere	Diagnosis	ICD-9-CM
582.89	Other chronic glomerulonephritis with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
582.9	Chronic glomerulonephritis with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
583.0	Nephritis and nephropathy, not specified as acute or chronic, with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
583.1	Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
583.2	Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
583.4	Nephritis and nephropathy, not specified as acute or chronic, with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
583.6	Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal cortical necrosis	Diagnosis	ICD-9-CM
583.7	Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal medullary necrosis	Diagnosis	ICD-9-CM
583.81	Nephritis and nephropathy, not specified as acute or chronic, with other specified pathological lesion in kidney, in diseases classified elsewhere	Diagnosis	ICD-9-CM
583.89	Other nephritis and nephropathy, not specified as acute or chronic, with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
583.9	Nephritis and nephropathy, not specified as acute or chronic, with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
584.5	Acute kidney failure with lesion of tubular necrosis	Diagnosis	ICD-9-CM
584.6	Acute kidney failure with lesion of renal cortical necrosis	Diagnosis	ICD-9-CM
584.7	Acute kidney failure with lesion of medullary [papillary] necrosis	Diagnosis	ICD-9-CM
584.8	Acute kidney failure with other specified pathological lesion in kidney	Diagnosis	ICD-9-CM
584.9	Acute kidney failure, unspecified	Diagnosis	ICD-9-CM
585.1	Chronic kidney disease, Stage I	Diagnosis	ICD-9-CM
585.2	Chronic kidney disease, Stage II (mild)	Diagnosis	ICD-9-CM
585.3	Chronic kidney disease, Stage III (moderate)	Diagnosis	ICD-9-CM
585.4	Chronic kidney disease, Stage IV (severe)	Diagnosis	ICD-9-CM
585.5	Chronic kidney disease, Stage V	Diagnosis	ICD-9-CM
585.6	End stage renal disease	Diagnosis	ICD-9-CM
585.9	Chronic kidney disease, unspecified	Diagnosis	ICD-9-CM
586	Unspecified renal failure	Diagnosis	ICD-9-CM
587	Unspecified renal sclerosis	Diagnosis	ICD-9-CM
588.0	Renal osteodystrophy	Diagnosis	ICD-9-CM
588.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-9-CM
588.81	Secondary hyperparathyroidism (of renal origin)	Diagnosis	ICD-9-CM
588.89	Other specified disorders resulting from impaired renal function	Diagnosis	ICD-9-CM
588.9	Unspecified disorder resulting from impaired renal function	Diagnosis	ICD-9-CM
591	Hydronephrosis	Diagnosis	ICD-9-CM
753.12	Congenital polycystic kidney, unspecified type	Diagnosis	ICD-9-CM
753.13	Congenital polycystic kidney, autosomal dominant	Diagnosis	ICD-9-CM
753.14	Congenital polycystic kidney, autosomal recessive	Diagnosis	ICD-9-CM
753.15	Congenital renal dysplasia	Diagnosis	ICD-9-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
753.16	Congenital medullary cystic kidney	Diagnosis	ICD-9-CM
753.17	Congenital medullary sponge kidney	Diagnosis	ICD-9-CM
753.19	Other specified congenital cystic kidney disease	Diagnosis	ICD-9-CM
753.20	Unspecified obstructive defect of renal pelvis and ureter	Diagnosis	ICD-9-CM
753.21	Congenital obstruction of ureteropelvic junction	Diagnosis	ICD-9-CM
753.22	Congenital obstruction of ureterovesical junction	Diagnosis	ICD-9-CM
753.23	Congenital ureterocele	Diagnosis	ICD-9-CM
753.29	Other obstructive defect of renal pelvis and ureter	Diagnosis	ICD-9-CM
794.4	Nonspecific abnormal results of kidney function study	Diagnosis	ICD-9-CM
A18.11	Tuberculosis of kidney and ureter	Diagnosis	ICD-10-CM
A52.75	Syphilis of kidney and ureter	Diagnosis	ICD-10-CM
B52.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
D30.00	Benign neoplasm of unspecified kidney	Diagnosis	ICD-10-CM
D30.01	Benign neoplasm of right kidney	Diagnosis	ICD-10-CM
D30.02	Benign neoplasm of left kidney	Diagnosis	ICD-10-CM
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E74.8	Other specified disorders of carbohydrate metabolism	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I70.1	Atherosclerosis of renal artery	Diagnosis	ICD-10-CM
I72.2	Aneurysm of renal artery	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
M10.30	Gout due to renal impairment, unspecified site	Diagnosis	ICD-10-CM
M10.311	Gout due to renal impairment, right shoulder	Diagnosis	ICD-10-CM
M10.312	Gout due to renal impairment, left shoulder	Diagnosis	ICD-10-CM
M10.319	Gout due to renal impairment, unspecified shoulder	Diagnosis	ICD-10-CM
M10.321	Gout due to renal impairment, right elbow	Diagnosis	ICD-10-CM
M10.322	Gout due to renal impairment, left elbow	Diagnosis	ICD-10-CM
M10.329	Gout due to renal impairment, unspecified elbow	Diagnosis	ICD-10-CM
M10.331	Gout due to renal impairment, right wrist	Diagnosis	ICD-10-CM
M10.332	Gout due to renal impairment, left wrist	Diagnosis	ICD-10-CM
M10.339	Gout due to renal impairment, unspecified wrist	Diagnosis	ICD-10-CM
M10.341	Gout due to renal impairment, right hand	Diagnosis	ICD-10-CM
M10.342	Gout due to renal impairment, left hand	Diagnosis	ICD-10-CM
M10.349	Gout due to renal impairment, unspecified hand	Diagnosis	ICD-10-CM
M10.351	Gout due to renal impairment, right hip	Diagnosis	ICD-10-CM
M10.352	Gout due to renal impairment, left hip	Diagnosis	ICD-10-CM
M10.359	Gout due to renal impairment, unspecified hip	Diagnosis	ICD-10-CM
M10.361	Gout due to renal impairment, right knee	Diagnosis	ICD-10-CM
M10.362	Gout due to renal impairment, left knee	Diagnosis	ICD-10-CM
M10.369	Gout due to renal impairment, unspecified knee	Diagnosis	ICD-10-CM
M10.371	Gout due to renal impairment, right ankle and foot	Diagnosis	ICD-10-CM
M10.372	Gout due to renal impairment, left ankle and foot	Diagnosis	ICD-10-CM
M10.379	Gout due to renal impairment, unspecified ankle and foot	Diagnosis	ICD-10-CM
M10.38	Gout due to renal impairment, vertebrae	Diagnosis	ICD-10-CM
M10.39	Gout due to renal impairment, multiple sites	Diagnosis	ICD-10-CM
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sicca syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
M35.0A	Sjogren syndrome with glomerular disease	Diagnosis	ICD-10-CM
N00.0	Acute nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N00.1	Acute nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N00.2	Acute nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
N00.3	Acute nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.4	Acute nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.5	Acute nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N00.6	Acute nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N00.7	Acute nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N00.8	Acute nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N00.9	Acute nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N00.A	Acute nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N01.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N01.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N01.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N01.3	Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.4	Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.5	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.3	Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.6	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM
N02.7	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.8	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic changes	Diagnosis	ICD-10-CM
N02.A	Recurrent and persistent hematuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N03.0	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N03.A	Chronic nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.A	Nephrotic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N05.2	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N05.3	Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.4	Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.4	Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM
N06.A	Isolated proteinuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N07.0	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.1	Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N07.2	Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
N07.3	Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.4	Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.5	Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N07.6	Hereditary nephropathy, not elsewhere classified with dense deposit disease	Diagnosis	ICD-10-CM
N07.7	Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N07.8	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.9	Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions	Diagnosis	ICD-10-CM
N07.A	Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N08	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N13.1	Hydronephrosis with ureteral stricture, not elsewhere classified	Diagnosis	ICD-10-CM
N13.2	Hydronephrosis with renal and ureteral calculous obstruction	Diagnosis	ICD-10-CM
N13.30	Unspecified hydronephrosis	Diagnosis	ICD-10-CM
N13.39	Other hydronephrosis	Diagnosis	ICD-10-CM
N14.0	Analgesic nephropathy	Diagnosis	ICD-10-CM
N14.1	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.2	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM
N14.3	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
N14.4	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM
N15.0	Balkan nephropathy	Diagnosis	ICD-10-CM
N15.8	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
N15.9	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM
N16	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N17.0	Acute kidney failure with tubular necrosis	Diagnosis	ICD-10-CM
N17.1	Acute kidney failure with acute cortical necrosis	Diagnosis	ICD-10-CM
N17.2	Acute kidney failure with medullary necrosis	Diagnosis	ICD-10-CM
N17.8	Other acute kidney failure	Diagnosis	ICD-10-CM
N17.9	Acute kidney failure, unspecified	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.30	Chronic kidney disease, stage 3 unspecified	Diagnosis	ICD-10-CM
N18.31	Chronic kidney disease, stage 3a	Diagnosis	ICD-10-CM
N18.32	Chronic kidney disease, stage 3b	Diagnosis	ICD-10-CM
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.6	End stage renal disease	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N19	Unspecified kidney failure	Diagnosis	ICD-10-CM
N25.0	Renal osteodystrophy	Diagnosis	ICD-10-CM
N25.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CM
N25.81	Secondary hyperparathyroidism of renal origin	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
N25.89	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CM
N25.9	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CM
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
Q61.02	Congenital multiple renal cysts	Diagnosis	ICD-10-CM
Q61.11	Cystic dilatation of collecting ducts	Diagnosis	ICD-10-CM
Q61.19	Other polycystic kidney, infantile type	Diagnosis	ICD-10-CM
Q61.2	Polycystic kidney, adult type	Diagnosis	ICD-10-CM
Q61.3	Polycystic kidney, unspecified	Diagnosis	ICD-10-CM
Q61.4	Renal dysplasia	Diagnosis	ICD-10-CM
Q61.5	Medullary cystic kidney	Diagnosis	ICD-10-CM
Q61.8	Other cystic kidney diseases	Diagnosis	ICD-10-CM
Q62.0	Congenital hydronephrosis	Diagnosis	ICD-10-CM
Q62.10	Congenital occlusion of ureter, unspecified	Diagnosis	ICD-10-CM
Q62.11	Congenital occlusion of ureteropelvic junction	Diagnosis	ICD-10-CM
Q62.12	Congenital occlusion of ureterovesical orifice	Diagnosis	ICD-10-CM
Q62.2	Congenital megaureter	Diagnosis	ICD-10-CM
Q62.31	Congenital ureterocele, orthotopic	Diagnosis	ICD-10-CM
Q62.32	Cecoureterocele	Diagnosis	ICD-10-CM
Q62.39	Other obstructive defects of renal pelvis and ureter	Diagnosis	ICD-10-CM
R94.4	Abnormal results of kidney function studies	Diagnosis	ICD-10-CM
<b>Colorectal Cancer</b>			
153.0	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-9-CM
153.1	Malignant neoplasm of transverse colon	Diagnosis	ICD-9-CM
153.2	Malignant neoplasm of descending colon	Diagnosis	ICD-9-CM
153.3	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-9-CM
153.4	Malignant neoplasm of cecum	Diagnosis	ICD-9-CM
153.5	Malignant neoplasm of appendix	Diagnosis	ICD-9-CM
153.6	Malignant neoplasm of ascending colon	Diagnosis	ICD-9-CM
153.7	Malignant neoplasm of splenic flexure	Diagnosis	ICD-9-CM
153.8	Malignant neoplasm of other specified sites of large intestine	Diagnosis	ICD-9-CM
153.9	Malignant neoplasm of colon, unspecified site	Diagnosis	ICD-9-CM
154.0	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-9-CM
154.1	Malignant neoplasm of rectum	Diagnosis	ICD-9-CM
230.3	Carcinoma in situ of colon	Diagnosis	ICD-9-CM
230.4	Carcinoma in situ of rectum	Diagnosis	ICD-9-CM
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
V10.05	Personal history of malignant neoplasm of large intestine	Diagnosis	ICD-9-CM
V10.06	Personal history of malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM
Z85.030	Personal history of malignant carcinoid tumor of large intestine	Diagnosis	ICD-10-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM

**Chronic Obstructive Pulmonary Disease**

490	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-9-CM
491.0	Simple chronic bronchitis	Diagnosis	ICD-9-CM
491.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-9-CM
491.20	Obstructive chronic bronchitis, without exacerbation	Diagnosis	ICD-9-CM
491.21	Obstructive chronic bronchitis, with (acute) exacerbation	Diagnosis	ICD-9-CM
491.22	Obstructive chronic bronchitis with acute bronchitis	Diagnosis	ICD-9-CM
491.8	Other chronic bronchitis	Diagnosis	ICD-9-CM
491.9	Unspecified chronic bronchitis	Diagnosis	ICD-9-CM
492.0	Emphysematous bleb	Diagnosis	ICD-9-CM
492.8	Other emphysema	Diagnosis	ICD-9-CM
494.0	Bronchiectasis without acute exacerbation	Diagnosis	ICD-9-CM
494.1	Bronchiectasis with acute exacerbation	Diagnosis	ICD-9-CM
496	Chronic airway obstruction, not elsewhere classified	Diagnosis	ICD-9-CM
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.8	Other emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J44.0	Chronic obstructive pulmonary disease with acute lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
J98.2	Interstitial emphysema	Diagnosis	ICD-10-CM
J98.3	Compensatory emphysema	Diagnosis	ICD-10-CM
<b>Coronary Angioplasty Bypass</b>			
V45.81	Postprocedural aortocoronary bypass status	Diagnosis	ICD-9-CM
V45.82	Postprocedural percutaneous transluminal coronary angioplasty status	Diagnosis	ICD-9-CM
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
Z98.61	Coronary angioplasty status	Diagnosis	ICD-10-CM
<b>Depression</b>			
296.20	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-9-CM
296.21	Major depressive disorder, single episode, mild	Diagnosis	ICD-9-CM
296.22	Major depressive disorder, single episode, moderate	Diagnosis	ICD-9-CM
296.23	Major depressive disorder, single episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.24	Major depressive disorder, single episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.25	Major depressive disorder, single episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.26	Major depressive disorder, single episode in full remission	Diagnosis	ICD-9-CM
296.30	Major depressive disorder, recurrent episode, unspecified	Diagnosis	ICD-9-CM
296.31	Major depressive disorder, recurrent episode, mild	Diagnosis	ICD-9-CM
296.32	Major depressive disorder, recurrent episode, moderate	Diagnosis	ICD-9-CM
296.33	Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.34	Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.35	Major depressive disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.36	Major depressive disorder, recurrent episode, in full remission	Diagnosis	ICD-9-CM
296.51	Bipolar I disorder, most recent episode (or current) depressed, mild	Diagnosis	ICD-9-CM
296.52	Bipolar I disorder, most recent episode (or current) depressed, moderate	Diagnosis	ICD-9-CM
296.53	Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.54	Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.55	Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.56	Bipolar I disorder, most recent episode (or current) depressed, in full remission	Diagnosis	ICD-9-CM
296.60	Bipolar I disorder, most recent episode (or current) mixed, unspecified	Diagnosis	ICD-9-CM
296.61	Bipolar I disorder, most recent episode (or current) mixed, mild	Diagnosis	ICD-9-CM
296.62	Bipolar I disorder, most recent episode (or current) mixed, moderate	Diagnosis	ICD-9-CM
296.63	Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.64	Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.65	Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission	Diagnosis	ICD-9-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
296.66	Bipolar I disorder, most recent episode (or current) mixed, in full remission	Diagnosis	ICD-9-CM
296.89	Other and unspecified bipolar disorders	Diagnosis	ICD-9-CM
298.0	Depressive type psychosis	Diagnosis	ICD-9-CM
300.4	Dysthymic disorder	Diagnosis	ICD-9-CM
309.1	Prolonged depressive reaction as adjustment reaction	Diagnosis	ICD-9-CM
311	Depressive disorder, not elsewhere classified	Diagnosis	ICD-9-CM
F06.31	Mood disorder due to known physiological condition with depressive features	Diagnosis	ICD-10-CM
F06.32	Mood disorder due to known physiological condition with major depressive-like episode	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.8	Other depressive episodes	Diagnosis	ICD-10-CM
F32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F32.A	Depression, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
<b>Diabetes</b>			
249.00	Secondary diabetes mellitus without mention of complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.01	Secondary diabetes mellitus without mention of complication, uncontrolled	Diagnosis	ICD-9-CM
249.10	Secondary diabetes mellitus with ketoacidosis, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.11	Secondary diabetes mellitus with ketoacidosis, uncontrolled	Diagnosis	ICD-9-CM
249.20	Secondary diabetes mellitus with hyperosmolarity, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.21	Secondary diabetes mellitus with hyperosmolarity, uncontrolled	Diagnosis	ICD-9-CM
249.30	Secondary diabetes mellitus with other coma, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.31	Secondary diabetes mellitus with other coma, uncontrolled	Diagnosis	ICD-9-CM
249.40	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.50	Secondary diabetes mellitus with ophthalmic manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.51	Secondary diabetes mellitus with ophthalmic manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.60	Secondary diabetes mellitus with neurological manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.61	Secondary diabetes mellitus with neurological manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.70	Secondary diabetes mellitus with peripheral circulatory disorders, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.71	Secondary diabetes mellitus with peripheral circulatory disorders, uncontrolled	Diagnosis	ICD-9-CM
249.80	Secondary diabetes mellitus with other specified manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.81	Secondary diabetes mellitus with other specified manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.90	Secondary diabetes mellitus with unspecified complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.91	Secondary diabetes mellitus with unspecified complication, uncontrolled	Diagnosis	ICD-9-CM
250.00	Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
250.01	Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.02	Diabetes mellitus without mention of complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.03	Diabetes mellitus without mention of complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.10	Diabetes with ketoacidosis, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.11	Diabetes with ketoacidosis, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.12	Diabetes with ketoacidosis, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.13	Diabetes with ketoacidosis, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.20	Diabetes with hyperosmolarity, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.21	Diabetes with hyperosmolarity, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.22	Diabetes with hyperosmolarity, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.23	Diabetes with hyperosmolarity, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.30	Diabetes with other coma, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.31	Diabetes with other coma, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.32	Diabetes with other coma, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.33	Diabetes with other coma, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.50	Diabetes with ophthalmic manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.51	Diabetes with ophthalmic manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.52	Diabetes with ophthalmic manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.53	Diabetes with ophthalmic manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.60	Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.61	Diabetes with neurological manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.62	Diabetes with neurological manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.63	Diabetes with neurological manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.70	Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.71	Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.72	Diabetes with peripheral circulatory disorders, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
250.73	Diabetes with peripheral circulatory disorders, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.80	Diabetes with other specified manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.81	Diabetes with other specified manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.82	Diabetes with other specified manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.83	Diabetes with other specified manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.90	Diabetes with unspecified complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.91	Diabetes with unspecified complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.92	Diabetes with unspecified complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.93	Diabetes with unspecified complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
357.2	Polyneuropathy in diabetes	Diagnosis	ICD-9-CM
362.01	Background diabetic retinopathy	Diagnosis	ICD-9-CM
362.02	Proliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.03	Nonproliferative diabetic retinopathy NOS	Diagnosis	ICD-9-CM
362.04	Mild nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.05	Moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.06	Severe nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
366.41	Diabetic cataract	Diagnosis	ICD-9-CM
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E09.00	Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E09.01	Drug or chemical induced diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E09.10	Drug or chemical induced diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E09.11	Drug or chemical induced diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E09.39	Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E09.40	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E09.41	Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E09.44	Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy	Diagnosis	ICD-10-CM
E09.49	Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication	Diagnosis	ICD-10-CM
E09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E09.59	Drug or chemical induced diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E09.610	Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E09.618	Drug or chemical induced diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E09.620	Drug or chemical induced diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E09.628	Drug or chemical induced diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E09.630	Drug or chemical induced diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E09.638	Drug or chemical induced diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.65	Drug or chemical induced diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E09.69	Drug or chemical induced diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E09.8	Drug or chemical induced diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E09.9	Drug or chemical induced diabetes mellitus without complications	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
<b>Drug Abuse</b>			
292.0	Drug withdrawal	Diagnosis	ICD-9-CM
292.11	Drug-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
292.12	Drug-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
292.2	Pathological drug intoxication	Diagnosis	ICD-9-CM
292.81	Drug-induced delirium	Diagnosis	ICD-9-CM
292.82	Drug-induced persisting dementia	Diagnosis	ICD-9-CM
292.83	Drug-induced persisting amnestic disorder	Diagnosis	ICD-9-CM
292.84	Drug-induced mood disorder	Diagnosis	ICD-9-CM
292.85	Drug induced sleep disorders	Diagnosis	ICD-9-CM
292.89	Other specified drug-induced mental disorder	Diagnosis	ICD-9-CM
292.9	Unspecified drug-induced mental disorder	Diagnosis	ICD-9-CM
304.00	Opioid type dependence, unspecified	Diagnosis	ICD-9-CM
304.01	Opioid type dependence, continuous	Diagnosis	ICD-9-CM
304.02	Opioid type dependence, episodic	Diagnosis	ICD-9-CM
304.10	Sedative, hypnotic or anxiolytic dependence, unspecified	Diagnosis	ICD-9-CM
304.11	Sedative, hypnotic or anxiolytic dependence, continuous	Diagnosis	ICD-9-CM
304.12	Sedative, hypnotic or anxiolytic dependence, episodic	Diagnosis	ICD-9-CM
304.2	Cocaine dependence	Diagnosis	ICD-9-CM
304.20	Cocaine dependence, unspecified	Diagnosis	ICD-9-CM
304.21	Cocaine dependence, continuous	Diagnosis	ICD-9-CM
304.22	Cocaine dependence, episodic	Diagnosis	ICD-9-CM
304.3	Cannabis dependence	Diagnosis	ICD-9-CM
304.30	Cannabis dependence, unspecified	Diagnosis	ICD-9-CM
304.31	Cannabis dependence, continuous	Diagnosis	ICD-9-CM
304.32	Cannabis dependence, episodic	Diagnosis	ICD-9-CM
304.4	Amphetamine and other psychostimulant dependence	Diagnosis	ICD-9-CM
304.40	Amphetamine and other psychostimulant dependence, unspecified	Diagnosis	ICD-9-CM
304.41	Amphetamine and other psychostimulant dependence, continuous	Diagnosis	ICD-9-CM
304.42	Amphetamine and other psychostimulant dependence, episodic	Diagnosis	ICD-9-CM
304.5	Hallucinogen dependence	Diagnosis	ICD-9-CM
304.50	Hallucinogen dependence, unspecified	Diagnosis	ICD-9-CM
304.51	Hallucinogen dependence, continuous	Diagnosis	ICD-9-CM
304.52	Hallucinogen dependence, episodic	Diagnosis	ICD-9-CM
304.6	Other specified drug dependence	Diagnosis	ICD-9-CM
304.60	Other specified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.61	Other specified drug dependence, continuous	Diagnosis	ICD-9-CM
304.62	Other specified drug dependence, episodic	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
304.7	Combinations of opioid type drug with any other drug dependence	Diagnosis	ICD-9-CM
304.70	Combinations of opioid type drug with any other drug dependence, unspecified	Diagnosis	ICD-9-CM
304.71	Combinations of opioid type drug with any other drug dependence, continuous	Diagnosis	ICD-9-CM
304.72	Combinations of opioid type drug with any other drug dependence, episodic	Diagnosis	ICD-9-CM
304.8	Combinations of drug dependence excluding opioid type drug	Diagnosis	ICD-9-CM
304.80	Combinations of drug dependence excluding opioid type drug, unspecified	Diagnosis	ICD-9-CM
304.81	Combinations of drug dependence excluding opioid type drug, continuous	Diagnosis	ICD-9-CM
304.82	Combinations of drug dependence excluding opioid type drug, episodic	Diagnosis	ICD-9-CM
304.9	Unspecified drug dependence	Diagnosis	ICD-9-CM
304.90	Unspecified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.91	Unspecified drug dependence, continuous	Diagnosis	ICD-9-CM
304.92	Unspecified drug dependence, episodic	Diagnosis	ICD-9-CM
305.2	Nondependent cannabis abuse	Diagnosis	ICD-9-CM
305.20	Nondependent cannabis abuse, unspecified	Diagnosis	ICD-9-CM
305.21	Nondependent cannabis abuse, continuous	Diagnosis	ICD-9-CM
305.22	Nondependent cannabis abuse, episodic	Diagnosis	ICD-9-CM
305.3	Nondependent hallucinogen abuse	Diagnosis	ICD-9-CM
305.30	Nondependent hallucinogen abuse, unspecified	Diagnosis	ICD-9-CM
305.31	Nondependent hallucinogen abuse, continuous	Diagnosis	ICD-9-CM
305.32	Nondependent hallucinogen abuse, episodic	Diagnosis	ICD-9-CM
305.4	Nondependent sedative, hypnotic or anxiolytic abuse	Diagnosis	ICD-9-CM
305.40	Nondependent sedative, hypnotic or anxiolytic abuse, unspecified	Diagnosis	ICD-9-CM
305.41	Nondependent sedative, hypnotic or anxiolytic abuse, continuous	Diagnosis	ICD-9-CM
305.42	Nondependent sedative, hypnotic or anxiolytic abuse, episodic	Diagnosis	ICD-9-CM
305.5	Nondependent opioid abuse	Diagnosis	ICD-9-CM
305.50	Nondependent opioid abuse, unspecified	Diagnosis	ICD-9-CM
305.51	Nondependent opioid abuse, continuous	Diagnosis	ICD-9-CM
305.52	Nondependent opioid abuse, episodic	Diagnosis	ICD-9-CM
305.6	Nondependent cocaine abuse	Diagnosis	ICD-9-CM
305.60	Nondependent cocaine abuse, unspecified	Diagnosis	ICD-9-CM
305.61	Nondependent cocaine abuse, continuous	Diagnosis	ICD-9-CM
305.62	Nondependent cocaine abuse, episodic	Diagnosis	ICD-9-CM
305.7	Nondependent amphetamine or related acting sympathomimetic abuse	Diagnosis	ICD-9-CM
305.70	Nondependent amphetamine or related acting sympathomimetic abuse, unspecified	Diagnosis	ICD-9-CM
305.71	Nondependent amphetamine or related acting sympathomimetic abuse, continuous	Diagnosis	ICD-9-CM
305.72	Nondependent amphetamine or related acting sympathomimetic abuse, episodic	Diagnosis	ICD-9-CM
305.8	Nondependent antidepressant type abuse	Diagnosis	ICD-9-CM
305.80	Nondependent antidepressant type abuse, unspecified	Diagnosis	ICD-9-CM
305.81	Nondependent antidepressant type abuse, continuous	Diagnosis	ICD-9-CM
305.82	Nondependent antidepressant type abuse, episodic	Diagnosis	ICD-9-CM
305.9	Other, mixed, or unspecified nondependent drug abuse	Diagnosis	ICD-9-CM
305.90	Other, mixed, or unspecified nondependent drug abuse, unspecified	Diagnosis	ICD-9-CM
305.91	Other, mixed, or unspecified nondependent drug abuse, continuous	Diagnosis	ICD-9-CM
305.92	Other, mixed, or unspecified nondependent drug abuse, episodic	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
648.3	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium	Diagnosis	ICD-9-CM
648.30	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care	Diagnosis	ICD-9-CM
648.31	Maternal drug dependence, with delivery	Diagnosis	ICD-9-CM
648.32	Maternal drug dependence, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
648.33	Maternal drug dependence, antepartum	Diagnosis	ICD-9-CM
648.34	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication	Diagnosis	ICD-9-CM
655.5	Suspected damage to fetus from drugs, affecting management of mother	Diagnosis	ICD-9-CM
655.50	Suspected damage to fetus from drugs, affecting management of mother, unspecified as to episode of care	Diagnosis	ICD-9-CM
655.51	Suspected damage to fetus from drugs, affecting management of mother, delivered	Diagnosis	ICD-9-CM
655.53	Suspected damage to fetus from drugs, affecting management of mother, antepartum	Diagnosis	ICD-9-CM
760.72	Noxious influences affecting fetus or newborn via placenta or breast milk, narcotics	Diagnosis	ICD-9-CM
760.73	Noxious influences affecting fetus or newborn via placenta or breast milk, hallucinogenic agents	Diagnosis	ICD-9-CM
760.75	Noxious influences affecting fetus or newborn via placenta or breast milk, cocaine	Diagnosis	ICD-9-CM
779.5	Drug withdrawal syndrome in newborn	Diagnosis	ICD-9-CM
94.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.64	Drug rehabilitation	Procedure	ICD-9-CM
94.65	Drug detoxification	Procedure	ICD-9-CM
94.66	Drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
94.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
94.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
965.0	Poisoning by opiates and related narcotics	Diagnosis	ICD-9-CM
965.00	Poisoning by opium (alkaloids), unspecified	Diagnosis	ICD-9-CM
965.01	Poisoning by heroin	Diagnosis	ICD-9-CM
965.02	Poisoning by methadone	Diagnosis	ICD-9-CM
965.09	Poisoning by opiates and related narcotics, other	Diagnosis	ICD-9-CM
E850.0	Accidental poisoning by heroin	Diagnosis	ICD-9-CM
E850.1	Accidental poisoning by methadone	Diagnosis	ICD-9-CM
E850.2	Accidental poisoning by other opiates and related narcotics	Diagnosis	ICD-9-CM
E854.1	Accidental poisoning by psychodysleptics (hallucinogens)	Diagnosis	ICD-9-CM
E935.0	Heroin causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
E935.1	Methadone causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.11	Opioid abuse, in remission	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F12.10	Cannabis abuse, uncomplicated	Diagnosis	ICD-10-CM
F12.11	Cannabis abuse, in remission	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
F12.120	Cannabis abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.121	Cannabis abuse with intoxication delirium	Diagnosis	ICD-10-CM
F12.122	Cannabis abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.129	Cannabis abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.13	Cannabis abuse with withdrawal	Diagnosis	ICD-10-CM
F12.150	Cannabis abuse with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.151	Cannabis abuse with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.159	Cannabis abuse with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.180	Cannabis abuse with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.188	Cannabis abuse with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.19	Cannabis abuse with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.20	Cannabis dependence, uncomplicated	Diagnosis	ICD-10-CM
F12.220	Cannabis dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.221	Cannabis dependence with intoxication delirium	Diagnosis	ICD-10-CM
F12.222	Cannabis dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.229	Cannabis dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.250	Cannabis dependence with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.251	Cannabis dependence with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.259	Cannabis dependence with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.280	Cannabis dependence with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.288	Cannabis dependence with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.29	Cannabis dependence with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.90	Cannabis use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F12.920	Cannabis use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.921	Cannabis use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.929	Cannabis use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.950	Cannabis use, unspecified with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.980	Cannabis use, unspecified with anxiety disorder	Diagnosis	ICD-10-CM
F12.988	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated	Diagnosis	ICD-10-CM
F13.11	Sedative, hypnotic or anxiolytic abuse, in remission	Diagnosis	ICD-10-CM
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium	Diagnosis	ICD-10-CM
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.130	Sedative, hypnotic or anxiolytic abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.131	Sedative, hypnotic or anxiolytic abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F13.132	Sedative, hypnotic or anxiolytic abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.139	Sedative, hypnotic or anxiolytic abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Diagnosis	ICD-10-CM
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium	Diagnosis	ICD-10-CM
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances	Diagnosis	ICD-10-CM
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F14.10	Cocaine abuse, uncomplicated	Diagnosis	ICD-10-CM
F14.11	Cocaine abuse, in remission	Diagnosis	ICD-10-CM
F14.120	Cocaine abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.121	Cocaine abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F14.122	Cocaine abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.129	Cocaine abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.13	Cocaine abuse, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.14	Cocaine abuse with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.180	Cocaine abuse with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F14.181	Cocaine abuse with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.182	Cocaine abuse with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.188	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.19	Cocaine abuse with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.20	Cocaine dependence, uncomplicated	Diagnosis	ICD-10-CM
F14.220	Cocaine dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.221	Cocaine dependence with intoxication delirium	Diagnosis	ICD-10-CM
F14.222	Cocaine dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.229	Cocaine dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.23	Cocaine dependence with withdrawal	Diagnosis	ICD-10-CM
F14.24	Cocaine dependence with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.280	Cocaine dependence with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.282	Cocaine dependence with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.288	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.29	Cocaine dependence with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.90	Cocaine use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F14.920	Cocaine use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.921	Cocaine use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.929	Cocaine use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.93	Cocaine use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.988	Cocaine use, unspecified with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F15.10	Other stimulant abuse, uncomplicated	Diagnosis	ICD-10-CM
F15.11	Other stimulant abuse, in remission	Diagnosis	ICD-10-CM
F15.120	Other stimulant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.121	Other stimulant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F15.122	Other stimulant abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.129	Other stimulant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.13	Other stimulant abuse with withdrawal	Diagnosis	ICD-10-CM
F15.14	Other stimulant abuse with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F15.151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.182	Other stimulant abuse with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.188	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.20	Other stimulant dependence, uncomplicated	Diagnosis	ICD-10-CM
F15.220	Other stimulant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.221	Other stimulant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F15.222	Other stimulant dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.229	Other stimulant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.23	Other stimulant dependence with withdrawal	Diagnosis	ICD-10-CM
F15.24	Other stimulant dependence with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.282	Other stimulant dependence with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.288	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.29	Other stimulant dependence with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.90	Other stimulant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.921	Other stimulant use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F15.922	Other stimulant use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.929	Other stimulant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.93	Other stimulant use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.980	Other stimulant use, unspecified with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.99	Other stimulant use, unspecified with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F16.10	Hallucinogen abuse, uncomplicated	Diagnosis	ICD-10-CM
F16.11	Hallucinogen abuse, in remission	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F16.120	Hallucinogen abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.121	Hallucinogen abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F16.129	Hallucinogen abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.20	Hallucinogen dependence, uncomplicated	Diagnosis	ICD-10-CM
F16.220	Hallucinogen dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.221	Hallucinogen dependence with intoxication with delirium	Diagnosis	ICD-10-CM
F16.229	Hallucinogen dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.283	Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.90	Hallucinogen use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.921	Hallucinogen use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F16.929	Hallucinogen use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
F18.10	Inhalant abuse, uncomplicated	Diagnosis	ICD-10-CM
F18.11	Inhalant abuse, in remission	Diagnosis	ICD-10-CM
F18.120	Inhalant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.121	Inhalant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F18.129	Inhalant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.14	Inhalant abuse with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.17	Inhalant abuse with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.180	Inhalant abuse with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.188	Inhalant abuse with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.19	Inhalant abuse with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.20	Inhalant dependence, uncomplicated	Diagnosis	ICD-10-CM
F18.220	Inhalant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.221	Inhalant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F18.229	Inhalant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.24	Inhalant dependence with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.250	Inhalant dependence with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.27	Inhalant dependence with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.280	Inhalant dependence with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.288	Inhalant dependence with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.29	Inhalant dependence with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.90	Inhalant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F18.920	Inhalant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.921	Inhalant use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F18.929	Inhalant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia	Diagnosis	ICD-10-CM
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.988	Inhalant use, unspecified with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F19.10	Other psychoactive substance abuse, uncomplicated	Diagnosis	ICD-10-CM
F19.11	Other psychoactive substance abuse, in remission	Diagnosis	ICD-10-CM
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.121	Other psychoactive substance abuse with intoxication delirium	Diagnosis	ICD-10-CM
F19.122	Other psychoactive substance abuse with intoxication with perceptual disturbances	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F19.129	Other psychoactive substance abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.130	Other psychoactive substance abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.131	Other psychoactive substance abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F19.132	Other psychoactive substance abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.139	Other psychoactive substance abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.20	Other psychoactive substance dependence, uncomplicated	Diagnosis	ICD-10-CM
F19.21	Other psychoactive substance dependence, in remission	Diagnosis	ICD-10-CM
F19.220	Other psychoactive substance dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.221	Other psychoactive substance dependence with intoxication delirium	Diagnosis	ICD-10-CM
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.229	Other psychoactive substance dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.231	Other psychoactive substance dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.239	Other psychoactive substance dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.90	Other psychoactive substance use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.939	Other psychoactive substance use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ41ZZZ	Group Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ42ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ43ZZZ	Group Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ44ZZZ	Group Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ45ZZZ	Group Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ46ZZZ	Group Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ47ZZZ	Group Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ48ZZZ	Group Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
HZ49ZZZ	Group Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ4BZZZ	Group Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ50ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ51ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ52ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ53ZZZ	Individual Psychotherapy for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ54ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ55ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interactive	Procedure	ICD-10-PCS
HZ56ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ57ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ58ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ59ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Supportive	Procedure	ICD-10-PCS
HZ5BZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis	Procedure	ICD-10-PCS
HZ5CZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic	Procedure	ICD-10-PCS
HZ5DZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychophysiological	Procedure	ICD-10-PCS
HZ63ZZZ	Family Counseling for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ83ZZZ	Medication Management for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ88ZZZ	Medication Management for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ89ZZZ	Medication Management for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ98ZZZ	Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
HZ99ZZZ	Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
O35.5XX0	Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified	Diagnosis	ICD-10-CM
O35.5XX1	Maternal care for (suspected) damage to fetus by drugs, fetus 1	Diagnosis	ICD-10-CM
O35.5XX2	Maternal care for (suspected) damage to fetus by drugs, fetus 2	Diagnosis	ICD-10-CM
O35.5XX3	Maternal care for (suspected) damage to fetus by drugs, fetus 3	Diagnosis	ICD-10-CM
O35.5XX4	Maternal care for (suspected) damage to fetus by drugs, fetus 4	Diagnosis	ICD-10-CM
O35.5XX5	Maternal care for (suspected) damage to fetus by drugs, fetus 5	Diagnosis	ICD-10-CM
O35.5XX9	Maternal care for (suspected) damage to fetus by drugs, other fetus	Diagnosis	ICD-10-CM
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.711A	Poisoning by cannabis, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.721A	Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.7X1A	Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.8X1A	Poisoning by lysergide [LSD], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.901A	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.991A	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
V65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
Z71.51	Drug abuse counseling and surveillance of drug abuser	Diagnosis	ICD-10-CM
<b>Endometrial Cancer</b>			
182.0	Malignant neoplasm of corpus uteri, except isthmus	Diagnosis	ICD-9-CM
233.2	Carcinoma in situ of other and unspecified parts of uterus	Diagnosis	ICD-9-CM
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM
V10.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-9-CM
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM
<b>Glaucoma</b>			
365.00	Unspecified preglaucoma	Diagnosis	ICD-9-CM
365.01	Borderline glaucoma, open angle with borderline findings, low risk	Diagnosis	ICD-9-CM
365.02	Borderline glaucoma with anatomical narrow angle	Diagnosis	ICD-9-CM
365.03	Borderline glaucoma with steroid responders	Diagnosis	ICD-9-CM
365.04	Borderline glaucoma with ocular hypertension	Diagnosis	ICD-9-CM
365.10	Unspecified open-angle glaucoma	Diagnosis	ICD-9-CM
365.11	Primary open-angle glaucoma	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
365.12	Low tension open-angle glaucoma	Diagnosis	ICD-9-CM
365.13	Pigmentary open-angle glaucoma	Diagnosis	ICD-9-CM
365.15	Residual stage of open angle glaucoma	Diagnosis	ICD-9-CM
365.20	Unspecified primary angle-closure glaucoma	Diagnosis	ICD-9-CM
365.21	Intermittent angle-closure glaucoma	Diagnosis	ICD-9-CM
365.22	Acute angle-closure glaucoma	Diagnosis	ICD-9-CM
365.23	Chronic angle-closure glaucoma	Diagnosis	ICD-9-CM
365.24	Residual stage of angle-closure glaucoma	Diagnosis	ICD-9-CM
365.31	Corticosteroid-induced glaucoma, glaucomatous stage	Diagnosis	ICD-9-CM
365.32	Corticosteroid-induced glaucoma, residual stage	Diagnosis	ICD-9-CM
365.41	Glaucoma associated with chamber angle anomalies	Diagnosis	ICD-9-CM
365.42	Glaucoma associated with anomalies of iris	Diagnosis	ICD-9-CM
365.43	Glaucoma associated with other anterior segment anomalies	Diagnosis	ICD-9-CM
365.51	Phacolytic glaucoma	Diagnosis	ICD-9-CM
365.52	Pseudoexfoliation glaucoma	Diagnosis	ICD-9-CM
365.59	Glaucoma associated with other lens disorders	Diagnosis	ICD-9-CM
365.60	Glaucoma associated with unspecified ocular disorder	Diagnosis	ICD-9-CM
365.61	Glaucoma associated with pupillary block	Diagnosis	ICD-9-CM
365.62	Glaucoma associated with ocular inflammations	Diagnosis	ICD-9-CM
365.63	Glaucoma associated with vascular disorders of eye	Diagnosis	ICD-9-CM
365.64	Glaucoma associated with tumors or cysts	Diagnosis	ICD-9-CM
365.65	Glaucoma associated with ocular trauma	Diagnosis	ICD-9-CM
365.81	Hypersecretion glaucoma	Diagnosis	ICD-9-CM
365.82	Glaucoma with increased episcleral venous pressure	Diagnosis	ICD-9-CM
365.83	Aqueous misdirection	Diagnosis	ICD-9-CM
365.89	Other specified glaucoma	Diagnosis	ICD-9-CM
365.9	Unspecified glaucoma	Diagnosis	ICD-9-CM
377.14	Glaucomatous atrophy (cupping) of optic disc	Diagnosis	ICD-9-CM
H40.001	Preglaucoma, unspecified, right eye	Diagnosis	ICD-10-CM
H40.002	Preglaucoma, unspecified, left eye	Diagnosis	ICD-10-CM
H40.003	Preglaucoma, unspecified, bilateral	Diagnosis	ICD-10-CM
H40.009	Preglaucoma, unspecified, unspecified eye	Diagnosis	ICD-10-CM
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM
H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CM
H40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CM
H40.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CM
H40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CM
H40.031	Anatomical narrow angle, right eye	Diagnosis	ICD-10-CM
H40.032	Anatomical narrow angle, left eye	Diagnosis	ICD-10-CM
H40.033	Anatomical narrow angle, bilateral	Diagnosis	ICD-10-CM
H40.039	Anatomical narrow angle, unspecified eye	Diagnosis	ICD-10-CM
H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.11X0	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.11X1	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.11X2	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.11X3	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.11X4	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1222	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1310	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1312	Pigmentary glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1313	Pigmentary glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1320	Pigmentary glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1410	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1420	Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1430	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1492	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1494	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.152	Residual stage of open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.20X0	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.20X1	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.20X2	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X4	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.213	Acute angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2210	Chronic angle-closure glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM
H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.50X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.50X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.50X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate stage	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
H40.50X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.50X4	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.51X0	Glaucoma secondary to other eye disorders, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage	Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage	Diagnosis	ICD-10-CM
H40.51X4	Glaucoma secondary to other eye disorders, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.52X0	Glaucoma secondary to other eye disorders, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage	Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage	Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.60X2	Glaucoma secondary to drugs, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM
H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye	Diagnosis	ICD-10-CM
H40.812	Glaucoma with increased episcleral venous pressure, left eye	Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral	Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye	Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye	Diagnosis	ICD-10-CM
H40.822	Hypersecretion glaucoma, left eye	Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM
H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM
<b>Heart Failure</b>			
398.91	Rheumatic heart failure (congestive)	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
428.0	Congestive heart failure, unspecified	Diagnosis	ICD-9-CM
428.1	Left heart failure	Diagnosis	ICD-9-CM
428.20	Unspecified systolic heart failure	Diagnosis	ICD-9-CM
428.21	Acute systolic heart failure	Diagnosis	ICD-9-CM
428.22	Chronic systolic heart failure	Diagnosis	ICD-9-CM
428.23	Acute on chronic systolic heart failure	Diagnosis	ICD-9-CM
428.30	Unspecified diastolic heart failure	Diagnosis	ICD-9-CM
428.31	Acute diastolic heart failure	Diagnosis	ICD-9-CM
428.32	Chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.33	Acute on chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.40	Unspecified combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.41	Acute combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.42	Chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.43	Acute on chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
428.9	Unspecified heart failure	Diagnosis	ICD-9-CM
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I42.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
I42.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
I42.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
I42.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
I43	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
P29.0	Neonatal cardiac failure	Diagnosis	ICD-10-CM
<b>Hyperlipidemia</b>			
272.0	Pure hypercholesterolemia	Diagnosis	ICD-9-CM
272.1	Pure hyperglyceridemia	Diagnosis	ICD-9-CM
272.2	Mixed hyperlipidemia	Diagnosis	ICD-9-CM
272.3	Hyperchylomicronemia	Diagnosis	ICD-9-CM
272.4	Other and unspecified hyperlipidemia	Diagnosis	ICD-9-CM
E78.0	Pure hypercholesterolemia	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.3	Hyperchylomicronemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.41	Elevated Lipoprotein(a)	Diagnosis	ICD-10-CM
E78.49	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
<b>Hypertension</b>			
362.11	Hypertensive retinopathy	Diagnosis	ICD-9-CM
401.0	Essential hypertension, malignant	Diagnosis	ICD-9-CM
401.1	Essential hypertension, benign	Diagnosis	ICD-9-CM
401.9	Unspecified essential hypertension	Diagnosis	ICD-9-CM
402.00	Malignant hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.10	Benign hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.90	Unspecified hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
403.00	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.10	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.90	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.00	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.10	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.90	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
405.01	Secondary renovascular hypertension, malignant	Diagnosis	ICD-9-CM
405.09	Other secondary hypertension, malignant	Diagnosis	ICD-9-CM
405.11	Secondary renovascular hypertension, benign	Diagnosis	ICD-9-CM
405.19	Other secondary hypertension, benign	Diagnosis	ICD-9-CM
405.91	Secondary renovascular hypertension, unspecified	Diagnosis	ICD-9-CM
405.99	Other secondary hypertension, unspecified	Diagnosis	ICD-9-CM
437.2	Hypertensive encephalopathy	Diagnosis	ICD-9-CM
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I15.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
<b>Ischemic Heart Disease</b>			
410.00	Acute myocardial infarction of anterolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	Diagnosis	ICD-9-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
410.02	Acute myocardial infarction of anterolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.10	Acute myocardial infarction of other anterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.11	Acute myocardial infarction of other anterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.12	Acute myocardial infarction of other anterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.20	Acute myocardial infarction of inferolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.21	Acute myocardial infarction of inferolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.22	Acute myocardial infarction of inferolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.30	Acute myocardial infarction of inferoposterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.32	Acute myocardial infarction of inferoposterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.40	Acute myocardial infarction of other inferior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.41	Acute myocardial infarction of other inferior wall, initial episode of care	Diagnosis	ICD-9-CM
410.42	Acute myocardial infarction of other inferior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.50	Acute myocardial infarction of other lateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.51	Acute myocardial infarction of other lateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.52	Acute myocardial infarction of other lateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.60	Acute myocardial infarction, true posterior wall infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	Diagnosis	ICD-9-CM
410.62	Acute myocardial infarction, true posterior wall infarction, subsequent episode of care	Diagnosis	ICD-9-CM
410.70	Acute myocardial infarction, subendocardial infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.71	Acute myocardial infarction, subendocardial infarction, initial episode of care	Diagnosis	ICD-9-CM
410.72	Acute myocardial infarction, subendocardial infarction, subsequent episode of care	Diagnosis	ICD-9-CM
410.80	Acute myocardial infarction of other specified sites, episode of care unspecified	Diagnosis	ICD-9-CM
410.81	Acute myocardial infarction of other specified sites, initial episode of care	Diagnosis	ICD-9-CM
410.82	Acute myocardial infarction of other specified sites, subsequent episode of care	Diagnosis	ICD-9-CM
410.90	Acute myocardial infarction, unspecified site, episode of care unspecified	Diagnosis	ICD-9-CM
410.91	Acute myocardial infarction, unspecified site, initial episode of care	Diagnosis	ICD-9-CM
410.92	Acute myocardial infarction, unspecified site, subsequent episode of care	Diagnosis	ICD-9-CM
411.0	Postmyocardial infarction syndrome	Diagnosis	ICD-9-CM
411.1	Intermediate coronary syndrome	Diagnosis	ICD-9-CM
411.81	Acute coronary occlusion without myocardial infarction	Diagnosis	ICD-9-CM
411.89	Other acute and subacute form of ischemic heart disease	Diagnosis	ICD-9-CM
412	Old myocardial infarction	Diagnosis	ICD-9-CM
413.0	Angina decubitus	Diagnosis	ICD-9-CM
413.1	Prinzmetal angina	Diagnosis	ICD-9-CM
413.9	Other and unspecified angina pectoris	Diagnosis	ICD-9-CM
414.00	Coronary atherosclerosis of unspecified type of vessel, native or graft	Diagnosis	ICD-9-CM
414.01	Coronary atherosclerosis of native coronary artery	Diagnosis	ICD-9-CM
414.02	Coronary atherosclerosis of autologous vein bypass graft	Diagnosis	ICD-9-CM
414.03	Coronary atherosclerosis of nonautologous biological bypass graft	Diagnosis	ICD-9-CM
414.04	Coronary atherosclerosis of artery bypass graft	Diagnosis	ICD-9-CM
414.05	Coronary atherosclerosis of unspecified type of bypass graft	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
414.06	Coronary atherosclerosis, of native coronary artery of transplanted heart	Diagnosis	ICD-9-CM
414.07	Coronary atherosclerosis, of bypass graft (artery) (vein) of transplanted heart	Diagnosis	ICD-9-CM
414.12	Dissection of coronary artery	Diagnosis	ICD-9-CM
414.2	Chronic total occlusion of coronary artery	Diagnosis	ICD-9-CM
414.3	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-9-CM
414.4	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-9-CM
414.8	Other specified forms of chronic ischemic heart disease	Diagnosis	ICD-9-CM
414.9	Unspecified chronic ischemic heart disease	Diagnosis	ICD-9-CM
I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.9	Angina pectoris, unspecified	Diagnosis	ICD-10-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
I24.1	Dressler's syndrome	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I24.9	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.2	Old myocardial infarction	Diagnosis	ICD-10-CM
I25.3	Aneurysm of heart	Diagnosis	ICD-10-CM
I25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
I25.42	Coronary artery dissection	Diagnosis	ICD-10-CM
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
I25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
I25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
<b>Lung Cancer</b>			
162.2	Malignant neoplasm of main bronchus	Diagnosis	ICD-9-CM
162.3	Malignant neoplasm of upper lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.4	Malignant neoplasm of middle lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.5	Malignant neoplasm of lower lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.8	Malignant neoplasm of other parts of bronchus or lung	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
162.9	Malignant neoplasm of bronchus and lung, unspecified site	Diagnosis	ICD-9-CM
231.2	Carcinoma in situ of bronchus and lung	Diagnosis	ICD-9-CM
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
V10.11	Personal history of malignant neoplasm of bronchus and lung	Diagnosis	ICD-9-CM
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
<b>Obesity</b>			
0D16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160Z9	Bypass Stomach to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D160ZB	Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
0D160ZL	Bypass Stomach to Transverse Colon, Open Approach	Procedure	ICD-10-PCS

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
0D16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZL	Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
0D168JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZL	Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D19079	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JB	Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190Z9	Bypass Duodenum to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D190ZA	Bypass Duodenum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D190ZB	Bypass Duodenum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D19479	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JB	Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
0D194K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194Z9	Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZA	Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZB	Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D19879	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JB	Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198Z9	Bypass Duodenum to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZA	Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZB	Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A07A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A07B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JB	Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
0D1A0KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0ZA	Bypass Jejunum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D1A0ZB	Bypass Jejunum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1A47A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A47B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JB	Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZA	Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZB	Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A87A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A87B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JB	Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZA	Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZB	Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZH	Bypass Jejunum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B07B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0JB	Bypass Ileum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
0D1B0ZB	Bypass Ileum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1B47B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4JB	Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4ZB	Bypass Ileum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B87B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8JB	Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZB	Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZH	Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
0DB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
0DB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
0DB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
0DB80ZZ	Excision of Small Intestine, Open Approach	Procedure	ICD-10-PCS
0DB90ZZ	Excision of Duodenum, Open Approach	Procedure	ICD-10-PCS
0DBB0ZZ	Excision of Ileum, Open Approach	Procedure	ICD-10-PCS
0DQ64ZZ	Repair Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
OTRB07Z	Replacement of Bladder with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
278.0	Overweight and obesity	Diagnosis	ICD-9-CM
278.00	Obesity, unspecified	Diagnosis	ICD-9-CM
278.01	Morbid obesity	Diagnosis	ICD-9-CM
278.03	Obesity hypoventilation syndrome	Diagnosis	ICD-9-CM
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
O99.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
O99.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O99.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
V85.3	Body Mass Index between 30-39, adult	Diagnosis	ICD-9-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
V85.30	Body Mass Index 30.0-30.9, adult	Diagnosis	ICD-9-CM
V85.31	Body Mass Index 31.0-31.9, adult	Diagnosis	ICD-9-CM
V85.32	Body Mass Index 32.0-32.9, adult	Diagnosis	ICD-9-CM
V85.33	Body Mass Index 33.0-33.9, adult	Diagnosis	ICD-9-CM
V85.34	Body Mass Index 34.0-34.9, adult	Diagnosis	ICD-9-CM
V85.35	Body Mass Index 35.0-35.9, adult	Diagnosis	ICD-9-CM
V85.36	Body Mass Index 36.0-36.9, adult	Diagnosis	ICD-9-CM
V85.37	Body Mass Index 37.0-37.9, adult	Diagnosis	ICD-9-CM
V85.38	Body Mass Index 38.0-38.9, adult	Diagnosis	ICD-9-CM
V85.39	Body Mass Index 39.0-39.9, adult	Diagnosis	ICD-9-CM
V85.4	Body Mass Index 40 and over, adult	Diagnosis	ICD-9-CM
V85.41	Body Mass Index 40.0-44.9, adult	Diagnosis	ICD-9-CM
V85.42	Body Mass Index 45.0-49.9, adult	Diagnosis	ICD-9-CM
V85.43	Body Mass Index 50.0-59.9, adult	Diagnosis	ICD-9-CM
V85.44	Body Mass Index 60.0-69.9, adult	Diagnosis	ICD-9-CM
V85.45	Body Mass Index 70 and over, adult	Diagnosis	ICD-9-CM
Z68.30	Body mass index (BMI) 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index (BMI) 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index (BMI) 32.0-32.9, adult	Diagnosis	ICD-10-CM
Z68.33	Body mass index (BMI) 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index (BMI) 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index (BMI) 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index (BMI) 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index (BMI) 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index (BMI) 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index (BMI) 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index (BMI) 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index (BMI) 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index (BMI) 50-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index (BMI) 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index (BMI) 70 or greater, adult	Diagnosis	ICD-10-CM
<b>Osteoporosis</b>			
733.00	Unspecified osteoporosis	Diagnosis	ICD-9-CM
733.01	Senile osteoporosis	Diagnosis	ICD-9-CM
733.02	Idiopathic osteoporosis	Diagnosis	ICD-9-CM
733.03	Disuse osteoporosis	Diagnosis	ICD-9-CM
733.09	Other osteoporosis	Diagnosis	ICD-9-CM
M80.00XA	Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.011A	Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.012A	Age-related osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.019A	Age-related osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
M80.021A	Age-related osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.022A	Age-related osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.029A	Age-related osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.031A	Age-related osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.032A	Age-related osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.039A	Age-related osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.041A	Age-related osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.042A	Age-related osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.049A	Age-related osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.051A	Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.052A	Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.059A	Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.061A	Age-related osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.062A	Age-related osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.069A	Age-related osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.071A	Age-related osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.072A	Age-related osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.079A	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.08XA	Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0AXA	Age-related osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.80XA	Other osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.811A	Other osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.812A	Other osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
M80.819A	Other osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.821A	Other osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.822A	Other osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.829A	Other osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.831A	Other osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.832A	Other osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.839A	Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.841A	Other osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.842A	Other osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.849A	Other osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.851A	Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.852A	Other osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.859A	Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.861A	Other osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.862A	Other osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.869A	Other osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.871A	Other osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.872A	Other osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.879A	Other osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.88XA	Other osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8AXA	Other osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M81.0	Age-related osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
M81.6	Localized osteoporosis [Lequesne]	Diagnosis	ICD-10-CM
M81.8	Other osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
<b>Overweight</b>			

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
E66.3	Overweight	Diagnosis	ICD-10-CM
Z68.25	Body mass index (BMI) 25.0-25.9, adult	Diagnosis	ICD-10-CM
Z68.26	Body mass index (BMI) 26.0-26.9, adult	Diagnosis	ICD-10-CM
Z68.27	Body mass index (BMI) 27.0-27.9, adult	Diagnosis	ICD-10-CM
Z68.28	Body mass index (BMI) 28.0-28.9, adult	Diagnosis	ICD-10-CM
Z68.29	Body mass index (BMI) 29.0-29.9, adult	Diagnosis	ICD-10-CM
<b>Prostate</b>			
185	Malignant neoplasm of prostate	Diagnosis	ICD-9-CM
233.4	Carcinoma in situ of prostate	Diagnosis	ICD-9-CM
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
V10.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-9-CM
Z85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CM
<b>Rheumatoid Arthritis</b>			
714.0	Rheumatoid arthritis	Diagnosis	ICD-9-CM
714.1	Felty's syndrome	Diagnosis	ICD-9-CM
714.2	Other rheumatoid arthritis with visceral or systemic involvement	Diagnosis	ICD-9-CM
714.30	Polyarticular juvenile rheumatoid arthritis, chronic or unspecified	Diagnosis	ICD-9-CM
714.31	Polyarticular juvenile rheumatoid arthritis, acute	Diagnosis	ICD-9-CM
714.32	Pauciarticular juvenile rheumatoid arthritis	Diagnosis	ICD-9-CM
714.33	Monoarticular juvenile rheumatoid arthritis	Diagnosis	ICD-9-CM
715.00	Generalized osteoarthritis, unspecified site	Diagnosis	ICD-9-CM
715.04	Generalized osteoarthritis, involving hand	Diagnosis	ICD-9-CM
715.09	Generalized osteoarthritis, involving multiple sites	Diagnosis	ICD-9-CM
715.10	Primary localized osteoarthritis, unspecified site	Diagnosis	ICD-9-CM
715.11	Primary localized osteoarthritis, shoulder region	Diagnosis	ICD-9-CM
715.12	Primary localized osteoarthritis, upper arm	Diagnosis	ICD-9-CM
715.13	Primary localized osteoarthritis, forearm	Diagnosis	ICD-9-CM
715.14	Primary localized osteoarthritis, hand	Diagnosis	ICD-9-CM
715.15	Primary localized osteoarthritis, pelvic region and thigh	Diagnosis	ICD-9-CM
715.16	Primary localized osteoarthritis, lower leg	Diagnosis	ICD-9-CM
715.17	Primary localized osteoarthritis, ankle and foot	Diagnosis	ICD-9-CM
715.18	Primary localized osteoarthritis, other specified sites	Diagnosis	ICD-9-CM
715.20	Secondary localized osteoarthritis, unspecified site	Diagnosis	ICD-9-CM
715.21	Secondary localized osteoarthritis, shoulder region	Diagnosis	ICD-9-CM
715.22	Secondary localized osteoarthritis, upper arm	Diagnosis	ICD-9-CM
715.23	Secondary localized osteoarthritis, forearm	Diagnosis	ICD-9-CM
715.24	Secondary localized osteoarthritis, involving hand	Diagnosis	ICD-9-CM
715.25	Secondary localized osteoarthritis, pelvic region and thigh	Diagnosis	ICD-9-CM
715.26	Secondary localized osteoarthritis, lower leg	Diagnosis	ICD-9-CM
715.27	Secondary localized osteoarthritis, ankle and foot	Diagnosis	ICD-9-CM
715.28	Secondary localized osteoarthritis, other specified site	Diagnosis	ICD-9-CM
715.30	Localized osteoarthritis not specified whether primary or secondary, unspecified site	Diagnosis	ICD-9-CM
715.31	Localized osteoarthritis not specified whether primary or secondary, shoulder region	Diagnosis	ICD-9-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
715.32	Localized osteoarthritis not specified whether primary or secondary, upper arm	Diagnosis	ICD-9-CM
715.33	Localized osteoarthritis not specified whether primary or secondary, forearm	Diagnosis	ICD-9-CM
715.34	Localized osteoarthritis not specified whether primary or secondary, hand	Diagnosis	ICD-9-CM
715.35	Localized osteoarthritis not specified whether primary or secondary, pelvic region and thigh	Diagnosis	ICD-9-CM
715.36	Localized osteoarthritis not specified whether primary or secondary, lower leg	Diagnosis	ICD-9-CM
715.37	Localized osteoarthritis not specified whether primary or secondary, ankle and foot	Diagnosis	ICD-9-CM
715.38	Localized osteoarthritis not specified whether primary or secondary, other specified sites	Diagnosis	ICD-9-CM
715.80	Osteoarthritis involving more than one site, but not specified as generalized, unspecified site	Diagnosis	ICD-9-CM
715.89	Osteoarthritis involving multiple sites, but not specified as generalized	Diagnosis	ICD-9-CM
715.90	Osteoarthritis, unspecified whether generalized or localized, unspecified site	Diagnosis	ICD-9-CM
715.91	Osteoarthritis, unspecified whether generalized or localized, shoulder region	Diagnosis	ICD-9-CM
715.92	Osteoarthritis, unspecified whether generalized or localized, upper arm	Diagnosis	ICD-9-CM
715.93	Osteoarthritis, unspecified whether generalized or localized, forearm	Diagnosis	ICD-9-CM
715.94	Osteoarthritis, unspecified whether generalized or localized, hand	Diagnosis	ICD-9-CM
715.95	Osteoarthritis, unspecified whether generalized or localized, pelvic region and thigh	Diagnosis	ICD-9-CM
715.96	Osteoarthritis, unspecified whether generalized or localized, lower leg	Diagnosis	ICD-9-CM
715.97	Osteoarthritis, unspecified whether generalized or localized, ankle and foot	Diagnosis	ICD-9-CM
715.98	Osteoarthritis, unspecified whether generalized or localized, other specified sites	Diagnosis	ICD-9-CM
720.0	Ankylosing spondylitis	Diagnosis	ICD-9-CM
721.0	Cervical spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.1	Cervical spondylosis with myelopathy	Diagnosis	ICD-9-CM
721.2	Thoracic spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.3	Lumbosacral spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.90	Spondylosis of unspecified site without mention of myelopathy	Diagnosis	ICD-9-CM
721.91	Spondylosis of unspecified site with myelopathy	Diagnosis	ICD-9-CM
L40.50	Arthropathic psoriasis, unspecified	Diagnosis	ICD-10-CM
L40.51	Distal interphalangeal psoriatic arthropathy	Diagnosis	ICD-10-CM
L40.54	Psoriatic juvenile arthropathy	Diagnosis	ICD-10-CM
L40.59	Other psoriatic arthropathy	Diagnosis	ICD-10-CM
M05.00	Felty's syndrome, unspecified site	Diagnosis	ICD-10-CM
M05.011	Felty's syndrome, right shoulder	Diagnosis	ICD-10-CM
M05.012	Felty's syndrome, left shoulder	Diagnosis	ICD-10-CM
M05.019	Felty's syndrome, unspecified shoulder	Diagnosis	ICD-10-CM
M05.021	Felty's syndrome, right elbow	Diagnosis	ICD-10-CM
M05.022	Felty's syndrome, left elbow	Diagnosis	ICD-10-CM
M05.029	Felty's syndrome, unspecified elbow	Diagnosis	ICD-10-CM
M05.031	Felty's syndrome, right wrist	Diagnosis	ICD-10-CM
M05.032	Felty's syndrome, left wrist	Diagnosis	ICD-10-CM
M05.039	Felty's syndrome, unspecified wrist	Diagnosis	ICD-10-CM
M05.041	Felty's syndrome, right hand	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
M05.042	Felty's syndrome, left hand	Diagnosis	ICD-10-CM
M05.049	Felty's syndrome, unspecified hand	Diagnosis	ICD-10-CM
M05.051	Felty's syndrome, right hip	Diagnosis	ICD-10-CM
M05.052	Felty's syndrome, left hip	Diagnosis	ICD-10-CM
M05.059	Felty's syndrome, unspecified hip	Diagnosis	ICD-10-CM
M05.061	Felty's syndrome, right knee	Diagnosis	ICD-10-CM
M05.062	Felty's syndrome, left knee	Diagnosis	ICD-10-CM
M05.069	Felty's syndrome, unspecified knee	Diagnosis	ICD-10-CM
M05.071	Felty's syndrome, right ankle and foot	Diagnosis	ICD-10-CM
M05.072	Felty's syndrome, left ankle and foot	Diagnosis	ICD-10-CM
M05.079	Felty's syndrome, unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.09	Felty's syndrome, multiple sites	Diagnosis	ICD-10-CM
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	Diagnosis	ICD-10-CM
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site	Diagnosis	ICD-10-CM
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	Diagnosis	ICD-10-CM
M06.1	Adult-onset Still's disease	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM
M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM
M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM
M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM
M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM
M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM
M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM
M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM
M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM
M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM
M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.88	Other specified rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M06.89	Other specified rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M06.8A	Other specified rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M06.9	Rheumatoid arthritis, unspecified	Diagnosis	ICD-10-CM
M08.00	Unspecified juvenile rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M08.011	Unspecified juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.012	Unspecified juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.021	Unspecified juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.022	Unspecified juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.031	Unspecified juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.032	Unspecified juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.041	Unspecified juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.042	Unspecified juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.049	Unspecified juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.051	Unspecified juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.052	Unspecified juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.059	Unspecified juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.061	Unspecified juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.062	Unspecified juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.069	Unspecified juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.08	Unspecified juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.0A	Unspecified juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.1	Juvenile ankylosing spondylitis	Diagnosis	ICD-10-CM
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site	Diagnosis	ICD-10-CM
M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder	Diagnosis	ICD-10-CM
M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder	Diagnosis	ICD-10-CM
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder	Diagnosis	ICD-10-CM
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow	Diagnosis	ICD-10-CM
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow	Diagnosis	ICD-10-CM
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist	Diagnosis	ICD-10-CM
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist	Diagnosis	ICD-10-CM
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist	Diagnosis	ICD-10-CM
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand	Diagnosis	ICD-10-CM
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand	Diagnosis	ICD-10-CM
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand	Diagnosis	ICD-10-CM
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip	Diagnosis	ICD-10-CM
M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip	Diagnosis	ICD-10-CM
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip	Diagnosis	ICD-10-CM
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee	Diagnosis	ICD-10-CM
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee	Diagnosis	ICD-10-CM
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee	Diagnosis	ICD-10-CM
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot	Diagnosis	ICD-10-CM
M08.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot	Diagnosis	ICD-10-CM
M08.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae	Diagnosis	ICD-10-CM
M08.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites	Diagnosis	ICD-10-CM
M08.2A	Juvenile rheumatoid arthritis with systemic onset, other specified site	Diagnosis	ICD-10-CM
M08.3	Juvenile rheumatoid polyarthritis (seronegative)	Diagnosis	ICD-10-CM
M08.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.421	Pauciarticular juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.422	Pauciarticular juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.431	Pauciarticular juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.432	Pauciarticular juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.441	Pauciarticular juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.442	Pauciarticular juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.451	Pauciarticular juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.452	Pauciarticular juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.461	Pauciarticular juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.462	Pauciarticular juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.4A	Pauciarticular juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.80	Other juvenile arthritis, unspecified site	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
M08.811	Other juvenile arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.812	Other juvenile arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.819	Other juvenile arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.821	Other juvenile arthritis, right elbow	Diagnosis	ICD-10-CM
M08.822	Other juvenile arthritis, left elbow	Diagnosis	ICD-10-CM
M08.829	Other juvenile arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.831	Other juvenile arthritis, right wrist	Diagnosis	ICD-10-CM
M08.832	Other juvenile arthritis, left wrist	Diagnosis	ICD-10-CM
M08.839	Other juvenile arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.841	Other juvenile arthritis, right hand	Diagnosis	ICD-10-CM
M08.842	Other juvenile arthritis, left hand	Diagnosis	ICD-10-CM
M08.849	Other juvenile arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.851	Other juvenile arthritis, right hip	Diagnosis	ICD-10-CM
M08.852	Other juvenile arthritis, left hip	Diagnosis	ICD-10-CM
M08.859	Other juvenile arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.861	Other juvenile arthritis, right knee	Diagnosis	ICD-10-CM
M08.862	Other juvenile arthritis, left knee	Diagnosis	ICD-10-CM
M08.869	Other juvenile arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.871	Other juvenile arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.872	Other juvenile arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.879	Other juvenile arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.88	Other juvenile arthritis, other specified site	Diagnosis	ICD-10-CM
M08.89	Other juvenile arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.90	Juvenile arthritis, unspecified, unspecified site	Diagnosis	ICD-10-CM
M08.911	Juvenile arthritis, unspecified, right shoulder	Diagnosis	ICD-10-CM
M08.912	Juvenile arthritis, unspecified, left shoulder	Diagnosis	ICD-10-CM
M08.919	Juvenile arthritis, unspecified, unspecified shoulder	Diagnosis	ICD-10-CM
M08.921	Juvenile arthritis, unspecified, right elbow	Diagnosis	ICD-10-CM
M08.922	Juvenile arthritis, unspecified, left elbow	Diagnosis	ICD-10-CM
M08.929	Juvenile arthritis, unspecified, unspecified elbow	Diagnosis	ICD-10-CM
M08.931	Juvenile arthritis, unspecified, right wrist	Diagnosis	ICD-10-CM
M08.932	Juvenile arthritis, unspecified, left wrist	Diagnosis	ICD-10-CM
M08.939	Juvenile arthritis, unspecified, unspecified wrist	Diagnosis	ICD-10-CM
M08.941	Juvenile arthritis, unspecified, right hand	Diagnosis	ICD-10-CM
M08.942	Juvenile arthritis, unspecified, left hand	Diagnosis	ICD-10-CM
M08.949	Juvenile arthritis, unspecified, unspecified hand	Diagnosis	ICD-10-CM
M08.951	Juvenile arthritis, unspecified, right hip	Diagnosis	ICD-10-CM
M08.952	Juvenile arthritis, unspecified, left hip	Diagnosis	ICD-10-CM
M08.959	Juvenile arthritis, unspecified, unspecified hip	Diagnosis	ICD-10-CM
M08.961	Juvenile arthritis, unspecified, right knee	Diagnosis	ICD-10-CM
M08.962	Juvenile arthritis, unspecified, left knee	Diagnosis	ICD-10-CM
M08.969	Juvenile arthritis, unspecified, unspecified knee	Diagnosis	ICD-10-CM
M08.971	Juvenile arthritis, unspecified, right ankle and foot	Diagnosis	ICD-10-CM
M08.972	Juvenile arthritis, unspecified, left ankle and foot	Diagnosis	ICD-10-CM
M08.979	Juvenile arthritis, unspecified, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.98	Juvenile arthritis, unspecified, vertebrae	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
M08.99	Juvenile arthritis, unspecified, multiple sites	Diagnosis	ICD-10-CM
M08.9A	Juvenile arthritis, unspecified, other specified site	Diagnosis	ICD-10-CM
M15.0	Primary generalized (osteo)arthritis	Diagnosis	ICD-10-CM
M15.1	Heberden's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.2	Bouchard's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.3	Secondary multiple arthritis	Diagnosis	ICD-10-CM
M15.4	Erosive (osteo)arthritis	Diagnosis	ICD-10-CM
M15.8	Other polyosteoarthritis	Diagnosis	ICD-10-CM
M15.9	Polyosteoarthritis, unspecified	Diagnosis	ICD-10-CM
M16.0	Bilateral primary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.10	Unilateral primary osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.11	Unilateral primary osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.12	Unilateral primary osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.2	Bilateral osteoarthritis resulting from hip dysplasia	Diagnosis	ICD-10-CM
M16.30	Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip	Diagnosis	ICD-10-CM
M16.31	Unilateral osteoarthritis resulting from hip dysplasia, right hip	Diagnosis	ICD-10-CM
M16.32	Unilateral osteoarthritis resulting from hip dysplasia, left hip	Diagnosis	ICD-10-CM
M16.4	Bilateral post-traumatic osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.50	Unilateral post-traumatic osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.51	Unilateral post-traumatic osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.52	Unilateral post-traumatic osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.6	Other bilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.7	Other unilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.9	Osteoarthritis of hip, unspecified	Diagnosis	ICD-10-CM
M17.0	Bilateral primary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.10	Unilateral primary osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.11	Unilateral primary osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.12	Unilateral primary osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.2	Bilateral post-traumatic osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.31	Unilateral post-traumatic osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.32	Unilateral post-traumatic osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.4	Other bilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.5	Other unilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.9	Osteoarthritis of knee, unspecified	Diagnosis	ICD-10-CM
M18.0	Bilateral primary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.10	Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.11	Unilateral primary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.12	Unilateral primary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.2	Bilateral post-traumatic osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.30	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.31	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.32	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
M18.4	Other bilateral secondary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.50	Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.51	Other unilateral secondary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.52	Other unilateral secondary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.9	Osteoarthritis of first carpometacarpal joint, unspecified	Diagnosis	ICD-10-CM
M19.011	Primary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.012	Primary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.019	Primary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.021	Primary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.022	Primary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.029	Primary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.031	Primary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.032	Primary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.039	Primary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.041	Primary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.042	Primary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.049	Primary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.071	Primary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.072	Primary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.079	Primary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.09	Primary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.111	Post-traumatic osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.112	Post-traumatic osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.119	Post-traumatic osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.121	Post-traumatic osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.122	Post-traumatic osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.129	Post-traumatic osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.131	Post-traumatic osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.132	Post-traumatic osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.139	Post-traumatic osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.141	Post-traumatic osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.142	Post-traumatic osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.149	Post-traumatic osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.171	Post-traumatic osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.172	Post-traumatic osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.179	Post-traumatic osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.19	Post-traumatic osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.211	Secondary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.212	Secondary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.219	Secondary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.221	Secondary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.222	Secondary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.229	Secondary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
M19.231	Secondary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.232	Secondary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.239	Secondary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.241	Secondary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.242	Secondary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.249	Secondary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.271	Secondary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.272	Secondary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.279	Secondary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.29	Secondary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.90	Unspecified osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.91	Primary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.92	Post-traumatic osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.93	Secondary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M45.0	Ankylosing spondylitis of multiple sites in spine	Diagnosis	ICD-10-CM
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.2	Ankylosing spondylitis of cervical region	Diagnosis	ICD-10-CM
M45.3	Ankylosing spondylitis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.4	Ankylosing spondylitis of thoracic region	Diagnosis	ICD-10-CM
M45.5	Ankylosing spondylitis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.6	Ankylosing spondylitis lumbar region	Diagnosis	ICD-10-CM
M45.7	Ankylosing spondylitis of lumbosacral region	Diagnosis	ICD-10-CM
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.9	Ankylosing spondylitis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A0	Non-radiographic axial spondyloarthritis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A1	Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.A2	Non-radiographic axial spondyloarthritis of cervical region	Diagnosis	ICD-10-CM
M45.A3	Non-radiographic axial spondyloarthritis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.A4	Non-radiographic axial spondyloarthritis of thoracic region	Diagnosis	ICD-10-CM
M45.A5	Non-radiographic axial spondyloarthritis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.A6	Non-radiographic axial spondyloarthritis of lumbar region	Diagnosis	ICD-10-CM
M45.A7	Non-radiographic axial spondyloarthritis of lumbosacral region	Diagnosis	ICD-10-CM
M45.A8	Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.AB	Non-radiographic axial spondyloarthritis of multiple sites in spine	Diagnosis	ICD-10-CM
M46.80	Other specified inflammatory spondylopathies, site unspecified	Diagnosis	ICD-10-CM
M46.81	Other specified inflammatory spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.82	Other specified inflammatory spondylopathies, cervical region	Diagnosis	ICD-10-CM
M46.83	Other specified inflammatory spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M46.84	Other specified inflammatory spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M46.85	Other specified inflammatory spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M46.86	Other specified inflammatory spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M46.87	Other specified inflammatory spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M46.88	Other specified inflammatory spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.89	Other specified inflammatory spondylopathies, multiple sites in spine	Diagnosis	ICD-10-CM
M46.90	Unspecified inflammatory spondylopathy, site unspecified	Diagnosis	ICD-10-CM
M46.91	Unspecified inflammatory spondylopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
M46.92	Unspecified inflammatory spondylopathy, cervical region	Diagnosis	ICD-10-CM
M46.93	Unspecified inflammatory spondylopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M46.94	Unspecified inflammatory spondylopathy, thoracic region	Diagnosis	ICD-10-CM
M46.95	Unspecified inflammatory spondylopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M46.96	Unspecified inflammatory spondylopathy, lumbar region	Diagnosis	ICD-10-CM
M46.97	Unspecified inflammatory spondylopathy, lumbosacral region	Diagnosis	ICD-10-CM
M46.98	Unspecified inflammatory spondylopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.99	Unspecified inflammatory spondylopathy, multiple sites in spine	Diagnosis	ICD-10-CM
M47.011	Anterior spinal artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.012	Anterior spinal artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.013	Anterior spinal artery compression syndromes, cervicothoracic region	Diagnosis	ICD-10-CM
M47.014	Anterior spinal artery compression syndromes, thoracic region	Diagnosis	ICD-10-CM
M47.015	Anterior spinal artery compression syndromes, thoracolumbar region	Diagnosis	ICD-10-CM
M47.016	Anterior spinal artery compression syndromes, lumbar region	Diagnosis	ICD-10-CM
M47.019	Anterior spinal artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.021	Vertebral artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.022	Vertebral artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.029	Vertebral artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.10	Other spondylosis with myelopathy, site unspecified	Diagnosis	ICD-10-CM
M47.11	Other spondylosis with myelopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.12	Other spondylosis with myelopathy, cervical region	Diagnosis	ICD-10-CM
M47.13	Other spondylosis with myelopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.14	Other spondylosis with myelopathy, thoracic region	Diagnosis	ICD-10-CM
M47.15	Other spondylosis with myelopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.16	Other spondylosis with myelopathy, lumbar region	Diagnosis	ICD-10-CM
M47.20	Other spondylosis with radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.21	Other spondylosis with radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.22	Other spondylosis with radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.23	Other spondylosis with radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.24	Other spondylosis with radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.25	Other spondylosis with radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.26	Other spondylosis with radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.27	Other spondylosis with radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.28	Other spondylosis with radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.819	Spondylosis without myelopathy or radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.891	Other spondylosis, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.892	Other spondylosis, cervical region	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
M47.893	Other spondylosis, cervicothoracic region	Diagnosis	ICD-10-CM
M47.894	Other spondylosis, thoracic region	Diagnosis	ICD-10-CM
M47.895	Other spondylosis, thoracolumbar region	Diagnosis	ICD-10-CM
M47.896	Other spondylosis, lumbar region	Diagnosis	ICD-10-CM
M47.897	Other spondylosis, lumbosacral region	Diagnosis	ICD-10-CM
M47.898	Other spondylosis, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.899	Other spondylosis, site unspecified	Diagnosis	ICD-10-CM
M47.9	Spondylosis, unspecified	Diagnosis	ICD-10-CM
M48.8X1	Other specified spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M48.8X2	Other specified spondylopathies, cervical region	Diagnosis	ICD-10-CM
M48.8X3	Other specified spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M48.8X4	Other specified spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M48.8X5	Other specified spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M48.8X6	Other specified spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M48.8X7	Other specified spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M48.8X8	Other specified spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M48.8X9	Other specified spondylopathies, site unspecified	Diagnosis	ICD-10-CM
<b>Smoking</b>			
1034F	Current tobacco smoker (CAD, CAP, COPD, PV) (DM)	Procedure	CPT-2
4001F	Tobacco use cessation intervention, pharmacologic therapy (COPD, CAD, CAP, PV, Asthma) (DM) (PV)	Procedure	CPT-2
4004F	Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD)	Procedure	CPT-2
99406	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes	Procedure	CPT-4
99407	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes	Procedure	CPT-4
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
G0436	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS
G0437	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS
G9016	Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]	Procedure	HCPCS
G9276	Documentation that patient is a current tobacco user	Procedure	HCPCS
G9458	Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or referral to external smoking or tobacco cessation support programs, or current enrollment in smoking or tobacco use cessation program) if identified as a tobacco user	Procedure	HCPCS
O99.330	Smoking (tobacco) complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.331	Smoking (tobacco) complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.332	Smoking (tobacco) complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.333	Smoking (tobacco) complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.335	Smoking (tobacco) complicating the puerperium	Diagnosis	ICD-10-CM
S4995	Smoking cessation gum	Procedure	HCPCS
S9075	Smoking cessation treatment	Procedure	HCPCS
S9453	Smoking cessation classes, nonphysician provider, per session	Procedure	HCPCS
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
Z87.891	Personal history of nicotine dependence	Diagnosis	ICD-10-CM
<b>Transient Ischemic Attack</b>			
430	Subarachnoid hemorrhage	Diagnosis	ICD-9-CM
431	Intracerebral hemorrhage	Diagnosis	ICD-9-CM
433.01	Occlusion and stenosis of basilar artery with cerebral infarction	Diagnosis	ICD-9-CM
433.11	Occlusion and stenosis of carotid artery with cerebral infarction	Diagnosis	ICD-9-CM
433.21	Occlusion and stenosis of vertebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.31	Occlusion and stenosis of multiple and bilateral precerebral arteries with cerebral infarction	Diagnosis	ICD-9-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
433.81	Occlusion and stenosis of other specified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.91	Occlusion and stenosis of unspecified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
434.00	Cerebral thrombosis without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.01	Cerebral thrombosis with cerebral infarction	Diagnosis	ICD-9-CM
434.10	Cerebral embolism without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.11	Cerebral embolism with cerebral infarction	Diagnosis	ICD-9-CM
434.90	Unspecified cerebral artery occlusion without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.91	Unspecified cerebral artery occlusion with cerebral infarction	Diagnosis	ICD-9-CM
435.0	Basilar artery syndrome	Diagnosis	ICD-9-CM
435.1	Vertebral artery syndrome	Diagnosis	ICD-9-CM
435.3	Vertebrobasilar artery syndrome	Diagnosis	ICD-9-CM
435.8	Other specified transient cerebral ischemias	Diagnosis	ICD-9-CM
435.9	Unspecified transient cerebral ischemia	Diagnosis	ICD-9-CM
436	Acute, but ill-defined, cerebrovascular disease	Diagnosis	ICD-9-CM
997.02	Iatrogenic cerebrovascular infarction or hemorrhage	Diagnosis	ICD-9-CM
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM
G45.3	Amaurosis fugax	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.3	Brain stem stroke syndrome	Diagnosis	ICD-10-CM
G46.4	Cerebellar stroke syndrome	Diagnosis	ICD-10-CM
G46.5	Pure motor lacunar syndrome	Diagnosis	ICD-10-CM
G46.6	Pure sensory lacunar syndrome	Diagnosis	ICD-10-CM
G46.7	Other lacunar syndromes	Diagnosis	ICD-10-CM
G46.8	Other vascular syndromes of brain in cerebrovascular diseases	Diagnosis	ICD-10-CM
G97.31	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure	Diagnosis	ICD-10-CM
G97.32	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
I60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM
I60.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

Code	Description	Code	
		Category	Code Type
I60.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
I60.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries	Diagnosis	ICD-10-CM
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.343	Cerebral infarction to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM



**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
I63.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
I63.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM

**Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
I63.89	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I66.01	Occlusion and stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I66.02	Occlusion and stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I66.03	Occlusion and stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I66.09	Occlusion and stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I66.11	Occlusion and stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I66.12	Occlusion and stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I66.13	Occlusion and stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I66.19	Occlusion and stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I66.21	Occlusion and stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I66.22	Occlusion and stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I66.23	Occlusion and stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I66.29	Occlusion and stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I66.3	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CM
I66.8	Occlusion and stenosis of other cerebral arteries	Diagnosis	ICD-10-CM
I66.9	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
I97.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
I97.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
I97.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
I97.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM

**Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request**

<b>Non-Proprietary Name</b>	<b>Proprietary Name</b>
<b>Obesity</b>	
Amino Acids/Multivit-Minerals/Dietary Supplement/Protein Sup	Optifast 70
Benzphetamine HCl	Benzphetamine
Benzphetamine HCl	Regimex
Diethylpropion HCl	Diethylpropion
Diethylpropion HCl	Diethylpropion HCl (bulk)
Liraglutide	Saxenda
Liraglutide	Victoza 2-Pak
Liraglutide	Victoza 3-Pak
Lorcaserin HCl	Belviq
Lorcaserin HCl	Belviq XR
Naltrexone HCl/Bupropion HCl	Contrave
Orlistat	Alli
Orlistat	Xenical
Phendimetrazine Tartrate	Bontril PDM
Phendimetrazine Tartrate	Phendimetrazine Tartrate
Phentermine HCl	Adipex-P
Phentermine HCl	Lomaira
Phentermine HCl	Phentermine
Phentermine HCl	Phentermine HCl (bulk)
Phentermine HCl	Suprenza
Phentermine HCl/Topiramate	Qsymia
Resveratrol/Chromium Pico/Green Tea/EGCG/Caffeine/Digestive3	Resveratrol Diet
<b>Smoking</b>	
Nicotine	NTS Step 1
Nicotine	Nicoderm CQ
Nicotine	Nicotine
Nicotine	Nicotrol
Nicotine	Nicotrol NS
Nicotine Bitartrate	Nicotine Tartrate
Nicotine Polacrilex	Nicorelief
Nicotine Polacrilex	Nicorette
Nicotine Polacrilex	Nicotine (Polacrilex)
Nicotine Polacrilex	Nicotine Polacrilex (bulk)
Nicotine Polacrilex	Quit 2
Nicotine Polacrilex	Quit 4
Nicotine Polacrilex	Stop Smoking Aid
Varenicline Tartrate	Chantix
Varenicline Tartrate	Chantix Continuing Month Box
Varenicline Tartrate	Chantix Starting Month Box
Varenicline Tartrate	Tyrvaya
Varenicline Tartrate	Varenicline

**Appendix F. Specifications Defining Parameters for this Request**

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 11.0.0, to assess utilization and uptake of the 2020 (part 1) New Molecular Entities (NME) to inform FDA in the Sentinel Distributed Database (SDD).

**Query period:** 01/01/2020 - 12/31/2022  
**Coverage requirement:** Medical and Drug Coverage  
**Pre-index enrollment requirement:** 183 days  
**Post-index requirement:** 0 days  
**Enrollment gap:** 45 days  
**Age groups:** 0-17, 18-24, 25-40, 41-64, 65+ years  
**Stratifications:** Age group, Sex  
**Restrictions:** Male and Female  
**Distribution of index-defining codes:** No  
**Envelope macro:** Reclassify encounters during inpatient stay as inpatient  
**Freeze data:** No

**Exposure**

Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
1	Avapritinib	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
2	Teprotumumab- Trbw	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
3	Tazemetostat	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

**Appendix F. Specifications Defining Parameters for this Request**

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 11.0.0, to assess utilization and uptake of the 2020 (part 1) New Molecular Entities (NME) to inform FDA in the Sentinel Distributed Database (SDD).

Exposure										
4	Lactitol	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
5	Bempedoic Acid	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
6	Eptinezumab-jjmr	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
7	Amisulpride	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
8	Rimegepant	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

**Appendix F. Specifications Defining Parameters for this Request**

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 11.0.0, to assess utilization and uptake of the 2020 (part 1) New Molecular Entities (NME) to inform FDA in the Sentinel Distributed Database (SDD).

Exposure										
9	Isatuximab	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
10	Osilodrostat	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
11	Ozanimod	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
12	Selumetinib	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
13	Tucatinib	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

**Appendix F. Specifications Defining Parameters for this Request**

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 11.0.0, to assess utilization and uptake of the 2020 (part 1) New Molecular Entities (NME) to inform FDA in the Sentinel Distributed Database (SDD).

Exposure										
14	Pemigatinib	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
15	Sacituzumab Govitecan-hziy	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
16	Opicapone	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

ICD-9, ICD-10, HCPCS, and CPT codes are provided by Optum360.  
 NDC codes are checked against First Data Bank's FDB MedKnowledge®.  
 N/A: Not Applicable

**Appendix G. Specifications Defining Parameters for Baseline Characteristics in this Request**

Baseline Characteristics						
Characteristic	Care setting/ Principal diagnosis <sup>1</sup>	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensing	Number of instances the covariate should be found in evaluation period	Forced supply to attach to dispensing
<i>Chronic Conditions Data</i>						
Acute Myocardial Infarction	IPP, IPS	-183	-1	N/A	1	N/A
Alzheimer's Disease and related conditions	Any	-183	-1	N/A	1	N/A
Atrial Fibrillation	IPP, IPS or	-183	-1	N/A	1	N/A
	AV*, ED*, OA*	-183	-1	N/A	2	N/A
Diabetes	IP*, IS*	-183	-1	N/A	1	N/A
	AV*, ED*, OA*	-183	-1	N/A	2	N/A
Heart Failure	IP*, AV*, ED*	-183	-1	N/A	1	N/A
Hyperlipidemia	IP*, IS*	-183	-1	N/A	1	N/A
	AV*, ED*, OA*	-183	-1	N/A	2	N/A
Hypertension	IP*, IS*	-183	-1	N/A	1	N/A
	AV*, ED*, OA*	-183	-1	N/A	2	N/A
Depression	Any	-183	-1	N/A	1	N/A
Ischemic Heart Disease	Any	-183	-1	N/A	1	N/A
Rheumatoid Arthritis/Osteoarthritis	Any	-183	-1	N/A	2	N/A
Stroke/TIA	IP*	-183	-1	N/A	1	N/A
	AV*, ED*, OA*	-183	-1	N/A	2	N/A
Breast Cancer	IP*, IS* or	-183	-1	N/A	1	N/A
	AV*, ED* OA*	-183	-1	N/A	2	N/A
Colorectal Cancer	IP*, IS* or	-183	-1	N/A	1	N/A
	AV*, ED* OA*	-183	-1	N/A	2	N/A



**Appendix G. Specifications Defining Parameters for Baseline Characteristics in this Request**

Baseline Characteristics						
Characteristic	Care setting/ Principal diagnosis <sup>1</sup>	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensing	Number of instances the covariate should be found in evaluation period	Forced supply to attach to dispensing
Prostate Cancer	IP*, IS* or	-183	-1	N/A	1	N/A
	AV*, ED* OA*	-183	-1	N/A	2	N/A
Lung Cancer	IP*, IS* or	-183	-1	N/A	1	N/A
	AV*, ED* OA*	-183	-1	N/A	2	N/A
Endometrial Cancer	IP*, IS* or	-183	-1	N/A	1	N/A
	AV*, ED* OA*	-183	-1	N/A	2	N/A
Acquired Hypothyroidism	IP*, IS*, or	-183	-1	N/A	1	N/A
	AV*, ED* OA*	-183	-1	N/A	2	N/A
Anemia	Any	-183	-1	N/A	1	N/A
Asthma	IP*, IS*, or	-183	-1	N/A	1	N/A
	AV*, ED* OA*	-183	-1	N/A	2	N/A
Benign Prostatic Hyperplasia	IP*, IS*, or	-183	-1	N/A	1	N/A
	AV*, ED* OA*	-183	-1	N/A	2	N/A
Chronic Kidney Disease	IP*, IS*, or	-183	-1	N/A	1	N/A
	AV*, ED* OA*	-183	-1	N/A	2	N/A
COPD and Bronchiectasis	IP*, IS*, or	-183	-1	N/A	1	N/A
	AV*, ED* OA*	-183	-1	N/A	2	N/A
Glaucoma	AV*, ED*, OA*	-183	-1	N/A	2	N/A

**Appendix G. Specifications Defining Parameters for Baseline Characteristics in this Request**

Baseline Characteristics						
Characteristic	Care setting/ Principal diagnosis <sup>1</sup>	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensing	Number of instances the covariate should be found in evaluation period	Forced supply to attach to dispensing
Osteoporosis	IP*, IS*, or	-183	-1	N/A	1	N/A
	AV*, ED* OA*	-183	-1	N/A	2	N/A
<i>Other</i>						
Obesity	Any	-183	-1	Evaluation period should search for evidence of days supply	1	N/A
Overweight	Any	-183	-1	N/A	1	N/A
Smoking	Any	-183	-1	Evaluation period should search for evidence of days supply	1	N/A
Alcohol Abuse or Dependence	Any	-183	-1	N/A	1	N/A
Drug Abuse or Dependence	Any	-183	-1	N/A	1	N/A
History of Cardiac Arrest	Any	-183	-1	N/A	1	N/A
History of Coronary Angioplasty or Bypass	Any	-183	-1	N/A	1	N/A

\*These codes must be within 365 days of the index date, not each other as in version 1.


Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

N/A: Not Applicable



<sup>1</sup> Includes all valid exposure episodes during the query period; only the first valid episode's incidence is assessed using the washout period.

<sup>2</sup> 16 scenarios defined based on initiation of NMEs approved in 2020 Part1 (one scenario per NME); Cohort entry date = first dispensing date for qualifying NME

<sup>3</sup> Baseline characteristics:

Window I: Age, sex, year

Window II: Chronic conditions warehouse (CCW), alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, history of coronary angioplasty or bypass, obesity, overweight, and smoking

<sup>4</sup> Censoring: earliest of death, disenrollment, data partner data end date, query end date